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1. ABBREVIATIONS  
µg Microgram 
µl Microliter 
µM Micromolar 
µm Micrometer 
AF10 ALL 1 fused gene from chromosome 10 (MLL10) 
AGM aorta/gonad/mesonephros region 
ALL Acute lymphoid leukemia 
AML Acute myeloid leukemia 
ANTH AP180 N-terminal homology  
APC Allophycocyanin 
AUL Acute Undifferentiated Leukemia 
bp base pair 
BSA Bovine serum albumin 
BMI1 B lymphoma Mo-MLV insertion region 
CALM Clathrin Assembly Lymphoid Myeloid Leukemia Gene 
CCR Cysteine-rich region 
CDH15 Cadherin 15, M-cadherin (myotubule) 
CEBP CAAT /enhancer binding protein 
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 
CFU Colony forming unit 
CLP Common lymphoid progenitor 
CMP Common myeloid progenitor  
CTNNA1 Catenin (cadherin-associated protein), alpha 1, 102kDa 
CTSZ Cathepsin Z 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethilsulfoxid   acid 
DNA Deoxyribonucleic acid 
dNTP Dinucleotide Triphosphate 
Dox doxycycline 
DPBS Distilled phosphate-buffered saline 
EBV Epstein-Barr virus 
ECFP Enhanced Cyan Fluorescent Protein 
EDTA Ethilene Diamine Tetracetic Acid 
EGFP Enhanced Green Fluorescent Protein 
ext-PHD extended plant homeodomain 
EYFP Enhanced Yellow Fluorescent Protein 
FBS Fetal Bovine Serum 
Abbreviations 2  
 
  
 
FCS Fetal Calf Serum 
g gram 
H2AFJ H2A histone family, member J 
HCK Hemopoietic cell kinase 
HEK Human embryonic kidney cell line 
HOX Homeo box 
HOXB4 Homeo box B 4 
HRP Horse Radish Peroxidase 
HSC Hematopoietic Stem Cell 
IgH Immunoglobulin heavy chain 
JAG1 Jagged 1 
kb kilo base pair 
kDa kilo dalton 
l liter 
LAP Leukemia-associated protein 
lck Lymphocyte protein tyrosine kinase 
LT-HSC Long-Term Hematopoietic Stem Cell 
LZ Leucine ziper 
M Molar 
m meter 
MEIS1 Myeloid Ecotropic viral Integration Site 1 
MLL Mixed Lineage Leukemia or Myeloid/Lymphoid Leukemia Gene 
MLLT10 Mixed Lineage Leukemia or Myeloid/Lymphoid Leukemia Gene 
Translocated to 10 
mm millimeter 
mM mili Molar 
MPP Multipotent progenitor 
ng nanogram 
NLS Nuclear localization signal 
OM Octapeptide domain 
ON overnight 
PAGE Polyacrylamid Gel Electrophoresis 
Pax 5 Paired box gene 5 
PBS Phosphate-buffered saline 
PCR Polimerase Chain Reaction 
PE Phycoerythrin 
pg picogram 
PHD Plant homeodomain 
PMSF Phenylmethylsulfonyl fluoride 
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RAB34 RAB34, member RAS oncogene family 
RNA Ribonucleic acid 
RPMI Rosewell Park Memorial Institute 
RT Room temperature 
RT-PCR Reverse Transcriptase Polymerase Chain Reaction 
SDS Sodium Dodecyl Sulphate 
SET Su (var) 3-9, Enhancer-of-zeste, Thithorax 
SSC Sodium Solution Concentrated 
ST7 Suppression of Tumorigenicity 7 
ST-HSC Short-Term Hematopoietic Stem Cell 
SV-40 Simian virus 40 
TBS Tris-buffered saline 
TCR T-cell receptor 
TEM7R Tumor endothelial marker 7-related precursor 
tet tetracycline 
TKR2 Toll-like receptor 2 
TRIO Triple functional domain (PTPRF interacting) 
USP3 Ubiquitin specific protease 3 
UV Ultra violet radiation 
Zf Zink finger  
ZNF185 Zink finger protein 185 (LIM domain) 
  
4 Introduction and objectives 
2. INTRODUCTION AND OBJECTIVES 
 
The analysis of genetic alterations in leukemia has been essential in understanding the 
pathogenesis of this disease. Somatic acquired chromosomal translocations or inversions occur 
in about 65% of acute leukemia-patients (Rowley, 1990). 
There are two major mechanisms by which translocations affect the genes near the 
translocation breakpoints: 1) fusion genes are generated and 2) the expression of one gene is 
altered by the juxtaposition of a different promoter/enhancer. The t(10;11)(p13;q14) 
translocation is a rare but recurring translocation and has been reported in patients with acute 
myeloid leukemia (AML), T-cell acute lymphoid leukemia (ALL), acute megakaryoblastic 
leukemia, acute byphenotypic leukemia and malignant lymphoma (Dreyling et al., 1998; 
Bohlander et al., 2000). It is associated with a poor prognosis. The exact role of the 
CALM/AF10 fusion gene in leukemogenesis is not known. At the present time we do not 
know, whether the expression of the CALM/AF10 fusion protein affects normal 
haematopoietic development and if this fusion-protein alone can cause malignant 
transformation.  
To answer the question whether this translocation occurs in stem cells or in committed 
progenitor cells (myeloid or lymphoid) leading to leukemia, the following approaches were 
persued: 
Transgenic mice were generated which expressed the CALM/AF10 fusion gene under 
the control of the immunoglobulin heavy chain enhancer promoter or under the control 
of the murine proximal Lck promoter. 
Molecular characterization of the t(10;11)(p13;q14) as well as gene expression 
profiling was performed in a series of CALM/AF10 positive patient samples. 
An inducible cell line model was established in which the CALM/AF10 expression can 
be induced by doxycycline. 
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3. REVIEW OF THE LITERATURE 
3.1. Hematopoiesis and Stem Cells  
Hematopoiesis is a tightly controlled process of blood cell production maintaining 
homeostasis (Smith, 2003). It is the differentiation of committed multipotent progenitors 
(MPP) giving rise to either lymphoid or erythro-myeloid lineages, resulting in the formation of 
common lymphoid (CLP) or common myeloid (CMP) progenitors (Busslinger, 2004). Some 
MPPs divide assymetricaly generating a non-committed MPP (self renew) and a committed 
MPP (differentiation).   
3.1.1. Early Hematopoiesis 
Hematopoiesis is a tissue-specific process which is developmentally regulated. The primary 
sites and patterns of hematopoiesis change throughout murine embryogenesis (Yoder, 2004).  
During embryonic development, hematopoiesis occurs sequentially in distinct organs. There is 
a close association between angiogenesis and hematopoiesis. The co-existence of vascular and 
blood cells found in the same embryonic structures indicate the existence of a common 
precursor, the hemangioblast. These structures, known as blood islands, are part of the 
haemogenicum endothelium and are distributed in limited locations in the embryo, such as the 
floor of the aorta and the proximal umbilical and vitelline arteries (Orkin, 2000). In the mouse, 
blood and endothelial progenitors are first found in these structures at about embryonic day 
7.5 (E7.5) (Haar and Acherman, 1971, cited by Kondo et al., 2003). The liver is the principal 
site of hematopoiesis from E12.0 through birth. At the same time, the spleen and the bone 
marrow become active sites of hematopoiesis prior to birth (E18.0) (Yoder, 2004). It is 
accepted that definitive hematopoiesis begins already in the embryo before the onset of 
circulation (at ~ E8.5). Cells giving rise to hematopoietic cells could be obtained in culture 
from the yolk sac and the aorta/gonad/mesonephros (AGM) region. The exact relationship 
between primitive yolk sac hematopoietic stem cells (HSCs) and definitive HSCs is still 
discussed (Yoder, 2001; Cumano and Godin, 2001 and Keller et al. 1999), but there is a 
consensus about the hepatic origin of the first stem cells which seed the bone marrow (Yoder, 
2001).  
Independently of their precise linear relationship, primitive and definitive hematopoiesis are 
regulated by different and independent microenvironments and transcription factors (Kondo et 
al., 2003). 
3.1.2. Definitive Hematopoiesis 
The ability of a population of progenitors to repopulate the hematopoietic system in adult 
recipients for a long period is defined as definitive hematopoiesis. These progenitors are 
defined as long term repopulation stem cells (LTR). LTR cells are found in the fetal liver and 
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bone marrow (Cumano and Godin, 2001). The hematopoietic activity of the spleen was 
experimentally demonstrated by Godin et al. (1999). It starts from E.16-E.17 until 
aproximately the first week after birth. They could detect the presence of long-term 
reconstituting progenitors and an increasing number of lymphoid and erythro-myeloid colony-
forming-units (CFU) at this embryonic stage. Shortly after birth, the bone marrow becomes 
the principal hematopoietic organ (Jain, 1993; Keller et al. 1999).  
3.1.3. Stem cells 
Stem cell defines a cell with differentiation potential and self-renewal capacity, giving rise to 
different lineages and multiple cell types. The stem cells can be classified into pluripotent and 
multipotent stem cells: 
Pluripotent stem cells, which are able to differentiate into cells of all three germ layers: 
ectoderm, mesoderm and endoderm. Embryonic stem cells are pluripotent stem cells which 
originate from the inner cell mass of the blastocyst. These cells have the ability to generate all 
cell types in the body and can be cultured in vitro almost infinitely. A common use for these 
cells is for the generation of gene-targeted mice (knock-in or knock-out) using homologous 
recombination (Kondo et al., 2003).  
Multipotent stem cells are cells with lineage specificity and can be isolated from various 
tissues of fetal and adult animals. Examples of multipotent stem cells are neuronal stem cells, 
hepatic stem cells and hematopoietic stem cells (HSC) (Kondo et al., 2003). Orlic and 
Bondine (1994) defined a murine HSC as a cell with the ability to restore normal 
hematopoiesis for a prolonged period in mice transplanted after lethal irradiation. This is the 
generally accepted definition of HSCs (Cumano and Godin, 2001; Weissman, 2002; Passegué 
et al., 2003).  
Hematopoietic stem cells are functionally divided into a long-term subset (LT-HSC), capable 
of indefinite self-renewal, and a short-term subset (ST-HSC) that self-renew for a defined 
interval (Weissman et al. 2001; Passegué et al., 2003; Coulombel, 2004). The lineage 
commitment in the blood cell development, progressing from pluripotent HSCs, through 
oligolineage progenitors, immature cells, and finally to functionally mature cells is 
accompanied by a loss of self-renewing capacity (Passegué et al., 2003). An overview of 
hematopoiesis is shown in figure 1.  
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Figure 1: Hematopoietic and progenitor cell lineages. HSCs can be divided into LT-
HSCs, highly self-renewing cells, ST-HSC, limited self-renewing cells. ST-
HSCs differentiate to MPPs (Multipotent progenitors), which differentiate 
into oligolineage-restricted progenitors CMPs (common myeloid progenitors) 
and CLPs (common lymphoid progenitors). The CMPs give rise to the GMPs 
(myelomonocytic progenitor) and MEPs (megakaryotic/erythroid 
progenitors). These oligolineage-restricted progenitors give rise to the 
differentiated mature blood cells (adapted from Passegué et al., 2003).  
 
Hematopoietic differentiation is dependent on an elaborated interplay between the intrinsic 
genetic processes of blood cells and external factors (microenvironment) (Tenen et al., 1997; 
Hackney et al., 2002). All these genetic and environmental mechanisms that are responsible 
for blood production act affecting the relative equilibrium of critical cellular processes. The 
sum of all these processes and factors will finally determine whether HSCs, progenitors, and 
mature blood cells remain quiescent, proliferate, differentiate, self-renew, or undergo 
apoptosis. In a physiological situation, most of HSCs and many progenitor cells are quiescent 
in the G0 phase of the cell cycle; however, many of the more mature progenitors are 
proliferating and giving rise to mature cells. In the absence of any stress factor, i.e. infection, 
poisoning or blood loss, the rate of apoptosis in progenitors and mature cells determines the 
rate of proliferation and differentiation (Smith, 2003). The possibility of examining gene 
expression of sorted cells by molecular biology has been essential to elucidate the function of 
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some genes involved in hematopoiesis. It remains a controversial question wether external 
induction instructs multipontent stem cell to go down a specific differentiation pathway or if 
the microenvironment only offers the conditions to the stem cell to carry out an intrinsically 
and pre-determined differentiation program (Schroeder et al., 2003). In this respect, two 
models for the developmental fate of stem cells are proposed: The instructive (extrinsic or 
deterministic) and the stochastic (intrinsic) model. 
The instructive or deterministic model: this model postulates that the cell fate of HSCs and 
progenitors is determined by external factors driving the cells toward any of the different 
maturation stages or cell lineages. HSCs or multipotential progenitors would be induced to 
follow a particular developmental pathway due to genetic changes directed by the environment 
(intercellular interactions or diffusible signals) (Lemischka, 1992; Enver et al., 1998; Metcalf, 
1998).   
Cytokines are very important players among the environmental regulators of hematopoiesis 
(Zhu et al, 2002). Cytokines are a family of proteins that mediate positive and negative effects 
on cellular quiescence, differentiation, proliferation, and apoptosis. They are produced by 
hematopoietic cells and frequently by non-hematopoietic cells such as stromal cells form the 
bone marrow and endothelium. As a rule, cytokines function by stimulating a specific receptor 
and activating several different signalling pathways. One example is the activation of tyrosine 
kinases, such as focal adhesion kinase, pp60src, cABL, MAP (mitogen-activated protein) 
kinases, jun Kinase (JNK), and protein kinase C (PKC). Some cytokines induce cell 
proliferation, such as interleukin-3 and GM-CSF, while others protect cells from apoptosis 
making the cells able to respond to cytokines that promote cell growth. To this group belong 
the flt-3 ligand and kit ligand (Smith 2003). Cytokines may also work as a bridge between the 
stem cells and the elements in the microenvironment including extra cellular matrix (ECM) 
components (Smith, 2003). Regulators of HCSs including transforming growth factor-beta 
(TGF-b) and tumor necrosis factor-alpha (TNF-a) modulate cell cycle activity and 
engraftment. The Wnt pathway and the notch ligand family of transmembrane receptors have 
also important effects on the regulation of hematopoiesis (Hackney et al., 2002; Schroeder et 
al., 2003).  
An important role as environmental regulators of hematopoiesis is also exerted by the 
chemokines. Chemokines are a large family of proteins which are involved in inflammation, 
leukocyte development and tissue recruitment, neovascularization, tumor development and 
metastasis. The name chemokines is a contraction of chemotatic cytokine, because they have 
the ability to stimulate leukocyte motility (Abbas et al., 1997). These molecules regulate HSC 
migration and homing to sites of need (Wright et al., 2002) and may also be negative and 
positive growth regulators. In hematopoiesis, they are able to inhibit progenitor growth, 
mediate thymic T-cell development and regulate the migration of hematopoietic progenitors 
(Smith, 2003).  
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Hematopoiesis is also regulated by a series of other essential molecules, and cells, such as: the 
extra-cellular matrix (ECM) components, hematopoietic and stromal cells, nutrients and 
vitamins, and a several different physiologic processes. ECM components bind to HSCs and 
progenitors providing the right conditions to these cells to interact with a large spectrum of 
stimulating and inhibiting cytokines and growth regulators (Hackney et al. 2002). Some of 
these ECM molecules are heparin sulfates, chemokines, collagens, thrombospondin-1, 
fibronectin and laminin. Additionally, adhesion molecules on progenitors and HSCs mediate 
the interaction with stromal cells which can induce growth, protect the cells from apoptosis 
and modulate regulatory factors. The binding of the HSCs and progenitors to ECM 
components is mediated by molecules localized on the surface of these cells. Examples for 
these molecules are integrins, selectins and mucins. The cells which may regulate 
hematopoiesis include NK cells, T-cells, macrophages, fibroblasts, osteoblasts, adipocytes, 
and perhaps neurons (Smith, 2003). 
The second model proposed for the developmental fate of hematopoietic cells is the stochastic 
model (Ogawa, 1993; Enver et al., 1998; Bonnet, 2002). This model proposes that many 
genetic events are pre-programmed in a certain sequence and timing by intrinsic genetic 
processes as it is the case in embryogenesis. The Rb family, the E2Fs, cyclins, SCL, Hox, 
Polycomb, and other gene families appear to regulate proliferation and self-renewal of early 
hematopoietic cells (Pineault et al., 2002; Park et al., 2003; Smith, 2003; Valk-Lingbeek et al., 
2004). The bcl family and others regulate apoptosis in hematopoietic cells. 
The observation that the addition of exogenous growth factors to hematopoietic progenitor 
cells in culture allowed growth and development of cell lineages, but did not influence their 
commitment (Enver et al., 1998) supports the idea that the primary function of the extrinsic 
signals, including the growth factors, would be to give conditions for the survival and 
development of committed cells, whereas intrinsic mechanisms have already driven the 
lineage commitment (Bonnet, 2002).  
Independently of whether the instructive or the intrinsic (stochastic) model is considered, the 
common pathway which will finally drive the progenitors to choose their differentiation to the 
one or the other cell lineage is directed by the alternative expression of a specific combination 
of transcription factors, inducing the expression of growth factors or their receptors (Tenen et 
al., 1997).   
Specific nuclear (transcription) regulatory factors are expressed in particular lineages, 
establishing specific gene expression programs related to cell diversification (Orkin, 2000). 
The observation that many genes which were cloned at the site of leukemic translocations are 
transcription factors suggests that they play a crucial role in leukemia development and normal 
hematopoiesis (Look, 1997; Tenen et al., 1997; Orkin, 2000). Table 1 lists some of these 
hematopoietic transcription factors, their expression pattern, overexpression effects and 
knock-out phenotypes. 
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Table 1. Transcriptional regulators of hematopoiesis (Orkin, 2000) 
Factor Type Expression pattern Overexpression effects Phenotype of 
mouse knockout 
GATA-1 Zn finger Prog, E, Meg, Eos, Mast ↑ E, Meg, Eos, Ø myeloid Blocked E, Meg 
GATA-2 Zn finger Prog, Meg, Mast Ø Mature E Ø Prog 
GATA-3 Zn finger Prog, T-cells, Th2 ↑ Th2 Ø Th1 No T-cells 
PU.1 Ets Prog, myeloid, B-cells ↑ Myeloid No myeloid, T or 
B-cells 
FOG-1 Multi-type- 
Zn fingers 
Prog, E, Meg, Mast Ø Eos Blocked E, no 
Meg 
C/EBPa B-zipper Myeloid, Eos ↑ Eos no Neutr, Eos 
MafB B-zipper Monocyte ↑ Monocyte  
Runx1 
(AML1) 
Runt Hematopoietic  No definitive 
hematopoiesis 
T-bet T-box TH1 cells ↑ TH1 Ø TH2  
Pax5 Paired box B-cells Ø Other lineages No B-cells 
Ikaros Zn finger Prog, T-cells  No lymphoid cells 
Prog: progenitors, Eos: eosinophils, E: erythrocytes, Meg: megakariocytes, Neutr: neutrophils. 
3.2. Leukemia and Leukemic Stem Cells 
Leukemia can be defined as the generation of a new population of blood cells resulting from 
an aberrant and poorly regulated proliferation process of a few leukemic stem cells (Passegué, 
2003). In the case of solid tumors as well as in leukemias it is difficult to identify the primary 
cell which suffered the transforming event leading to malignancy. Normal and leukemic stem 
cells (LSC) have in common the self-renew potential and share several developmental 
pathways. These similarities led to the conclusion that LSCs are HSCs that become leukemic 
as the result of accumulated mutations. HSCs have the machinery for self-renewal already 
activated and therefore may require fewer mutations to maintain it than more differentiated 
cells would require to re-activate self-renewal. HSCs also persist throughout life and therefore 
have much greater opportunities to accumulate mutations than more mature cells which persist 
only for a shorter period (Gilliland et al., 2004). Leukemia can be the result of a mutation 
which conferred growth advantage and/or caused developmental arrest of progenitor blood 
cells (Guzman and Jordan, 2004).  
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Leukemic stem cells are defined as transformed hematopoietic stem cells or committed 
progenitor cells that have amplified or acquired the stem cell capacity for self-renewal (Lin 
and Sessa, 2004) but do not differentiate and have impaired functional properties (Guzman 
and Jordan, 2004). With the development of appropriate functional assays and methods for 
cell sorting, investigators have isolated and characterized malignant cells for both acute and 
chronic myelogenous leukemia (Gilliland et al., 2004). The immunophenotypying of normal 
and leukemic stem cells can demonstrate that certain subtypes of human AML and CML are 
the consequence of mutations that accumulate in HSCs. There are experimental evidences 
suggesting that for most AML, independently of the lineage differentiation and phenotype of 
the leukemic cells HSCs and not committed progenitors are the target for leukemic 
transformation. This can be concluded analyzing the fact that, with exception of the M3 acute 
promyelocytic leukemia (APML), only the cells which are phenotypically similar to normal 
stem cells (CD34+, CD38-) were able to cause AML in transplanted nonobese diabetic/severe 
combined immunodeficient (NOD/SCID) mice, whereas leukemic CD34+, CD38+ cells were 
not able to cause disease (Passegué et al., 2003).  
Based on their clinical courses and on their lineage commitment, leukemias have been 
classified as acute or chronic or lymphoid versus myeloid, respectively. Based on the 
cytomorphology of the blast cells the FAB (French-American-British consortium) developed a 
widely used classification system for acute leukemias (Bennet et al., 1976; Bennet et al., 
1985). This system identifies eight categories (M0-M7) of acute myeloid leukemia (AML) and 
three categories (L1-L3) of acute lymphoblastic leukemia (ALL). This classification 
established a standardization of diagnoses allowing comparisons of efficiency between 
different treatment regimens, especially in AML. The distinction between L1 and L2 subtypes 
in ALL is of no clinical importance. The cytomorphological observations, however, are still 
very important in diagnosis and treatment of leukemia. The informations obtained by 
immunologic techniques such as immunophenotyping or immunocytochemistry have proven 
to be extremely useful in the analysis of lineage commitment and leukemic cell differentiation 
(Burmeister and Thiel, 2001). Analyses of leukemia-specific changes on a molecular level 
using cytogenetic analysis, supplemented by fluorescence in situ hybridization (FISH) and 
molecular techniques, such as polymerase chain reaction (PCR) together with the 
cytomorphology and immunophenotyping are essential to provide a final diagnosis and to give 
an insight into the pathogenesis (Burmeister and Thiel, 2001; Haferlach et al., 2005). 
3.3. Chromosomal Translocations 
A chromosomal translocation is defined by a rearrangement in which part of a chromosome is 
detached by breakage and then becomes attached to another chromosome (Lewin, 2000). 
Chromosomal abnormalities in tumors were already recognized since the beginning of the 20th 
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century, but their significance has only become clear in the last decade (Rabbitts, 1994). The 
analysis of clonal chromosomal abnormalities in blast cells from leukemia patients gained lot 
of importance for understanding of the molecular changes involved in leukemogenesis. The 
importance of chromosomal abnormalities in leukemias is demonstrated by the fact that more 
than 65% of acute leukemias cases are found to have non-random, somatically acquired 
chromosomal translocations or inversions (Rowley, 1990; Look, 1997).  
On the molecular level, there are two major mechanisms by which chromosomal 
translocations lead to malignant cell transformation. They can either lead to the formation of 
fusion genes (e.g. the t(9;22)(q34;q11) results in the BCR/ABL fusion gene) or they cause 
gene deregulation (e.g. the t(8;14)(q24;q11) causes up-regulation of CMYC) (McKeithan et 
al., 1986; Rabbitts, 1994). 
 3.4. The t(10;11)(p13;q14) 
The t(10;11)(p13;q14) translocation was described in the U937 cell line  which was derived 
from a diffuse hystiocytic lymphoma (Ralph et al., 1976). It was noted that this translocation 
was distinct from a similar 10;11 translocation, the t(10;11)(p11-13;q23), found in AML, 
which results in the fusion of the MLL gene at 11q23 to the AF10 gene at 10p12 (Chaplin et 
al., 1995).  The t(10;11)(p13;q14) translocation was shown by Bohlander and coworkers to 
lead to the fusion of CALM (Clathrin assembly lymphoid myeloid leukemia), a member of the 
ap-3-like family of clathrin assembly proteins with the putative zinc finger transcription factor 
AF10 (ALL 1 fused gene from chromosome 10) located at 10p13 (Dreyling et al., 1996). A 
schematic representation of the t(10;11)(p13;q14) translocation and the orientation of the 
resulting fusion genes is shown in figure 2. 
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Figure 2: Diagram of the t(10;11)(p13;q14) translocation and the CALM/AF10 fusion 
gene on the der(10) chromosome and AF10/CALM fusion gene on the der(11) 
chromosome. 
 
3.5. CALM, AF10 and CALM/AF10 
3.5.1. CALM 
The CALM (clathrin assembly lymphoid myeloid leukemia gene) or PICALM 
(phosphatidylinositol-binding clathrin assembly protein) gene encodes a 652 amino acid long 
ubiquitously expressed protein, which is a member of the AP-3 like family of clathrin 
assembly proteins (Dryeling et al., 1996). Clathrin assembly proteins have a C-terminal 
domain which mediates the association between AP-3 and clathrin and play a critical role in 
the clathrin assembly in endocytosis (Dell’Angelica et al., 1998; Marsh and McMahon, 1999).  
Clathrin-mediated endocytosis is a process by which virtually all eukaryotic cells internalize 
nutrients, antigens, growth factors, pathogens and cell surface receptors (receptor recycling).  
Endocytosis of plasma membrane or synaptic vesicle component is performed by the 
progressive and sequential assembly of clathrin-coated vesicles that serve to concentrate cargo 
proteins and lipids into the emerging vesicle and provide a mechanical means to deform the 
membrane into a vesicular bud.  The assembly of clathrin-coated buds is aided by an array of 
mostly cytosolic proteins that form a dynamic network of protein-protein interactions by 
associating with multiple partner proteins during the different stages of endocytosis (Takei and 
Haucke, 2001). Clathrin is the major component of the coat forming protein, a highly ordered 
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structure on the cytoplasmic surface of the vesicle. Soluble clathrin is composed of three 
identical 160 kDa heavy chains and three 22-28 kDa light chains. These three heavy and light 
chain complexes form three legged trimers, called clathrin triskelions. Triskelions assemble 
into a basketlike framework of hexagons and pentagons to form coated pits on the cytoplasmic 
surface of the membrane. The second major coat proteins are adaptor proteins (AP, assembly 
or adaptor proteins). CALM and AP180 are monomeric APs involved in the formation of the 
clathrin coats (Kim and Kim, 2001; Kalthoff et al., 2002; Stahelin et al., 2003). 
CALM is the non neuronal homologue of the adaptor protein 180 (AP180) and interacts with 
phosphatidylinositol with its N-terminal domain which is homologous to AP180 (ANT180) 
(Ford et al., 2001; Legendre-Guillemin et al., 2004).  Tebar et al. (1999) showed that the 
major binding partner of CALM is clathrin and that the over-expression of the clathrin-binding 
fragments of CALM dramatically affects clathrin-mediated endocytosis and the trafficking of 
receptors between the trans-Golgi network (TGN) and endosomes. CALM appears to assist 
the coat formation in clathrin-mediated endocytosis defining the size of the coated vesicle 
(Takei and Haucke, 2001). In subcellular localization studies, CALM was shown diffusely 
distributed within the cytoplasm when a GFP-CALM fusion was overexpressed in COS-7 
cells, and also appeared to accumulate in the Golgi area (Tebar et al., 1999). Vecchi and 
coworkers (2001) showed accumulation of CALM in the nucleus of COS-7 cells when nuclear 
export was blocked by leptomycin B. Two other genes (AF-1p and EEN) which encode 
endocytosis-related proteins are also involved in chromosomal translocations in leukemia, 
suggesting a potential link between endocytic proteins and cancer (Floyd and De Camilli, 
1998). Both AF-1p and EEN are found fused to MLL, a gene involved in translocations with 
more than 50 different fusion partner genes, including AF10 (So et al., 2003). 
Our group performed yeast two hybrid interaction studies to identify CALM interacting 
proteins in order to learn more about the possible functions of CALM. CALM was found to 
interact with CATS, a protein with nuclear localization which is probably involved in cell 
proliferation. Overexpression of CATS in NIH3T3 cells was able to change the subcellular 
localization of both CALM and CALM/AF10 (Bohlander et al., 2003). CALM was found also 
to interact with the four and a half LIM domain protein 2 (FHL2) (Pasalic et al., 2005).  FHL2 
is an antagonist to the promyelocytic leukemia zink finger protein (PLZF), which is fused to 
the retinoic acid receptor-a as a result of the chromosomal translocation t(11,17)(q23;q21).  
Interestingly, FHL2 interacts with the proto-oncogene SKI1 and with b-catenin, both having 
important roles in the Wnt signaling pathway (McLoughlin et al., 2002), which is important in 
the process of T-cell development (Osborne and Kee, 2005).  
CALM was recently found fused to another gene, MLL, in an infant AML case (Wechsler et 
al., 2003). Curiously, as mentioned above, AF10 was first identified as the fusion partner of 
MLL in the t(10;11)(p12;q23) which is found in AML. This observations lead to the 
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interesting question of whether the role played by the CALM portion in the CALM/AF10 
fusion gene is the same as the role of the MLL portion in the MLL/AF10 fusion gene in 
leukemogenesis.  
Potter and coworkers (1997) performed a phenotypical characterization of mice expressing a 
N-ethyl-N-nitrosourea (ENU) mutation in the mouse Calm (Fitness 1 or Picalm) and observed 
that the mice suffered from a severe hypochromic anemia, characterized by anisocytosis and 
poikilocytosis. The hematopoiesis was shown to be defective in fit1 mutants at an early 
progenitor stage, and cells representative of multiple hematopoietic lineages are significantly 
reduced. In addition to these hematopoietic defects, fit 1 mutants were growth-retarded in 
uterus and remained dwarfed throughout their shortened life span. Detailed studies on an 
allele of intermediate severity, fit14R, showed that the anemia was mildly regenerative and 
demonstrated functional iron deficiency and abnormal iron distribution suggestive of impaired 
iron transport from the liver to other tissues. These mice also had increased myeloid/erythroid 
ratios in the bone marrow, scoliosis and lumbar vertebral abnormalities (Klebig et al., 2003).  
The structure of CALM is schematically represented in the figure 3. 
3.5.2. AF10 
AF10 (ALL 1 fused gene from chromosome 10), also called MLLT10 (myeloid lymphoid 
leukemia gene, translocated to 10) was cloned as a fusion partner of MLL in the 
t(10;11)(p12;q23) in three AML patients. This rearrangement fuses the carboxy-terminal 
portion of AF10 to the amino-terminal third of MLL. AF10 encodes a 109 kDa protein of 
1,027 amino acids (Chaplin et al., 1995). The predicted structure of AF10 contains also an N-
terminal LAP/PHD-finger (PHD = plant homeodomain), followed by a cysteine-rich region or 
extended PHD finger region (CRR), a putative AT-hook, a nuclear localization signal (NLS) 
and a C-terminal leucine zipper (amino acids 766 to 794) (Linder et al., 2000). The leukemia-
associated-protein (LAP) motif is a cysteine-rich region (CRR) which binds DNA in a 
sequence-independent manner (Saha et a.l, 1995). LAP domains are zink fingers which are 
found in chromatin-associated proteins, e.g. CBP and MLL, suggesting that this domain could 
be involved in chromatin-mediated gene expression mechanisms (Perrin et al, 2003). The 
CRR or extended PHD finger domain, localized C-terminal to the LAP/PHD-finger, interacts 
with itself, and is probably responsible for the oligomerization of AF10. The AT-hook binds 
to cruciform DNA. The NLS identified by protein sequence analysis was demonstrated to 
direct AF10 to the nucleus (Linder et al., 2000). The zinc fingers (ZF) take their name from its 
structure, in which a small group of conserved amino acids binds to a zinc ion and forms a 
relatively independent domain in the protein. ZF are a common motif in DNA binding and 
protein interaction and are found in transcription factors that assist both RNA polymerases II 
and III. Zn finger are one of the most abundant domains in the human genome (Lewin, 2000; 
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Petsko and Ringe, 2004). The leucine zipper (LZ) is a stretch of amino acids rich in leucine 
residues that provide a dimerization motif. Dimer formation itself has emerged as a common 
principle in the action of proteins (transcription factors) that recognize specific DNA 
sequences. An adjacent region of the LZ is responsible for binding to DNA (Lewin, 2000). 
The Drosophila AF10 (dAF10) contains a pentameric protein-protein interaction motiv and 
can associate in vitro with HP1, the Drosophila heterochromatin protein 1, which is encoded 
by the Su(var)2-5 gene. HP1 takes part in a gene silencing phenomenon, termed position 
effect variegation (PEV), which refers to mosaic expression of euchromatic genes if they 
become relocated next to heterochromatin due to chromosomal rearrangements. This 
interaction suggests that dAF10 participates in chromatin mediated gene silencing (Linder et 
al., 2001). 
AF10 was shown to bind to GAS41 (glioma amplified sequence 41), a protein previously 
identified as the product of an amplified gene in glioblastoma. GAS41 shows significant 
homology to the Sacharomyces cerevisae protein ANC1 and to the human MLL fusion 
partners AF9 and ENL. In the same study, GAS41 was coimmunoprecipitated with INI1 
(integrase interactor 1) and INI1 was present in the AF10 immunoprecipitate. INI1 is the 
human homologue of the yeast SNF5 protein, a component of the SWI/SNF complex, which 
acts to remodel chromatin and to modulate transcription (Debernardi et al., 2002).  
DiMartino and colleagues (2002) observed that the N-terminal portion of MLL, which is 
present in the MLL-AF10 fusion, alone is incapable of immortalizing myeloid progenitors and 
suggested that portions of AF10 were required for the transforming activity of MLL/AF10. To 
investigate this requirement, they tested the ability of various deletion mutants of MLL/AF10 
to immortalize myeloid progenitors in vitro. They found one 82 amino acid region containing 
two sequences that are highly conserved in AF10-related proteins from Drosophila and C 
elegans. These homology regions include an almost perfectly conserved octapeptide 
(EQLLERQW) motiv (OM) separated by a nonconserved sequence from a leucine zipper 
(LZ). A minimal portion of AF10 encoding amino acids spanning the OM and LZ homology 
regions fused to the N terminal portion of MLL was sufficient for immortalization. These 
studies suggested that the ability to recruit parts of the transcriptional machinery may be the 
function of AF10 in MLL/AF10-mediated leukemogenesis and that the OM/LZ motif is 
essential for this function (DiMartino et al., 2002). Perrin and colleagues (2003) showed that 
the LZ alone, without the PHD domain, of the Drosophila homolog of AF10 (dAF10), 
activates the Polycomb group-responsive elements (PREs). The absence of the PHD domain 
was essential to confer this activity of the LZ. This deregulation is conserved in the human 
AF10 leucine zipper domain, which confers the same activity on an oncogenic MLL/AF10 
fusion protein expressed in Drosophila melanogaster. MLL is a protein which shows 
homology to the Drosophila trithorax protein (TRX) in several domains. The trx gene and 
related trx- group genes are required to positively maintain the correct expression of a number 
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of Drosophila loci, including the homeotic genes. It is thought that TRX regulates homeotic 
gene expression at the level of chromatin organization, and it is likely that MLL plays the 
same role in vertebrates (Yu et al., 1995). Another group of genes, the Polycomb group, has 
the opposite function, since these genes are required to maintain the repressed state of the 
same Drosophila loci (Perrin and Dura, 2004).  
Covalent modifications of histone tails are very important features in regulating chromatin 
dynamics and gene expression (Strahl and Allis, 2000). Among the various modifications, 
histone methylation has attracted great attention due to its diverse functions, which include 
transcriptional regulation (Zhang and Reinberg, 2001; Lachner et al., 2003). Many of the 
methylases have been linked to cancer, for example, the H3-lysine 4 (H3-K4) 
methyltransferase MLL, has been found to be involved in up to 50 leukemia-associated 
chromosomal translocations (Ayton and Cleary, 2001; So et al., 2003).  hDOT1L is a histone 
methyltransferase which methylates lysine 79 of histone H3 (H3-K79). hDOT1L was found to 
interact with AF10. This interaction is mediated by the octapeptide motiv and by the leucine 
zipper of AF10 (Okada et al., 2005). The same authors showed that in the MLL/AF10 fusion, 
the OM/LZ domain is necessary to recruit hDOT1, and that the transformation of murine 
myeloid progenitor cells by a fusion of MLL and hDOT1L  (MLL/hDOT1L) requires the 
histone methyltransferase activity of hDOT1L. The same OM/LZ domain of AF10 was 
mentioned before as essential for the malignant transformation capability of the MLL/AF10 
fusion (DiMartino et al., 2002). 
The important protein domains of CALM and AF10 and of the fusion proteins AF10/CALM 
and CALM/AF10 are shown in figure 3.       
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Figure 3: Diagram of AF10, CALM, CALM/AF10 and the AF10/CALM fusion protein. 
PHD: plant homeo domain; ext PHD: extended PHD; NLS: nuclear 
localization signal; AT: AT hook; OM/LZ: octapeptide/leucine zipper; Q: 
glutamic acid rich; ANTH: AP180 N-terminal homology. The arrows point to 
the alternative breakpoints in AF10 and CALM. 
3.5.3. CALM/AF10 
The CALM/AF10 fusion gene found in the U937 cell line comprises almost the complete open 
reading frame of CALM and of AF10, whereas the AF10/CALM fusion gene would encode for 
only of the first 80 amino acids of AF10 and the last four amino acids of CALM (Dreyling et 
al., 1996). Both fusion mRNA (CALM/AF10 and AF10/CALM) can be detected in U937 
(Dreyling et al. 1996). This translocation is a rare, but recurring translocation in AML 
associated with a poor prognosis (Dreyling et al., 1998).  
The CALM/AF10 fusion transcript has been observed in the leukemic cells of patients with 
AML, ALL, malignant lymphoma (Bohlander et al., 2000; Narita et al., 1999; Ou et al., 
2004), acute megakaryoblastic leukemia (Jones et al., 2001), monocytic leukemia with 
mediastinal infiltration (Nakamura et al. 2003), as well as in the leukemia-derived cell lines  
U937 and two other monocytic cell lines (P31/Fujioka, KP-Mo-TS) (Narita et al. 1999). 
Kumon et al. (1999) detected co-expression of both myeloid and lymphoid antigens on the 
leukemic cells of 7 out of 9 CALM/AF10 positive leukemias, suggesting that CALM/AF10 
leukemias may be characterized by a mixed-lineage immunophenotype with coexpression of 
T-cell and myeloid antigens. Salmon-Nguyen et al. (2000) reported also the association of an 
inversion in the chromosome 11 and the t(10;11) translocation in a CALM/AF10 patient. The 
singular feature in this T-cell ALL patient was a marked abnormal eosinophil proliferation. 
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Three different breakpoints of CALM (1926, 1987 and 2091), and four of AF10 (423, 589, 
883, 979) are described in CALM/AF10 fusions (Dreyling et al., 1998; Kumon et al., 1999; 
Bohlander et al., 2000). Silliman et al. (1998) analyzed a T-ALL CALM/AF10 – positive 
patient and detected multiple variants of the AF10/CALM and CALM/AF10 fusion transcripts 
which arose from alternative splicing of CALM or AF10. 
CALM/AF10 fusion transcripts were found in 9% of 131 unselected T-ALL patients and were 
described as the most common fusion gene in patients with T-ALL with T cell receptor gd 
rearrangements (Asnafi et al., 2003). The reciprocal fusion transcript, AF10/CALM, is not 
found in all CALM/AF10 patients (Dreyling et al., 1998; Narita et al., 1999; Bohlander et al. 
2000; Carlson et al., 2000; Krause et al., 2004). It should be noted that cytogenetics alone is 
often insufficient to distinguish a t(10;11) leading to a CALM/AF10 rearrangement from a 
t(10;11) which results in an MLL/AF10 rearrangement (Kobayashi et al., 1997; Klaus et al., 
2003).  
Dik et al. (2005) performed expression profile analysis of + T-ALL patients with the 
CALM/AF10 and observed that these leukemias are characterized by the overexpression of 
HOXA5, HOXA9, HOXA10, MEIS1 and BMI1.  
In a mouse bone marrow transplantation model, mouse bone marrow cells, retrovirally 
engineered to express the CALM/AF10 fusion, were able to cause leukemia in all transplanted 
animals (n=13). The transplanted mice died of the leukemia after a mean survival of 125 days. 
The leukemia-initiating cells were identified as progenitor cells with lymphoid characteristics. 
These cells could give rise to leukemic cell co-expressing myeloid and lymphoid markers or 
myeloid markers alone. All cells were positive for the genomic DJ rearrangement at the IgH 
locus, demonstrating its lymphoid origin (Deshpande et al., 2005). These results clearly 
showed that the CALM/AF10 fusion gene is a very potent inducer of leukemia. 
 
3.6. HOX genes 
The homeobox gene family encodes a large group of transcription factors which all contain a 
similar DNA-binding region of around 60 amino acids called the homeodomain. The 
homeodomain contains a helix-turn-helix DNA binding motif which is characteristic of many 
DNA-binding proteins. This domain is encoded by a DNA sequence of 180 base pairs termed 
the homeobox. Many homeobox genes are involved in development, and the homeobox was 
originally identified in genes that control patterning in Drosophila development (Acampora et 
al., 1989). The name ‘homeobox’ comes from the fact that mutations in some of these genes 
result in what is known as a homeotic transformation, in which one structure of the body plan 
is replaced by another.  For example, in one homeotic mutation in Drosophila, a segment in 
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the fly’s body that does not normally bear wings is transformed into an adjacent segment that 
does bear wings, resulting in a fly with four wings. Clusters of homeotic genes involved in 
specifying segment identity were first discovered in Drosophila. Similar complexes of 
homeotic genes have been identified in many animals. In vertebrates, the related clusters are 
known as the Hox complexes, and the homeoboxes of these genes are related to the 
Antennapedia homeobox of Drosophila.  
In humans and mice there are 39 Hox genes organized in four clusters (A, B, C and D) on four 
different chromosomes (McGinnis and Krumlauf, 1992). In the hematopoietic system, the Hox 
gene expression was first analyzed by Adams and co-workers, who showed the presence of 
several Hox transcripts some of which appeared specific to subsets of hematopoietic cells 
(Kongsuwan et al., 1988). Important clues to their potential roles have emerged from more 
detailed analysis of their expression pattern, which revealed that the members of the A, B and 
C, but none of the Hox D genes were most highly expressed in purified sub-populations of 
human BM cells enriched in stem cells and primitive progenitors, and that their expression 
was extinguished or sharply reduced in more differentiated cells (Pineault et al., 2002).  The 
function of Hox genes in hematopoiesis was initially investigated through overexpression 
studies showing that Hoxb4 overexpression in mouse bone marrow cells conferred an 
enhanced proliferative and self-renewal potential to the bone marrow cells. The Hoxb4-
overexpressing HSCs were 43-55 times more competitive than untransduced cells in 
reconstituting the HSC compartment in vivo (Sauvageau et al., 2004).  In addition, several 
members of the HoxB cluster were shown to be up-regulated following cytokine-induced 
differentiation of human BM progenitors in liquid culture (Gianpaolo et al., 1994).  The 
overexpression of HOXB4 in mouse embryonic stem cells (ES) by retroviral transduction 
showed marked enhancement in the generation of definitive erythroid and mixed colony 
progenitors providing evidence implicating Hox genes in the control of very early stages of 
hematopoietic development (Helgason et al., 1996).  
Hox genes have also been associated with leukemic transformation. The first link between 
Hox gene overexpression and leukemia was obtained from genetic analyses of the WEHI-3B 
leukemic cell line, which was shown to contain proviral integrations resulting in the 
transcriptional activation of Hoxb8 and interleukin-3 (IL-3) expression (Blatt et al., 1988). 
Mice transplanted with bone marrow overexpressing Hoxb8 and IL-3 died from an aggressive, 
polyclonal acute leukemia (Kroon et al., 1998). A human HOX gene has also been implicated 
in leukemic transformation. HOXA9 is overexpressed in a subset of human myeloid leukemias 
in the form of a fusion with a sub-domain of NUP98, as the result of a reciprocal translocation 
between chromosomes 7 and 11 (Borrow et al., 1996).The importance of murine Hoxa9 in the 
regulation of hematopoietic cell proliferation was revealed directly through gene targeting 
procedures, which showed that Hoxa9-/- mice have abnormal B lymphopoiesis and 
granulocyte-macrophage progenitors (CFU-GM) differentiating to cells from the lymphoid 
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lineage (Lawrence et al., 1997). In contrast, CFU-GM are hyperproliferative in Hoxa10-/- mice 
(Zhang et al., 1996), suggesting that proliferation of GM progenitors is at least in part 
regulated by Hoxa9 and Hoxa10. The trx gene and related trx-group genes are required to 
positively maintain the correct expression of a number of Drosophila loci, including the 
homeotic genes.  
As already mentioned, MLL, the human homologue of the Drosophila Trx, is involved in the 
regulation of the HOX genes. Ayton and Cleary (2003) showed that the myeloid 
transformation observed in murine primary myeloid progenitor cell lines immortalized by 
MLL fusion genes is associated with the expression of a specific subset of HOX genes from 
the A cluster. Cell lines immortalized by five different MLL fusion genes showed a 
characteristic Hox A gene expression profile. All lines expressed Hoxa7, Hoxa9, Hoxa10 and 
Hoxa11. They demonstrated also that the MLL fusion proteins were required for the Hox A 
gene expression in the transduced cell lines. Hoxa7 and Hoxa9 were found to contribute 
independently to efficient MLL-associated myeloid immortalization in vitro and that Hoxa9 
was essential for induction of MLL-associated myeloid leukemias in vivo. Soulier et al. (2005) 
identified a new recurring translocation t(7;7)(p15;q34) in a T-ALL patient, targeting the 
major homeobox gene cluster HOXA and the TCRB locus and found that the expression of the 
whole HOXA gene cluster was dramatically dysregulated in the HOXA-rearranged cases. 
Upregulation of HOXA cluster genes was also demonstrated in cases with MLL and 
CALM/AF10 rearrangements, suggesting that the HOXA genes are oncogenic in these 
leukemias. CALM/AF10 positive T-ALL leukemias are characterized by overexpression of 
certain HOXA genes and also show overexpression of the HOX cofactor and TALE-homeobox 
gene (three amino acid loop extension) MEIS1 (Myeloid Ecotropic viral Integration Site 1) 
(Bürglin, 1997). In the same study, the authors found overexpression of the polycomb group 
gene BMI1 (B lymphoma Mo-MLV insertion region) (Dik et al., 2005).    
The polycomb group (PcG) gene family is highly conserved (Müller et al., 1995). PcG genes 
are implicated in Homeobox gene regulation and their biological activity lies in stable 
silencing of specific sets of genes through chromatin modifications (Valk-Lingbeek et al., 
2004). The PcG antagonize the positive influence exerted by MLL on the regulation of the 
HOX genes. PcG genes are required to maintain the repressed state of the same Drosophila 
loci (Perrin and Dura, 2004). Some evidences indicate that the PcG are important for stem cell 
fate. Bmi1-deficient mice suffer from progressive loss of hematopoietic stem cells and 
cerebellar neurons. In addition, Mph1/Rae28, which directly interacts with Bmi1 in the PRC1 
complex, is required for sustaining activity of hematopoietic stem cells as well as the 
proliferation of early cerebellar progenitors (Valk-Lingbeek et al., 2004). Bmi1 is regulated by 
an extracellular-signaling molecule, the morphogen Sonic hedgehog (Shh), providing a 
connection between PcG genes and a major developmental signaling pathway (Leung et al., 
2004). Park and co-workers (2003) showed that Bmi1 is required for maintenance of adult 
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self-renewing HSCs in mice. The mechanism by which Bmi1 modulates HSC self-renewal 
could be by the regulation of genes important for stem cell fate decisions as well as that of 
survival genes, anti-proliferative genes and stem-cell-associated genes. 
3.7. The transgenic mouse model 
3.7.1. Transgenic animals 
Transgenic animals have a DNA sequence (the transgene) experimentally introduced and 
stably integrated in their genomes (Gassman et al, 1998).  
The introduction of gene sequences into mammalian embryos has become a powerful tool to 
understand gene function. Transgenic animals have been instrumental in providing new 
insights into mechanisms of development, developmental gene regulation, into the action of 
oncogenes (Hanahan, 1984), and into the intricate cell interactions in the immune system. The 
transgenic technology offers exciting possibilities for generating precise animal models for 
human genetic diseases and for producing large quantities of economically important proteins 
by means of genetically engineered farm animals (Jaenisch, 1988). 
The so called classic method for generation of transgenic mouse consists in the microinjection 
of cloned DNA directly into the male pronucleus of fertilized mouse oocytes. Viable embryos 
are subsequently implanted into pseudopregnant foster mothers (Gassmann and Hennet, 
1998). This technique has been developed by Gordon and co-workers (1980) and has the 
principal advantage in the efficiency of generating transgenic lines that express most genes in 
a predictable manner (Jaenisch, 1988). Although the transgenic DNA is present in all cells, 
transgene expression is dependent on many factors such as the chosen promoter and enhancer 
elements, the number of incorporated copies, and the locus of integration. The main limitation 
of the classical transgenic approach is linked to the uncontrolled integration of the transgene 
into the genome. This random integration may influence the expression of genes situated close 
to the transgene, and the chromatin environment of the integration site may affect the 
expression of the transgene itself (Gassmann and Hennet, 1998).  
Transgenic mice provide the means to assess directly the potency of oncogenes in vivo. Since 
a gene injected into a fertilized oocyte typically integrates into a host chromosome within a 
few cell divisions, all tissues of the transgenic mouse usually acquire the gene, but the 
regulatory elements of the gene may direct tissue-specific expression (Palmiter and Brinster, 
1985). 
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3.7.2. Tissue-specific gene expression 
The specificity of gene expression for cell types of developmental stages and the response of 
genes to physiological stimuli are mediated through a combitional interaction of promoter 
sequences, enhancers, and suppressors. These regulatory elements are composed of short 
stretches of DNA that are generally found in the promoter region of genes but also can be 
located in introns or dispersed over many kilobases upstream and downstream of genes 
(Brenner et al., 2001). The design of the transgenic construct will determine the specificity 
and level of expression in the tissues.  
The first cellular eukaryotic enhancer to be identified was the murine Ig heavy chain gene. 
This enhancer lies between the JH gene segment cluster and m constant region coding 
sequences. Upon V region assembly, a V region promoter comes to lie near the IgH introns 
enhancer (EIgH) and thereby becomes subject to its control. The discovery of the IgH intron 
enhancer proved of particular interest because of the tissue specificity of the enhancer 
(Eckhardt, 1992). The expression of microinjected Ig m gene was shown to be tissue-specific 
in transgenic mice, and although the functionally rearranged heavy chain gene was present in 
all organs, it did not produced gene-specific transcripts in non-lymphoid tissues. This lead to 
the conclusion that cis-acting DNA sequences residing in the introduced rearranged m gene 
must control its selective transcription (Grosschedl et al., 1984). Adams and colleagues (1985) 
described the expression of the c-myc oncogene in B-cells driven by the Ig heavy chain 
enhancer causing lymphoid malignancy in transgenic mice. To mimic the translocated myc 
genes found in lymphoid tumors, they introduced a DNA sequence designated Em-myc, 
isolated from a mouse plasmacytoma in which a normal myc gene had become coupled to the 
Ig heavy chain enhancer. The resultant mice expressed the transgene exclusively in B-
lymphoid cells and developed tumors within 6 to 14 weeks among 12 founders, another mouse 
died at the 34th week. The IgH enhancer was shown to be specifically active in splenic B-cells 
in these mice (Harris et al., 1988). Gerlinger and colleagues (1986) targeted the expression of 
the rabbit b-globin structural gene to lymphocytes with the immunoglobulin heavy chain (IgH) 
enhancer and promoter sequences from either the chicken conalbumin or mouse k light chain 
genes. They could demonstrate that a rabbit b-globin gene, in which the chicken conalbumin 
promoter replaced b-globin promoter elements, was not expressed in five transgenic mouse 
lines. The addition of the IgH enhancer allowed the specific expression in B lymphocytes. 
Nevertheless, replacing the conalbumin promoter by the Ig k promoter resulted in higher 
specific expression. These results showed the specificity of the IgH enhancer in stimulating 
transcription in B-lymphocytes, and that an immunoglobulin promoter element can increase 
the level of specific expression.  
The Lck gene encodes a lymphocyte-specific protein-tyrosine kinase (p56Lck) that is a member 
of the src family. The src gene family includes seven closely related sequences (fgr, fyn, hck, 
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Lck, lyn, src and yes), all of which diverged from a common evolutionary precursor before the 
mammalian radiation. Considerable evidence suggests that the src family kinases can 
participate in the regulation of cell growth (Marth et al., 1988). The expression of Lck is found 
in essentially all T cells, in most B cells, and in a few human cell lines derived from colon 
adenocarcinomas and small cell lung carcinomas (Adler et al., 1998). The Lck gene is 
specifically implicated in the pathogenesis of lymphoid malignancy because of its 
rearrangements and overexpression in two independently obtained murine lymphoma cell 
lines, and by its localization at a site of frequent chromosomal abnormalities in human non 
Hodgkin lymphomas (Garvin et al. 1988). In mammals, the transcription of the Lck gene is 
regulated by two independent promoters, the proximal promoter, which is active in 
thymocytes, and the distal promoter, which predominates in mature T cells (Brenner et al., 
2001). Transcripts from the Lck locus are detectable as soon as hematopoietic progenitors first 
colonize the thymic anlage and are present in all thymocyte subpopulations defined by CD4 
and CD8 expression. Since that the CD4 molecule appears on at least a fraction of immature 
lymphoid there is reason to believe that p56Lck contributes to signal transduction in these cells. 
Studies with transgenic animals using the mouse Lck gene, demonstrate that the proximal and 
the distal promoter elements can function independently (Allen et al., 1992). T cells contain 
two kinds of Lck mRNA, which are called type I and type II. The proximal promoter is 
responsible for the transcription of the type I mRNA and the distal promoter, for the type II 
mRNA. Reynolds and colleagues (1990) analysed the relative abundance of type I and type II 
Lck mRNA transcripts and observed that the type I mRNA, product of transcription under the 
control of the proximal promoter, is expressed in all T-cells, but predominantly in immature 
thymocytes. 
3.8. Inducible gene expression 
The ability to individually manipulate the activity of a single gene or a few genes in a cell or a 
whole living organism represents a very powerful approach for study of complex biological 
processes.  
Several inducible gene expression systems have been developed in an attempt to meet the need 
for regulated gene expression. Most of the commonly used methods for inducing gene 
expression, such as heat shock, steroids, or metallothionein, presents as disadvantages either 
high basal levels of gene expression under noninduced conditions (noise), pleiotropic effects 
on host cell genes, or both. Two systems have been developed that appear to overcome many 
of the problems associated with the first generation of inducible vectors in that the inducers 
are specific to the gene of interest and lead to low basal and high inducible levels of gene 
expression: the tetracycline (tet) and the progesterone antagonist (RU486) regulatable systems 
(Hoffmann et al., 1996).   
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The tetracycline-regulatable gene expression system (Tet system) has, for a number of 
reasons, gained wide acceptance. By adapting prokaryotic transcription control elements to the 
eukaryotic transcriptional machinery, a highly selective regulatory circuit was established 
(Gossen and Bujard, 1992).  
Tetracycline inhibits bacterial growth by binding to ribosomes and disrupting codon-anticodon 
interactions. Specifically, tetracycline prevents attachment of aminoacyl-tRNA to the acceptor 
site on the 30S ribosomal subunit. Tetracycline binds tightly, albeit reversibly, to a single site 
on the 30S subunit that is composed of residues from at least four proteins (S3, S7, S14 and 
S19) and residues from the 893-1054 regions of 16S rRNA. The principal mechanism by 
which E.coli becomes resistent to tetracycline involves multimeric antiporter proteins, known 
as Tet proteins, that are embedded in the bacterial inner membrane and, in exchange for a 
proton, catalyse the outward transport of tetracycline-Mg+2 complexes from the cytosol. Of the 
several known classes of Tet antiporters, the TetA proteins encoded by transposon Tn10 and 
the plasmid pBR322 are the most important in molecular cloning; 399 amino acids in length, 
they consist of two domains, each containing six transmembrane segments. The two domains 
are connected by a cytoplasmic loop of 30-40 amino acids rich in positively charged residues. 
When TetA is present in high concentrations, cations are transported from the bacterial cell at 
such a rate that the membrane becomes depolarized and the viability of the cell is threatened. 
To prevent catastrophe, expression of TetA is tightly controlled by a helix-turn-helix repressor 
protein (TetR), the product of the tetR gene. In the absence of antibiotic, homodimers of the 
repressor bind tightly to the major grooves of two 15-bp palindromic operator sequences (tetO 
1,2), thus preventing expression of the divergently transcribed genes tetR and tetA. TetR is 
therefore a powerful negative regulator of transcription both of its own gene and of tetA 
(Sambrook and Russel, 2001).  
Two complementary systems have been developed in which the addition of the tetracycline 
derivative doxycycline (Dox) either switches transcription of a target gene off (tTA or ‘Tet 
Off’ system) (Gossen and Bujard, 1002) or on (rtTA or ‘Tet On’ system) (Gossen et al., 
1995). An additional advantage of the system is that it also enables control of the level of gene 
expression by titrating the dose of Dox. The Tet system, as initially designed, consists of two 
components: a tetracycline controlled transcriptional activator (rTA or rtTA) and a tTA/rtTA 
responsive promoter Ptet directing the transcription of the gene of interest. Bidiretional 
rTA/rtTA responsive promoters, Ptetbi-1 have been developed, allowing the coordinate 
expression of two genes, of which one may be used as a reporter for the expression of the gene 
of interest. The best results are obtained when the genes encoding the two components of the 
Tet system including the genes of interest, are introduced into cell lines or transgenic animals 
separately from each other in a two-step procedure, whereby in a first step, cell or mouse lines, 
for example, are generated to produce appropriately tTA or rtTA.  These lines are suitable for 
introducing a variety of genes of interest controlled by Ptet or Ptetbi-1 (Bornkamm et al., 2005).  
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In the case of cell lines, this second step is accomplished by a second transfection and 
selection of appropriate clones, whereas for transgenic animals double transgenic individuals 
are obtained by breeding. In practice, the establishment of well-regulated clones using the 
system with two plasmids is a technically difficult process and results in a low number of 
inducible clones (Hoffmann et al., 1996).  The arguments exposed indicate a series of 
advantages in a system based on the one-step transfer of Ptet controlled genes along with the 
tTA/rtTA encoding transcription. 
Bornkamm and colleagues (2005) reported the development of an EBV (Epstein-Barr virus) -
based vector that contains all the elements for controlling the activity of a gene of interest via 
Dox. This vector, designated pRTS-1, accommodate all the elements required for Dox-
regulated gene expression on one epissomally replicating plasmid including the gene of 
interest. It is reported to show low background, high inducibility and a proportional rate of 
response to different Dox concentrations.  
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4. MATERIALS AND METHODS 
4.1 Patients 
Bone marrow cells or RNA samples from five patients, three with acute myeloid leukemia 
(AML) and two with T-cell acute lymphoid leukemia (T-ALL) with translocation t(10;11) 
were kindly provided by Dr. Cristina Mecuci, Perugia, Italy. cDNA from seven patients with 
AML, ALL or acute undifferentiated leukemia (AUL) with translocation t(10;11) were 
obtained from the Laboratory for Leukemia Diagnostics, Grosshadern. Bone marrow cell 
samples from twenty-nine T-ALL patients with TCR - gd rearrangement were obtained from 
Prof. Dr. Ludwig from the Immunologic Marker Laboratory, Charité University Clinic, Berlin.  
4.2 Animals 
For the production of transgenic mice, the inbred mouse strain FVB/N, established at the 
National Institute of Health (Bethesda, USA) in the late 70’s, (Taketo et al., 1991) was used. 
The transgenic mice were obtained by the classic transgenic method of microinjection in the 
male pronucleus (Gordon and Ruddle, 1982). The mice were maintained in the animal 
facilities of the Gene Center under non-barrier conditions. Acidified water (6 mM HCl) was 
provided ad libitum in bottles. Pregnant mice received breeding diet (Ssniff®M-Z extruded 
pellets) ad libitum. Maintenance diet (Ssniff®R/M-H pellets) was fed ad libitum to the others. 
Fodder pellets, as well as any other solid objects entering the mouse facility, were autoclaved. 
Mice were kept, separated by sex, in standard macrolon cages with grid lids on softwood fibre, 
paper and hay. Enrichment was provided in all cages of sufficient size with aspen wood pieces 
and activity wheels. The environmental conditions in the mouse facility were: Conventional 
facility (non-barrier), temperature 21°C (+/- 1°C), relative humidity 60% (+/- 5%), ventilation 
rate 15 air changes/hour, 2 pascal positive air-pressure and a lighting regimen of 12 hours 
light/12 hours dark. 
Breeding strategy 
Founders obtained from DNA-microinjection were bred from the age of 8 weeks to 6 months 
(females) or up to 12 months (males) with FVB/N inbred mice to generate transgenic lines. 
Female and male mice were caged together until the appearance of a vaginal plug. Males were 
thereafter caged singly. 
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4.3 Material and Reagents 
Table 2a: Chemicals, commercial solutions and kits 
Reagent Company 
T4 DNA Ligase New England Biolabs, Frankfurt, Germany 
100 MM dNTP Set, PCR Grade Invitrogen life technologies, Karlsruhe, Germany 
1Kb DNA Ladder Invitrogen life Life Technologies, Karlsruhe, Germany 
Acetic acid Merck, Darmstadt, Germany 
Agar-Agar Carl Roth GmbH, Karlsruhe, Germany 
Agarose  ICN Biomedicals, Inc. 
BigDye‰ Terminator Cycle Sequencing Applied Biosystems, Foster City, CA, USA  
Bio-rad Protein Assay Bio-rad Laboratories GmbH, Munich, Germany 
Boric Acid Carl Roth GmbH, Karlsruhe, Germany 
Bromophenol blue Carl Roth GmbH, Karlsruhe, Germany 
Buffer Y/Tango‰ MBI Fermentas, St. Leon-Roth, Germany 
Chloroform Sigma-Aldrich, Steinheim, Germany 
Coomassie blue Bio-Rad Laboratories, Hercules, California, US 
Deoxyribonuclease I, Amplification Grade Invitrogen life technologies, Karlsruhe, Germany 
Dextransulfate Carl Roth GmbH, Karlsruhe, Germany 
Dietyl pyrocarbonate (DEPC) Sigma-Aldrich Chemie GmbH 
DMEM PAN Biotech GmbH 
DPBS PAN Biotech GmbH 
ECL‰ Western blotting Detection reagents Amersham Biosciences, Buckinghamshire, England 
Endofree‚Plasmid Maxi Kit (10) Qiagen GmbH, Hilden, Germany 
Ethanol Merck, Darmstadt, Germany 
Ethidiumbromide Carl Roth GmbH, Karlsruhe, Germany 
Fetal Bovine Serum Gibco BRL, Life Technologies. Paisley, Scotland 
Giemsa’s solution Merck KgaA, Darmstadt, Germany 
Glycerin Carl Roth GmbH, Karlsruhe, Germany 
Glycin Carl Roth GmbH, Karlsruhe, Germany 
Hydrochloridric acid 37% Merck, Darmstadt, Germany 
Isopropanol Carl Roth GmbH, Karlsruhe, Germany 
May-Grünwald’s eosine-methylene blue solution 
modified 
Merck KgaA, Darmstadt, Germany 
Megaprime DNA Labelling System Amersham Biosciences, Buckinghamshire, England 
Methanol Merck, Darmstadt, Germany 
Milk powder Carl Roth GmbH, Karlsruhe, Germany 
Oligo (dT)12-18 Primer Invitrogen Life Technologies, Karlsruhe, Germany 
 
Materials and Methods 
  
29 
Table 2b: Chemicals, commercial solutions and kits 
Reagent Company 
Paraformaldehyd Carl Roth GmbH, Karlsruhe, Germany 
Penicilin/Streptomycin PAN Biotech GmbH, Aidenbach, Germany 
Peptone, meat pancreatic digested Merck, Darmstadt, Germany 
Phenol-chloroform  Carl Roth GmbH, Karlsruhe, Germany 
PolyFect‚ Transfection Reagent Qiagen GmbH, Hilden, Germany 
Propidium iodide Calbiochem, San Diego, USA 
Proteinase inhibitor cocktail Sigma-Aldrich Chemie –GmbH, Steinheim, Germany 
Proteinase K Sigma-Aldrich Chemie –GmbH, Steinheim, Germany 
QIAshredder‰  Qiagen GmbH, Saint Louis, USA 
Restriction enzymes and buffers MBI Fermentas, St. Leon-Roth, Germany and 
 New England Biolabs, Frankfurt, Germany 
RNeasy‰ Mini Kit Qiagen GmbH, Hilden, Germany 
RPMI 1640 PAN Biotech GmbH, Aidenbach, Germany 
SDS ultra pure Carl Roth GmbH, Karlsruhe, Germany 
SeeBlue‚Plus@  Invitrogen life technologies, Karlsruhe, Germany 
Shrimp Alkaline Phosphatase  MBI Fermentas, St. Leon -Rot, Germany 
Sodium acetate Sigma-Aldrich, Steinheim, Germany 
Sodium acetate Merck, Darmstadt, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate Carl Roth GbmH, Karlsruhe, Germany 
Sodium hydroxide Merck, Darmstadt, Germany 
SuperScript‰ II Rnase H- Reverse Transcriptase  Invitrogen Life Technologies, Karlsruhe, Germany 
Taq DNA Polymerase New England Biolabs, Frankfurt, Germany 
T4 DNA Ligase New England Biolabs, Frankfurt, Germany 
TEMED Carl Roth GmbH, Karlsruhe, Germany 
Testes salmon DNA Sigma-Aldrich, Steinheim, Germany 
TRIS – (hydroxymethl)-aminomethane Carl Roth GmbH, Karlsruhe, Germany 
Trypsin/EDTA PAN Biotech GmbH, Aidenbach, Germany 
Tween‚20 Carl Roth GmbH, Karlsruhe, Germany 
Yeast extract Carl Roth GmbH, Karlsruhe, Germany 
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Table 3: Labware and suppliers  
Material Company 
1.5 ml microcentrifuge tube Eppendorf, Hamburg, Germany 
15 ml polypropylene conical tubes Becton Dickinson Europe, Meylan Cedex, France 
50 ml polypropylene conical tubes Becton Dickinson Europe, Meylan Cedex, France 
6 Well cell culture plate Nunc Brand Products, Roskilde, Denmark 
Cell culture flask 75cm2 Sarstedt, Nümbrecht, Germany 
Cell culture flask 75cm2 Sarstedt, Nümbrecht, Germany 
Cell culture plate 35 mm2 Nunc Brand Products, Roskilde, Denmark  
Cell Scraper 25cm Sarstedt, Inc., Newton, USA 
Cuvettes 10x4x45 mm Sarstedt AG & Co., Nümbrecht, Germany 
Nunc Cryotube™ vials Nalge Nunc International, Denmark 
FALCON‚ 14 ml Polystrene Round-bottom tube Becton Dickinson Europe, Meylan Cedex, France  
Gel-Blotting paper 0.8mm Schleicher & Schleicher, Dassel, Germany 
Hybond‰-P PVDF Transfer membrane 0.45µm Amersham Biosciences, Bucks, UK 
Hypercassete 18x24 cm Amersham Biosciences, Buckinghamshire, England 
Hyperfilm‰ ECL Chemiluminescence reagent Amersham Biosciences, Buckinghamshire, England 
Hyperfilm‰ ECL High performance 
chemiluminescence film 
Amersham Biosciences, Buckinghamshire, England 
Lab-Tek II Chambered Coverglass w/cover Nalge Nunc International, Naperville, IL, USA 
MicroSpin‰ S-300 HR Columns Amersham Biosciences, Piscataway, NJ, USA 
Nescofilm sealing film  Carl Roth GmbH, Karlsruhe, Germany 
Pipette tips 0.5-10 µl Carl Roth GmbH, Karlsruhe, Germany 
Pipette tips 100-1000 µl Carl Roth GmbH, Karlsruhe, Germany 
Pipette tips 1-200 µl Carl Roth GmbH, Karlsruhe, Germany 
Surgical blade Feather Safety Razor Co. Med. Div., Japan 
Syringe 10 ml Braun, Melsungen, Germany 
Syringe Driven Filter Unit Millex -GP 0.22 mm Millipore, Carrigtwohill, Ireland 
Syringe Driven Filter Unit Millex -HV 0.45 mm Millipore, Carrigtwohill, Ireland 
Syringe Driven Filter Unit Millex -LG 0.20 mm Millipore, Japan 
Tissue Culture Plate 6-Well Flat Bottom Cell+ Sarstedt, Inc. Newton, USA 
Tissue Culture Plate 6-Well Flat Bottom Cell+ Sarstedt, Inc. Newton, USA 
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Table 4: Antibodies  
Antibody Isotype Label Company Concentration 
Anti-CALM C -18 Goat IgG Primary Santa Cruz Biotechnology 200µg/ml 
Anti-CALM S -19 Goat IgG Primary Santa Cruz Biotechnology 200µg/ml 
Anti-CALM G -17 Goat IgG Primary Santa Cruz Biotechnology 200µg/ml 
Anti-GFP IgG Rabbit IgG Primary Molecular Probes 2 mg/ml 
Anti-goat  IgG 
HRP – conjugated 
Donkey IgG HRP Santa Cruz Biotechnology 400µg/l 
Anti-rabbit IgG  Donkey IgG HRP Santa Cruz Biotechnology 400µg/ml 
GR-1 Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
CD11b (Mac-1) Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
Sca-1 Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
Ter119 Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
B220 Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
CD3 Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
CD4 Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
CD8 Rat IgG2a PE/APC BD Pharmingen 200µg/ml 
CD19 Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
CD43 Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
CD117 (c-kit) Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
Isotype control Rat IgG2b PE/APC BD Pharmingen 200µg/ml 
 
Table 5: Plasmids   
Plasmid Supplier 
pEGFP-C1 BD Biosciences Clontech, Heidelberg, Germany 
pEYFP-C1 BD Biosciences Clontech, Heidelberg, Germany 
pECFP-C1 BD Biosciences Clontech, Heidelberg, Germany 
pPepB-Splice Werner Müller 
pGEMT‚-easy™ vector Promega Corporation, Madison, USA. 
pRTS-1 Georg Bornkam, GSF, Grosshadern, Germany 
pUC19Sfi1 Robert Chapmann, GSF, Grosshadern, Germany  
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Table 6: Primers used for CALM/AF10 amplification 
Primer Name Annealing  
(oC) 
Nucleotide position in cDNA  
and genomic sequence* 
Sequence 
NG.T 45 57 CALM(1730-1753) Exon 15 5’ – CCAAACTCCCACCTAGCAAGTTAG – 3’  
NA.T 501 57 CALM(1998-2023) Exon 20 5’ – GGAAGTGTTCCTGTAATGACGCAAC – 3’  
ANB 497 57 CALM(2165-2144) Exon 22 5’– AAGGATTTTGCTGCTTGAGCAC – 3’ 
AF10 949B 57 AF10(949-929) Exon 14 5’ – CCAATGCAGGTGATGGTTCTG – 3’ 
AF10 1086B 57 AF10(1086-1066) Exon 15 5’ – GGTGTGTGCAGAGACTTCCTG – 3’ 
AF10 651B 57 AF10(651-632) Exon 11 5’ – TGTCATGCAAGCACCAGTGG – 3’ 
AF10 T288 57 AF10(288-308) Exon 2 5’– CGAGAACCCGCTGGTTTATTG – 3’ 
CALM 
1900T 
56 CALM(1900-1920) Exon 17 5’ – ACAACCGCTTGGAATGCTGC – 3’  
AF10448B 56 AF10(448-424) Exon 8 5’ – CCTTATGGGGACAAAGTTCACATC – 3’ 
CAJN fw 58 CALM(1929-1948) Exon 19 5’ – ACCCCCTGTAATGGCCTATC – 3’ 
CAJN rev 58 AF10(636-617) Exon 11 5’ – AGTGGCTGCTTTGCTTTCTC – 3’ 
CA2 60 CALM(448-471) Exon 3 5’ – AACACGTTGTTTAACTTAAGCAA – 3’ 
CA3 60 CALM(682-704) Exon 7 5’ – CTTGACATCTATAAGAAGTTCC – 3’ 
CA4 60 CALM(1195-1216) Exon 11 5’ – CCTCATACCTCTTTAACAACTG – 3 
CA5 60 CALM(1497-1519) Exon 13 5’ – CATTTCTTCAGATGTATCTACTT – 3’  
CA6 60 CALM(1808-1831) Exons 16 
and 17 
5’– GAAATGGAACCACTAAGAATGATG – 3’  
CA7 60 AF10(443-460) Exon 8 5’ – CCCATAAGGATGGAGCTTTAA – 3’ 
CA8 60  AF10(737-757) Exon 12 5’ – CCGATAATGTCCAATACTGTG – 3’ 
CA9 60 AF10(1144-1162) Exon 15 5’ – TCAGCTCACAGCTCAGGTC – 3’ 
CA10 60 AF10(1427-1446) Exon 16 5’ – GTACCTTAATTGGCCTCCCT – 3’ 
CA11 60 AF10(1764-1783) Exon 16 5’ – TTTACAGAGCCTCAGTGTTG – 3’ 
CA12 60 AF10(2132-2150) Exon 22 5’ – CTCTCAGTCAGGCACCATC – 3’  
CA13 60 AF10(2491-2509) Exon 25 5’ – AACCGAAGATTAGAGGAAC – 3’ 
CA14 60 AF10(2839-2859) Exon 27 5’ – GTCAATGGCGTGACAGTGGGG – 3’  
CA15 60 CALM/AF10 (4782-4800)  5’ – CTTCAGCAGCTGCAGATCC – 3’  
AF10T182 
XhoI 
58 AF10(182-199) Exon 2 5’ - CATCCTCGAGGAATGGTCTCTAGCGACC -
3’ 
AF10B728 
SalI 
58 AF10(728-705) Exon 12 5’ – CCTTCTTCTTCACAAAGCAGTCCG – 3’ 
* Gene Bank acc. NM_007166 (CALM) and NM_08705.15 (AF10). 
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Table 7: PCR primers used to generate inserts for the various expression constructs or 
for house keeping genes. 
Primer Name Annealing 
(oC) 
Nucleotide 
position 
Sequence 
IgHStartXhoIa 60  Mouse Chr 
12 
5’ – CTTCTCGAGTAAATACATTTTAGAAGTCGATA -
3’ 
IgHProEndSac1b 60 Mouse Chr 
12 
5’ – CTTGAGCTCGTGAGGTCCTGTGTGCTC – 3’ 
SV40splStartXba1 60  5’ – CTTTCTAGATCTTTGTGAAGGAACCTTAC – 3’ 
SV40polAEndNot1 60  5’ – CTTGCGGCCGCCTAATTTAAATGAGGAC – 3’ 
MLCKprom64-
84topXhoI 
59 64-84 5’ – GTACTCGAGGACCAGTGCTCAGGAAGG – 3’ 
MLCKprom702-
681bottomSac1 
59 702-681 5’ – GATGAGCTCAAGCTCCTGACTGGGTTCC – 3’ 
D10 Mit105F 56 Mouse STS 
Chr 10 
5’ - AATCTGGTCACACAGATTTGACC – 3’ 
D10 Mit105R 56 Mouse STS 
Chr 10 
5’ - GTCATCCCTGTGTAGTGTCAACA – 3’ 
mouseGAPDHfc 60 271 - 291 5’ – CATCACCATCTTCCAGGAGC – 3’ 
mouseGAPDHr 60 714 - 695 5’ – ATGACGTTGCCCACAGCCTT – 3’ 
pEGFP-C11240 59 1240 - 1258 5’- AAAGACCCCAACGAGAAGC -3’ 
hTBPfd exon 5 and 6 57 653 - 672 5’ – GCACAGGAGCCAAGAGTGAA – 3’ 
hTBPr exon 6 57 779 - 760 5’ – TCACAGCTCCCCACCATGTT – 3’ 
mHPRTfe exon 3 59 295 - 314 5’ – GGGGGCTATAAGTTCTTTGC – 3’ 
mHPRTr exon 6 59 606 - 587 5’ – TCCAACACTTCGAGAGGTCC – 3’ 
Access number: aNT_039551.4, bNC_000078.2, cNM_001001303, dNM_007583.11, 
eNM_013556 
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4.4 Media and Solutions 
4.4.1Cell Culture 
Media and phosphate-buffered-saline were purchased from Pan Biotech GmbH. 
 
Complete cell culture medium 
50 ml heat-inactivated FCS, sterile filtered 
5 ml penicillin/streptomycin solution (10,000 U penicillin/ml, 10 mg/ml, respectively) 
RPMI1640 or DMEM to complete 500 ml volume   
 
Cell-freezing solution 
10% DMSO sterile-filtered diluted in sterile filtered and heat-inactivated FCS 
 
DMEM 
With 4.5 g/l glucose, L-Glutamine, Sodium Pyruvate, 3.7g NaHCO3 
Sterile filtered 
   
Doxycyclin Stock Solution 
1 mg doxycyclin hyclate/ ml DPBS  
 
Puromycin Stock Solution 
1 mg puromycin/ml DPBS 
4.4.2 Western blotting 
RIPA buffer 
1X PBS,  
1% TritonX100. 
0.5% sodium deoxycholate 
0.1%SDS 
Protease inhibitors (freshly added): 
PMSF (stock 10 mg/ml diluted in isopropanol) 10 µl/ml RIPA 
Sodium orthovanadate (100 mM stock diluted in distilled water) 10 µl/ml RIPA 
Proteinase inhibitors cocktail  (Sigma) 1:100 dilution  
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Tris buffered saline (TBS) 
10 MM Tris, pH adjusted to 8.0 with HCl 
150 MM NaCl 
 
Phosphate buffered saline (PBS) 
9.1 mM dibasic sodium phosphate 
1.7 mM monobasic sodium phosphate 
150 MM NaCl 
pH 7.4 
 
Blotto A 
1 x TBS, 5% milk powder 0.05% Tween 20 
 
Transfer Buffer for Western blotting 
25 mM Tris HCl (pH 8.8) 
200 MM glycin 
20% methanol 
 
Separating electrophoresis gel buffer 
1.5 m Tris-HCl pH 8.8, SDS 2% 
 
Stacking Gel buffer 
1.5 m Tris-HCl, SDS 2% pH 6.8 
Electrophoresis running buffer 
250 mM Tris (HCl, pH 8.5) 
2 M Glycin 
1% SDS 
 
Electrophoresis Sample buffer 
125 mM Tris  
4% SDS 
20% Glycerol 
10% b-Mercaptoethanol 
0.01% bromophenol blue 
 
Materials and Methods 
  
36 
Table 8: SDS Electrophoresis Separating Gel 6% for a 5 ml single mini gel (Sambrook 
and Russel, 2001) 
H2O 2.7 ml 
1.5 m Tris (pH 8.8)  1.3 ml 
30% Acrylamide mix  1 ml 
10%SDS  50 µl 
TEMED 4 µl 
10% APS  50 µl 
 
Table 9: SDS Electrophoresis Stacking Gel 5% for a single 2 ml mini gel (Sambrook and 
Russel, 2001) 
H2O 1.4 ml 
1.5 m Tris (pH 6.8)  0.25 ml 
30% Acrylamide mix  0.33 ml 
10%SDS  20 µl 
TEMED 4 µl 
10% APS  20 µl 
 
 
 
4.4.3 Southern Blotting 
Lysis buffer for mouse tail genomic DNA extraction 
100 mM EDTA pH 8.0 
100 mM NaCl 
50 mM Tris HCl pH 8.0 
0.5 mg/ml proteinase K  
 
Denaturation solution 
1.5 M NaCl 
0.5 N NaOH 
 
Neutralization solution 
1 M Tris HCl pH 7.4 
1.5 M NaCl 
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20 x SSC pH7.0 
3 M NaCl 
0.3 M Sodium Citrate 
 
Hybridization solution 
0.2 g fat free milk 
17 ml water 
2 g dextran sulfate 
6 ml 20 x SSC 
2 ml Formamide 
1 ml 20% SDS  
80 µl 500 mM EDTA  
DEPC water 
0.1% diethylpyrocarbonate in bi-distilled water 
mixed vigorously and autoclaved 
 
4.4.4 Bacterial Culture, DNA preparation/manipulation/extraction 
LB (Luria Bertani) Medium 
10g Peptone 
5g Yeast extract 
10g NaCl 
1l H2O 
For plates, add 15g Agar-Agar 
 
Solution E1 (Cell Resuspending): 
50 mM Tris HCl (pH 8.0) 
10 mM EDTA 
Adjust pH with HCl to 8.0 
Add RNaseA to 100µg per ml final concentration, store at 4°C  
 
Solution E2 (Cell Lysis) 
200 mM NaOH 
1% SDS 
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Solution E3 (Neutralization) 
3.1 M potassium acetate 
adjust pH to 5.0 with acetic acid  
 
TE buffer 
10 mM Tris-HCl, pH 8.0 
1 mM EDTA, pH 8.0 
 
TE buffer for DNA microinjection 
5 mM Tris-HCl, pH 7.4 
0.1 mM EDTA, pH 7.4 
 
4.4.5 FACS Solutions 
FACS Buffer 
PBS 
1% FCS 
1 mg/l propidium iodide 
Materials and Methods 
  
39 
4.5 Methods 
4.5.1 Chemically Competent Bacteria 
Competent bacterial cells of E. coli strain XL-1 blue (Stratagene) were prepared according to 
the calcium chloride method (Sambrook and Russel, 2001). A single colony was picked and 
transferred to a 14 ml falcon tube containing 5 ml of LB culture medium and incubated 
overnight in a shaking incubator at 37ºC and 200 rpm. This pre-culture was transferred to an 
Erlenmeyer flask containing 200 ml of LB and incubated in a shaker at 37ºC, 200 rpm for 
about 2 hours until the OD600 was between 0.5 and 0.7. After centrifuging for 10 minutes 
6000 rpm, the bacterial pellet was resuspended in 60 ml TFB I and incubated 10 minutes on 
ice. Finally, the cells were centrifuged again and the pellet was resuspended in 4 ml TFB II. 
The bacteria were transferred to Eppendorf microcentrifuge tubes in 100 µl aliquots. The cells 
were used immediately for transformation or stored at –80ºC after shock freezing in liquid 
nitrogen. The competence of bacteria was tested using 10 pg of plasmid DNA to transform the 
bacteria. Typically 107-108 colonies per µg of plasmid DNA were obtained.  
4.5.2 Electrocompetent Bacteria 
Eletrocompetent bacterial cells of E. coli strain XL-1 blue (Stratagene) were prepared 
according to Sambrook and Russel, 2001. A bacterial pre-culture was prepared overnight as 
described for chemically competent bacteria. This pre-culture was transferred to a tube 
containing 400 ml of LB medium and incubated in a shaking incubator at 37ºC and 200 rpm as 
described until reaching the same OD600 range for chemically competent bacteria. The cells 
were pelleted and immediately washed (3000 rpm at 4ºC) with ice cold sterile distilled water. 
The pellet was washed again with ice cold sterile water containing 10% glycerol. The bacterial 
pellet was re-suspended in 4 ml water with 10% glycerol and 50 ml bacterial aliquots were 
transferred to Eppendorf microcentrifuge tubes in 50 µl aliquots and used or stored as 
described above. Typically 108 – 109 colonies per µg of plasmid DNA were obtained.  
4.5.3 Bacterial Transformation 
Chemical Transformation 
For transformation experiments, 10 pg of DNA or a 5 µl aliquot from a 20 µl ligation reaction 
was used. 100 µl of freshly prepared or stored competent bacteria were put on ice and the 
DNA for transformation was pipetted into the tube. The DNA and the bacteria were carefully 
mixed by flicking the tube. After 50 minutes incubation on ice, the bacteria were heat shocked 
by transferring them to a 42ºC water bath for exactly 90 seconds. The tube was immediately 
chilled on ice. After 2 minutes, 120 µl of 37ºC pre-warmed LB medium was pipetted into the 
tube, which was incubated in a water bath or thermoblock at 37ºC. After 30 minutes 
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incubation, the bacteria were plated on LB agar plates containing the specific antibiotic 
(ampicilin, 50 µg/ml or kanamycyn 25 µg/ml) for selection of transformed bacteria. The plates 
were incubated overnight at 37ºC. 
Electroporarion 
For electroporation procedures, 10 pg of DNA or a 2 µl aliquot from a 20 µl ligation reaction 
was used. 50 µl of freshly prepared or stored competent bacteria were put on ice and the DNA 
for transformation was pipetted into the tube. The DNA and the bacteria were carefully mixed 
by flicking the tube. After one minute incubation on ice, the bacteria and DNA were 
transferred to the electroporation cuvette which was put in the electroporator (Easyjet Prima, 
Equibio) and submitted to a pulse of 1800 v. One ml of 37ºC pre-warmed LB medium was 
pipetted into the cuvette and the content was transferred to an 1,5 ml eppendorf tube, which 
was incubated in a thermomixer at 37ºC for one hour. After one hour incubation, the bacteria 
were plated on LB agar plates containing the specific antibiotic (ampicilin, 50 µg/ml or 
kanamycyn 25 µg/ml) for selection of transformed bacteria. The plates were incubated 
overnight at 37ºC. 
4.5.4 Plasmid Preparation 
Depending on the DNA amount and purity desired, plasmid DNA was obtained by alkaline 
lysis method from bacteria using mini, midi or maxi endonuclease-free preparation kit. 
Miniprep 
Miniprep plasmid preparations were performed using solutions prepared in our laboratory and 
a modification of the alkaline lysis protocol from the Genomed Company: 
The bacterial culture was grown overnight in a polystyrene Round-bottom tube (FALCON, 
BD Labware, France) containing 4 ml LB medium at 37ºC in a shaking incubator with a 
rotation of 220 rpm. 1.5 ml of the culture was pelleted in an Eppendorf tube by 
micocentrifugation 10000 rpm for 5 minutes at room temperature. The pellet was resuspended 
in 300 µl of E1 solution. After resuspension of the bacterial pellet, 300 µl E2 lysis solution 
was added and 5 minutes room temperature incubation was carried out to allow complete lysis 
of bacteria. After 5 minutes, 300 µl of the neutralization buffer E3 was added and gently 
mixed by inverting the tube about ten times. The tubes were centrifuged 14000 rpm in a 
microcentrifuge (Eppendorf 1754c) at room temperature for 15 minutes. 
After centrifugation, the supernatant was transferred to a new Eppendorf tube and 630 µl 
Isopropanol was added for DNA precipitation. The tube was put at -20ºC for 10 minutes and 
subsequently centrifuged at 20000x g at 4ºC for 20 minutes. After centrifugation, the 
supernatant was discarded and the DNA pellet was washed using 400 µl 70% ethanol. The 
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tube was centrifuged again at 4ºC for 15 minutes. The ethanol was carefully removed and the 
pellet air-dried. The DNA pellet was dissolved in 30 µl TE.  
4.5.5 Determination of DNA concentration 
The DNA concentration was determined either by spectrophotometry or by comparing 
different dilutions of DNA with a standard amount of DNA in an agarose Gel. 
4.5.6 Agarose Gel Electrophoresis  
To test restriction enzyme reactions, size of DNA fragments, estimate DNA concentration, 
DNA fragment extraction, analysis of PCR reactions products, separation of DNA or RNA for 
subsequent Southern or Northern blotting procedures, horizontal agarose gel electrophoresis 
was performed. The agarose concentration of the gel was between 0.7 and 1.5% in 1X TBE 
buffer, depending on the expected size of the DNA bands. The agarose was dissolved in 
boiling TBE in an Erlenmeyer bottle and cooled down to approximately 55ºC. Ethidium 
bromide was added at a concentration of 0.3µg/ml to allow the DNA visualization on the gel 
under UV light The agarose was poured in the gel cassette and allowed to solidify for about 40 
minutes. Before applying the samples, the DNA to be applied was diluted 1:1 in 2X loading 
buffer.  300 ng DNA standard were also loaded to determine the size or to estimate the 
concentration of the fragments separated on the gel. The electrophoresis was carried out at 
room temperature and at constant voltage of (100V for a 13 cm minigel) (Bio-Rad Powerpac 
200).   
4.5.7 DNA Gel Extraction 
For gel extraction of PCR products or DNA enzymatically digested for cloning or 
microinjection, the QIAquick Gel Extraction Kit was used (QIAGEN GmbH, Hilden) 
according to the manufacturater’s instructions.  The desired DNA band visualized on the gel 
under UV light was cut  out using a sterile surgical blade, put into a sterile 1.5 ml Eppendorf 
tube and weighed. For each 100 mg of gel, 300 µl of buffer QG solution was added to the 
tube. The tube was incubated 10 minutes at 50°C. After complete gel dissolution, an amount 
of isopropanol equal to the gel volume was added and the gel was homogenized by vortexing. 
The content of the tube was transferred to the QIAquick column provided in the kit. The tube 
was centrifuged for 1 minute at top speed in a microcentrifuge. The flow-through was 
discarted, the column put back in the same collection tube and 500 µl of buffer QG were 
added to the column to remove all traces of agarose. To wash the column, 750 µl of buffer PE 
containing ethanol were added and the column was centrifuged as in the previous steps. To 
remove ethanol residues from the column, after centrifugation and discarding the flow-
through, the column was centrifuged for one more minute. Then, the column was placed in a 
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new 1.5 ml Eppendorf tube. For elution, 50 µl of EB buffer was pipetted directly to the center 
of the membrane and centrifuged as before. 
The eluted DNA was visualized on an agarose gel to verify the recovered amount from the gel 
and estimate the concentration. 
 
4.5.8 Restriction enzyme digestion of plasmid and genomic DNA 
The restriction digestion of DNA was carried out to determine the size of plasmid DNA 
fragments, for cloning procedures (in this case, vector or insert fragments were purified by gel 
extraction), prior to Southern transfer or to separate the DNA constructs from the vector 
backbone for microinjection.  
 
Table 10: Conditions for restriction enzyme digestion 
Plasmid DNA (testing) Plasmid DNA (cloning) Genomic DNA 
1 µg DNA 5 µg DNA 10 µg DNA 
10 U enzyme 30U enzyme 80 U enzyme 
2 µl enzyme buffer 5 µl enzyme buffer 10 µl enzyme buffer 
H2O to 20 µl H2O to 50 µl H2O to 100 µl 
1 to 2 hours incubation 3 to 4 hours incubation 12 to18 hours incubation 
 
The cleavage reaction was pipetted in a 1.5 ml Eppendorf tube and incubated in a thermoblock 
at the optimal temperature as recommended for each enzyme.    
4.5.9 DNA cloning 
For plasmid construction standard procedures as described by Sambrook and Russel, 2001 
were used. After plasmid preparation, the cDNA was digested with restriction enzymes to 
generate suitable 5´ and 3´ ends for directional cloning, separated by agarose gel 
electrophoresis and purified by gel extraction. The vector and insert concentration was 
estimated by comparing the bands in an ethidium bromide stained agarose gel with known 
amounts of DNA from a DNA ladder. The molar ratio between insert and vector was adjusted 
to about 3:1. The ligation reaction was performed as recommended by the suppliers of T4 
DNA ligase: 
 
x µl vector DNA 
y µl insert DNA 
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1 µl T4 DNA ligase (400U/µl) (New England Biolabs, Frankfurt) 
2 µl T4 DNA ligase buffer 
z µl Water to 20 µl 
The ligation was carried out at room temperature for 2 hours, followed by an overnight 
incubation at 4°C or 16°C.  
4.5.10 Automated fluorescent sequencing of PCR products or plasmid DNA 
For the sequencing reaction, we used a DNA sequencing Kit (ABI Prism Sequencing Kit) and 
the following reagents were pipetted into a 0.2 ml PCR tube as shown in table 11: 
Table 11: Reagents for sequencing reaction 
Reagent Volume (µl) Final Concentration  
DNA 2 0.7 to 1 µg 
Big Dye Sequence Terminator 4  
Sequencing primer 0.5 10 pmol 
Distilled H2O 3.5  
 
The table 12 shows the sequencing program for all the sequencing reactions performed: 
Table 12: Program for Sequencing reaction       
25 cycles 
Denaturation Denaturation Annealing Elongation Cooling 
96°C: 2 min 96°C: 30 sec 50°C: 15 sec 60°C: 4 min 4°C: • 
4.5.11 Cell culture 
The cell culture procedures were carried out in a vertical laminar flow hood (BDK Luft- und 
Reinraumtechnick GmbH) to ensure the sterile conditions required for mammalian cell 
culture. The cells were grown in commercially available cell culture flasks or plates (see table 
3) and incubated at 37ºC in a humid atmosphere containing 5% CO2. The cell culture medium 
used for adherent cells was commercial-available DMEM, supplemented with 10% FCS and 
antibiotics (100U penicillin and 100 ng streptomycin/ml medium). The cells were split 
according to the cell growth rate and density on the culture flasks or plates. In order to 
maintain the cell lines in a stock, 6 millions of healthy cells in the growing phase were 
suspended in 1.5 ml of FCS with 10% DMSO in 1.8 ml cryotubes and frozen in liquid 
nitrogen. The cells were frozen in three cooling steps: Primarily, the suspension of cells was 
chilled in ice for 5 minutes in pre-cold freezing medium. The tubes were transferred to a -80°C 
freezer for two hours and further stored in liquid nitrogen. The table 13 lists the cell lines 
cultivated in this project;    
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Table 13: Cell lines used for co-localization, protein expression and protein-targeting 
studies. 
Cell Line Origin Morphology 
HEK293T* Established from a human primary 
embryonal kidney transformed by 
adenovirus type 5 (Ad 5) 
adherent fibroblastoid cells 
growing as monolayer 
NIH3T3* Swiss mouse embryo adherent fibroblast cells growing as 
monolayer 
• reference  in www.dsmz.de 
 
4.5.12 Examination of CALM/AF10 transgenicity in FVB mice by PCR and Southern 
blotting  
Mouse-tail genomic DNA extraction 
To isolate genomic DNA from mouse tails we followed a protocol that was recommended by 
The Jackson’s Laboratory (www.jax.org/imr/tail_phenol.html): A 0.5cm tail piece from a one 
month old FVB mouse was cut and digested overnight at 50°C on a rotator  (900 rpm) in an 
Eppendorf tube containing 0.5 ml of proteinase K (0.5 mg/ml) diluted in lysis buffer. After 
complete digestion of the tail tissue, 0.7 ml phenol-chloroform-isoamyl alcohol was added to 
the tube and put on the rotator. After one hour, the Eppendorf tube was centrifuged at 14 000 
rpm for 15 minutes at RT. In the tube three phases separated out: the upper phase, containing 
genomic DNA, the middle phase, containing RNA and protein debris and the bottom phase 
containing cell debris. The upper phase was carefully transferred to a new sterile 1.5 ml 
Eppendorf tube. To the supernatant, 1 ml of absolute ethanol was added and the tube was 
mixed for one minute by gentle inversion. The tube was centrifuged  at 4°C (22,800 x g). The 
supernatant was carefully removed and the DNA pellet was washed with 70% ethanol. The 
tube was centrifuged again at top speed at 4°C. The ethanol was further removed and the pellet 
was air-dried for 10 minutes. The genomic DNA was resuspended in TE by pipette 
homogenization and to facilitate DNA solubilization, incubated 65°C for 15 minutes. The 
quality of genomic DNA was assessed by agarose electrophoresis and the concentration 
measured by spectrophotometry. 
Polymerase Chain Reaction (PCR) 
The PCR reaction was used as screening to identify the transgenic mice. The primer used for 
the reaction anneal in CALM and AF10 regions adjacent to the breakpoint of CALM/AF10 in 
the transgenic construct The table 14 illustrates the general condition for genomic DNA PCR     
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Table 14: General setting-up for PCR samples 
Reagent Volume (µl) Final Concentration  
Template DNA (200 ng/µl) 1  10 pg 
Taq polymerase (5 U/µl) 0.125 0.75 U 
Forward primer (10 µM) 0.5  0.25 µM 
Reverse primer (10 µM) 0.5  0.25 µM 
10 X Buffer 2 1 x 
dNTP mix 2 0.2 mM/each 
MgCl2 (50 mM) 0.6 1.5 mM 
 
PCR to verify the mouse DNA quality: 
The PCR program for this primer pair is shown in Table 14: 
 
Table 15: PCR program for STS primers       
  25 cycles   
Denaturation Denaturation Annealing Elongation Cooling 
95°C: 5 min 95°C: 45 sec 56°C: 45 sec 72°C: 45 sec 72°C 7 min; 4°C: • 
Southern Blotting 
To confirm the presence of the transgene, Southern hybridisation was performed.  15 µg of 
mouse genomic DNA was digested overnight at 37°C with EcoR1 and size-fractionated on a 
0.7% agarose gel. The gel was photographed with a ruler before Southern transfer. To improve 
the transfer of DNA fragments bigger than 15 kb, the gel was immersed for 10 minutes in 0.1 
N HCl (acid depurination). The gel was then rinsed with distilled water and soaked for 45 
minutes in several volumes of 1.5 m NaCl, 0.5 N NaOH with constant gentle agitation for 
DNA denaturation. After denaturation, the gel was briefly rinsed in deionized water, and then 
neutralized by soaking for 30 minutes in several volumes of a solution of 1 M Tris (pH 7.4), 
1.5 m NaCl at room temperature with constant, gentle agitation. The neutralization solution 
was changed and the gel incubated for further 15 minutes. While the gel was in the 
neutralization solution, a piece of whatman 3 MM paper was cut in the same size of the 
agarose gel. Another paper was cut to have the same width, but was left long enough to reach 
the bottom of both sides of the electrophoresis chamber used for the blotting. The chamber 
was filled with transfer buffer (10XSSC) until the level of the liquid reached almost the top of 
the gel support. When the 3 MM paper on the top of the support was thoroughly wet, all air 
bubbles were removed using a 10 ml pipette. Using a paper cutter a piece of nitrocellulose 
filter about 1 Mm larger than the gel in both dimensions was cut and floated on the surface of 
a dish containing deionized water until it was completely wet, and then immersed in transfer 
buffer for at least 5 minutes. Using a clean scalpel blade a corner from the nitrocellulose filter 
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was cut to match the cut corner of the gel. The gel was removed from the neutralization 
solution and inverted so that its bottom side was on the top. The inverted gel was placed on the 
support so that it was centred on the wet 3 MM papers. Air bubbles between the 3 MM paper 
and the gel were removed. To prevent liquid flowing directly from the reservoir to the paper 
towels placed on top of the gel, which would impair DNA transfer, sealing film (Nescofilm, 
Carl Roth, Karlsruhe) was placed around the gel and membrane. The wet nitrocellulose was 
placed to the top of the gel, avoiding air bubbles. Two pieces of 3 MM paper (cut to exactly 
the same size as the gel) were wet in 2XSSC and placed top of the wet nitrocellulose filter. On 
top of the last two 3 MM papers, a stack of paper towels (5-8cm high) just smaller than the 3 
MM papers was placed. A glass plate was put on top of the stack and weighed down with a 
500-g weight. The objective was to set up a flow of liquid from the reservoir through the gel 
and the nitrocellulose filter, so that fragments of denatured DNA were eluted from the gel and 
were trapped in the nitrocellulose filter. The transfer was carried out for 14 to 18 hours. After 
the transfer, the presence of ethidium bromide stained DNA on the membrane could be 
observed under UV light. 
DNA labelling 
The labelling of the Southern probes with radiocative isotopes was performed using the 
Megaprime DNA Labelling System (Amersham Biosciences, England). In a 1.5 ml Eppendorf 
tube, 30 ng DNA, 5 ml Primer and 22 ml TE were pipetted to a final volume of 33 µl. The tube 
was put in a thermoblock at 98°C for 5 minutes. After denaturation, the tube was cooled down 
on ice for 5 minutes.  10 ml of 5x reaction buffer (dATP, dGTP, dTTP), 2 ml Klenow fragment 
and 5 ml (50mCi) [a-32P] dCTP were added.  The tube was incubated for 1 hour at 37°C in a 
water bath. After vortexing and centrifugating a microspin column at 3000 rpm for one 
minute, 25 µl TE were added to the labeled DNA probe which was applied on the microspin 
column and centrifuged using the same spin and time. After collecting the probe in a new 
Eppendorf tube, 200 ml salmon sperm DNA (9.5 mg/ml) were added to the solution.  
DNA hybridization on nitrocellulose membranes 
After the DNA transfer, the DNA was cross-linked to the membrane using an UV irradiation. 
The membrane was transferred to a glass tube and pre-heated with 25 ml of pre-hybridization 
solution for 30 minutes at 62°C. 100 µl of salmon sperm were denatured at 100°C and added 
to the pre-hybridization solution with the membrane. The pre-hybridization was carried out for 
a further 2 hours at 62°C. After this time, the labeled probe was denatured at 98°C and added. 
The hybridization was performed overnight at 62°C in a hybridization oven.  
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After the hybridization, the membrane was washed four times at low stringency: twice for 10 
minutes in 2 X SSC at 65°C and twice for ten minutes in 2 X SSC + 0.1% SDS at 65°C. Then 
a high stringency wash for ten minutes with 0.2 X SSC + 0.1% SDS at 65°C. 
Film Exposure 
The membrane was taken out of the tube, wrapped in Saran wrap and put into the film cassette 
(Hypercassete™, Amersham Biosciences, England). The film was put over the membrane and 
the exact location of the membrane on the film was marked with a pen. A first test-exposure 
was carried out for 15 minutes and the film was developed. If the signals on the film were 
weak, the exposure was extended for some hours or even days. In these cases, the film was 
kept at -80°C. 
4.5.13 Transient transfection of mammalian cells 
For co-localization and protein expression experiments, mouse (NIH3T3) or human (293T) 
cell lines were transiently transfected using an activated-dendrimer transfection reagent 
(Hudde et al., 1999) from a commercial kit (PolyFect® Transfection Reagent, Qiagen).  
Protein expression: 
One day before the transfection, cells in an exponential stage of growth were washed once 
with PBS, detached from the 75 cm2 cell culture flasks with 2 ml of trypsin-EDTA solution, 
counted using a Neubauer improved hemocytometer and put in 100 mm cell culture plates at a 
density of 106 cells/plate. 
The plates were 80% confluent on the next day. For the transfection, 23 µg of plasmid DNA 
was suspended in 625 µl of DMEM without FCS and antibiotics. This solution was mixed 
with 135 µl of Polyfect and incubated at room temperature for 10 minutes. To the 
DNA/Polyfect complex, 6.7 ml of complete DMEM medium (with 10% FCS and antibiotics) 
was added and added to the cells. After 2 hours and 30 minutes, the cells were washed once 
with PBS and incubated with new complete DMEM. The transfection efficiency was 
controlled 20 hours later for the expression of the reporter gene using an inverted fluorescence 
microscope (Axiovert 200 Carl Zeiss, Germany). 
Co-localization: 
24 hours before transfection, exponentially growing mouse fibroblast cells (NIH3T3) in 75 
cm2 cell culture flasks were washed, detached and the cell number was determined as 
described. 8 x 104 cells were transferred to a 4-well (2 cm2) special chamber (Lab-Tek II 
Chambered coverglass, Nalge Nunc) with a borosilicate bottom for visualization of cells 
transfected with GFP constructs by fluorescence microscopy. The transfection followed the 
protocol of the manufacturer: Initially, the DNA was suspended in 20 µl of DMEM without 
FCS and antibiotics. To the DNA/medium mix, 2 µl of PolyFect‚ were pipetted and vortexed 
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for 10 sec. The DNA/transfection reagent complex was incubated at RT for 10 min. During 
the incubation time, the cells were washed once with PBS and 300 µl of complete DMEM 
medium was added to the cells. 120 µl DMEM containing 10% FCS and antibiotics were 
added to the DNA complex, the content of the tube was mixed by pipetting up and down and 
added to the cells.  The cells were incubated at 37°C under 5% CO2 atmosphere for 22 to 26 
hours before the cells were examined with the inverted fluorescence microscope. 
Cell fixation for microscopy 
After the observation of the positively transfected cells on the inverted microscope, the cells 
were fixed with formaldehyde as described by Dernburg and Sedat (1998). Briefly, the cell 
culture medium was removed, the cells washed once with PBS and put in a 3% formaldehyde 
diluted in PBS for 10 min at RT. The cells were washed three times with PBS and analysed on 
the microscope or stored at 4°C protected from the light.  
4.5.14 Stable transfection of mammalian cells 
In order to establish stable cell lines for the inducible expression of CALM/AF10, expression 
constructs were trasfected into NIH3T3 cells as described for transient transfection. The 
efficiency of the transfection was evaluated 22 hours after transfection by observing the green 
GFP fluorescence in cells transfected with the pEGFP control plasmid. 48 hours after 
transfection, 1 µg/ml medium with puromycin (was added for the selection of the stably 
transfected cells). The addition of puromycin for the selection was carried out for two weeks.  
 
4.5.15 Obtaining and processing of microscope images 
The transfected cells were observed using an Axiovert 200 fluorescent microscope (Zeiss, 
Germany), the images captured using a digital camera (Hamamatsu C474295) and processed 
in a Power Mac G4 computer using the Open Lab software (Improvision, Heidelberg, 
Germany). The pictures were saved as Tiff files and the images processed using the program 
adobe photoshop. 
4.5.16 Examination of CALM/AF10 expression at RNA Level by Reverse Transcriptase 
PCR and Microarrays 
RNA extraction from frozen cells 
The RNA extraction was performed using a denaturing guanidine isothiocyanate-containing 
buffer for cell lysis and a silica-gel-based membrane for RNA isolation. The reagents and the 
protocol from the Rneasy‚ MiniKit (Qiagen) were used as described: Initially, the cells were 
thawed in a water bath at 37oC and quickly centrifuged at 300 x g for 5 minutes at 4°C. The 
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cell pellet was immediately suspended in lysis solution RLT (350 µl or 600 µl RLT buffer 
with 1% freshly added beta mercaptoethanol depending on the cell number available). The 
sample was homogenized using a QIAshredder spin column and mixed with an equal volume 
of 70% ethanol. The sample was applied to an RNeasy mini column placed in a 2 ml 
collection tube and centrifuged for 15 seconds at 8000 x g. The flow-through was discarded, 
and 700 µl of RW1 buffer was added to the Rneasy column. The column placed in the same 
collection tube was centrifuged as before. The column was transferred into a new 2 ml 
collection tube and 500 µl of buffer RPE were pipetted into the column, which was 
centrifuged as before. This step was repeated and the column was put into a new RNase free 
1.5 ml Eppendorf tube. 30 to 50 µl RNase free water was pipetted into the column for RNA 
elution. The column was centrifuged for one minute at 8000 x g. The RNA obtained was used 
for cDNA systhesis or analyzed with an Affymetrix gene chip array at the laboratory for 
leukemia diagnostics, Department of Medicine III at the Klinikum Grosshadern. The 
expression profiling with the Affymetrix chips was performed by Alexander Kohlmann. 
For microarray analysis, the GeneChip System was used (Affymetrix, Santa Clara, CA). The 
targets for GeneChip analysis were prepared according to the current Expression Analysis 
Technical Manual. 5 to 10 µg total RNA was used as a started material in the subsequent 
cDNA synthesis with oligo [(dT)24T7promotor]65 primer (cDNA Synthesis System, Roche 
Diagnostics). The cDNA was purified by phenol/chlorophorm/isoamylalcohol extraction 
(Ambion, Austin, TX) and acetate/ethanol-precipitated overnight. For detection of the 
hybridized target nucleic acid biotin-labelled ribonucleotides were incorporated during the in 
vitro transcription (Enzo BioArray High Yield RNA Transcript Labelling Kit, Enzo 
Diagnostics). After quantification of the purified cRNA (RNeasy Mini Kit, Qiagen), 15 µg 
was fragmented by alkaline treatment (200 mM Tris-acetate, pH 8.2 / 500 mM potassium 
acetate / 150 mM magnesium acetate) and added to the hybridization cocktail sufficient for 
five hybridizations on standard GeneChip microarray. Before hybridization onto U95Av2, 
Test3 microarrays (AffymetricX) were chosen for monitoring the integrity of the cDNA. 
Washing and staining of the probe arrays were performed according to the current protocols 
(Micro_1v1, EukGE-WS2v2). The Affymetrix software (Microarrays Suite, version 4.0.1) 
extracted fluorescence intensities from each element on the microarrays as detected by 
confocal laser scanning according to the manufacturer’s recommendations. The hybridization 
cocktails which demonstrated high-quality cRNA characteristics were selected for the 
analysis. 
The expression analysis of the patients samples was carried out by Alexander Kohlmann, 
using the unsupervised analysis methods, principal component analysis (PCA) and 
hierarchical clustering. In the PCA, most of expression information is reduced dimensionally 
and represented in a linear transformation matrix. Principal components are the projections of 
the data in a three-dimensional vector. The hierarchical clustering organizes the expression 
data into groups with similar expression signatures (Schock et al., 2004).    
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RNA from FACS-sorted cells 
Cells from spleen, bone marrow or thymus were obtained from organs of mice immediately 
after euthanasia and passed through a cell strainer to obtain separate cells. The cells were 
suspended in DMEM or RPMI containing 15% FCS and the erythrocytes were lysed for 20 
minutes RT using ammonium chloride 1:1 diluted in the cell suspension. The cells were count, 
ressuspended in PBS, transferred to FACS tubes and incubated 20 minutes at 4°C with the 
antibodies used for the cell sorting. After incubation, the cells were washed once (300 x g at 
4°C for 10 minutes) and ressuspended in FACS buffer. Sorted cells were collected in 
eppendorf or FACS tubes containing cell culture medium with 50% FCS. The cells were 
centrifuged and lysed with RLT buffer according to the cell number and the RNA of the sorted 
cells was extracted as as described for frozen cells using the Rneasy‚ MiniKit.  
RNA preparation from mouse tissue 
RNA extraction of mouse tissue was carried out using the peqGOLD TriFast‰ kit (Peqlab 
Biotechnologie GmbH, Germany). This kit is based on guanidine isothiocyanate lysis buffer 
and a phenol chloroform RNA extraction. The tissue RNA extraction was carried out as 
follow: Immediately after resection from euthanized mice, spleen, thymus and bone marrow 
were put into Eppendorf tubes and frozen in liquid nitrogen. The frozen organs were 
subsequently processed or stored at –80°C.  For RNA extraction a steel bar was washed with 
autoclaved bidistilled DEPC-treated (0.1%) water. The frozen organ was transferred to a 15 ml 
falcon tube, which was kept in a vessel containing liquid nitrogen. The steel bar was used to 
grind the organ until it became as fine as sand. The organ fragments were lysed with 1 ml of 
peqGOLD Trifast solution (containing phenol and guanidin isothiocyanate) for each 100 mg 
of organ. After 5 minutes incubation at RT, 0.2 ml chloroform was added and the tube 
vortexed for 15 seconds. The tube was incubated for 3 to 5 minutes at RT and further 
centrifuged at 1400 rpm, RT for 5 minutes. Three phases were obtained after centrifugation: 
the upper phase, containing the RNA, the intermediate phase, containing DNA and protein, 
and the lower phase, containing phenol-chloroform. The upper phase was transferred to a new 
tube and precipitated using 0.5 ml of 100% ethanol for each 1 ml of peqGOLD Trifast solution 
initially used for the lysis. After mixing and centrifuging the tubes (14000 rpm for 15 minutes 
at 4°C), the RNA pellet was washed with 500 µl of 75% ethanol and centrifuged as before. 
The supernatant was carefully removed, the RNA air-dried and resuspended in RNAse free 
water. To assess the RNA quality after extraction, 2 µl of RNA were loaded on a 0.7% agarose 
gel containing ethidium bromide and observed with UV light. 
cDNA synthesis (Reverse Transcriptase Reaction) 
For cDNA synthesis, the reagents and protocols used were purchased from Invitrogen. To 
avoid DNA contamination, the RNA was treated with Deoxyribonuclease I before the cDNA 
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synthesis. For DNase treatment of RNA, 1 µg RNA was mixed with 1 µl 10X DNase I 
reaction buffer, 1 µl DNase I (1 U/µl) and in a total volume of 10 µl. The tube was incubated 
at RT for 40 minutes and the DNase was inactivated by adding 1 µl 25 mM EDTA to the 
Eppendorf tube and incubating at 65°C for ten minutes. After DNase treatment, an RNA 
aliquote was loaded on an agarose gel for quality control and to estimate the RNA 
concentration. For the Reverse Transcriptase reaction,  2 to 4 µl of RNA were pipetted into an 
1.5 ml RNase-free Eppendorf tube together with 1 µl Oligo (dT)12-18, 1 µl 10 MM dNTP mix 
(containing 10 MM each dATP, dGTP, dCTP and dTTP at neutral pH) and sterile water in a 
total volume of 12 µl. The mixture was heated to 65°C for five minutes and quickly chilled on 
ice. To the tube contents 4 µl 5 x First-Strand Buffer, 2 µl 0.1 M DTT and 1 µl RNaseOUT‰ 
were added. The tube contents was mixed and incubated at 42°C. After 2 minutes, 1 µl of 
Superscript‰II Reverse Transcriptase was added, and the incubation at 42 oC was continued 
for 50 Min. The reverse transcriptase was then heat-inactivated at 70°C for 15 min. 
4.5.17 Western blotting 
Sample preparation 
Cell lysis (total cell extract) 
Between 5 to 10x107 cells in a cell culture dish (e.g. transiently transfected 293 cells) were 
lysed using 150 µl RIPA buffer with freshly added protease inhibitors. The cells with the 
RIPA buffer were transferred to an Eppendorf microcentrifuge tube and mixed by inversion 
for 30 minutes at 4°C. After this step, the sample was centrifuged at 14000 rpm for 30 minutes 
and the supernatant was transferred to a new Eppendorf tube, the protein concentration was 
determined by the Bradford method (see below) and frozen at -80°C.   To obtain protein 
extracts form the tissues of transgenic mice, 50 to 100 mg of organ tissue (e.g. thymus or 
spleen) were taken from euthanized mice and frozen in liquid nitrogen. The organs were 
smashed using a steel bar in a 15 ml falcon tube submersed in liquid nitrogen to avoid thawing 
of the sample. After complete rupture of the tissue, RIPA buffer was added to the cells and the 
lysis procedure was carried out as described above.  
Determination of Protein Concentration 
Protein concentrations were determined with the Bradford (Bio-Rad Protein Assay, Germany) 
method. The assay is based on the observation that the absorbance maximum for an acidic 
solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 nm when binding to 
protein occurs. Both hydrophobic and ionic interactions stabilize the anionic form of the dye, 
causing a visible color change. The extinction of a dye-albumin complex solution is 
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proportional to the protein amount over a 10-fold concentration range (5-25 µg/ml). The 
protein concentration of the sample was determined by comparing the extinction of the sample 
to values obtained from a range of protein standards. The protein standard used was Bovine 
Serum Albumin (BSA). Six different amounts of albumin (2.5 µg, 5 µg, 10 µg, 15 µg, 20 µg 
and 25 µg) were diluted in distilled water to a final volume of 800 µl. One µl of cell lysate was 
diluted in distilled water for the measurement. 200 µl of Protein Assay solution was added to 
the tubes. The tubes were incubated at RT for 15 minutes. For the measurements in 
spectrophotometer polystyrol cuvettes (10x4x45 mm Sarstedt, Germany) were used.  
Protein gel electrophoresis 
Total cell extract (TCE) proteins were separated with SDS-PAGE . A 5% polyacrylamid 
stacking gel and a 6 to 10% separation gel (tris-glycine buffer) were used (Sambrook and 
Russel, 2001). The protein lysates were diluted 1:1 with 2x loading buffer and heated in a 
boiling water bath for 10 minutes. 80 µg of protein in 15 to 30 µl volume was loaded in each 
gel lane. The electrophoresis was performed with constant voltage (100 V for a 15 cm gel) for 
1 hour and 30 minutes in the cold room at 4°C. 
Western blotting and Detection 
After electrophoresis, the gel was taken from the cassette and washed once with TBS. For the 
blotting, the wet system was used (Bio-Rad Miniprotean‚ II system, Biorad Laboratories, 
Germany). To permit a better transfer of large molecular weight proteins such as 
CALM/AF10, which has a predicted size of about 170 kDa, a PVDF membrane was chosen 
after comparing the transfer efficiency between PVDF and nitrocellulose. The PVDF 
membrane was wetted in methanol for 30 seconds, rinsed in distilled water and equilibrated in 
transfer buffer for 10 minutes. The transfer system was assembled by putting a sponge on the 
bottom of the sandwich (in contact to the negative pole), a 0.8 mm filter paper in contact to the 
sponge, and the gel on the paper. Care was taken to eliminate all air bubbles in the stack. The 
transfer assembly was completed by another filter and a second sponge. The PVDF membrane 
was oriented to the positive pole to permit the protein (negatively charged) to migrate from the 
gel to the membrane. The transfer was performed at constant amperage of 250 mA for 4 hours 
at 4°C with buffer recirculation. The observation of the high molecular weight proteins of the 
pre-stained protein standard (SeeBlue Plus2, Invitrogen, Germany) on the membrane was used 
as an indicator for successful transfer. The proteins were fixed by air-drying to the membrane. 
The antibody-detection of protein was performed following the instructions of the antibody’s 
supplier (Santa Cruz Biotechnology, USA). After the transfer, the membrane was blocked to 
prevent non-specific binding of antibodies to the membrane by incubating with Blotto A 
buffer for one hour at room temperature or overnight at 4°C with constant agitation. All 
incubation of the membrane were performed in a 50 ml Falcon tube on a roller mixer (CAT 
RM5 Digisystem Laboratory Instruments Inc ). The membrane was washed once with TBS for 
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five minutes and incubated with the primary antibody at the appropriate dilution (e.g. 1:1000 
in 4 ml volume) in Blotto A overnight. After incubation with the primary antibody, the 
membrane was washed three times with TBS 0.05% Tween-20 (TBST). The secondary 
antibody conjugated to Horse Radish Peroxidase (HRP) was diluted 1:2000 in Blotto A (4 ml) 
and put on the membrane for a 45 to 90 minutes-incubation at room temperature. The 
membrane was rinsed with distilled water, washed again tree times with TBST and once with 
TBS for 5 minutes. To detect the antibodies on the membrane, a commercial 
chemiluminescence kit (ECL Western blotting Detection Reagents Amersham Biosciences, 
Germany) was used according to the manufacturer’s instructions. After washing, the ECL 
detection solution (0.125 ml/cm2 membrane) was put on the membrane for 90 seconds. The 
exceeding amount of ECL was removed from the membrane using tissue paper. The 
membrane was covered with a plastic film and put in a film cassette and exposed to a 
chemiluminescence film4 for various exposure times (15 sec to 10 minutes). 
4.5.18 Blood analysis of transgenic mice 
Venous blood from transgenic mice was obtained from the orbital sinus using a 
microhematocrit tube under general anaesthesia with ethyl ether. The blood was collected in 
an EDTA microtube (Mikro-Probengefass, Sarstedt, Germany), mixed gently by inverting ten 
times and analyzed within two hours after blood collection (Jain, 1993). A blood smear was 
made on a glass slide at the collection time and air dried before staining. For the staining, the 
glass slide was put in a chamber with May-Grünwald solution for three minutes, washed with 
distilled water for two minutes, and immersed in a chamber with a 10% Giemsa solution for 
30 minutes. After Giemsa staining, the slide was washed again with distilled water and air-
dried. The cell morphology and relative blood cell count were analyzed with a standard optic 
microscope (Carl Zeiss, Germany). The complete blood cell count was performed using a 
Neubauer hemocytometer. For counting the erythrocytes, the blood was diluted 1:1000 in 
PBS, and for counting the leukocytes dilution was  1:50 in PBS with 3% glacial acetic acid for 
red blood cell lysis. The hematological values obtained were compared to reference values for 
the FVB/N mouse strain (www.jax.org). 
 
                                            
4 Hyperfilm‰ECL Amersham Biosciences 
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4.5.19 Flow cytometry 
In order to analyse the development of the lymphoid lineages of the transgenic mice, spleen, 
thymus, lymph nodes and bone marrow cells were taken and analyzed for the expression of 
surface antigens. The mice were euthanized as described, the organs removed and the cells 
harvested and passed trough a cell strainer to obtain a cell suspension. The cells were 
suspended in RPMI1640 with 5% FCS and put on ice. The cell number was determined by 
counting using a Neubauer chamber as described above (chapter 4.5.16). 100,000 cells were 
resuspended in 100 µl PBS and incubated with different fluorescence–conjugated antibodies 
against cell surface markers for 20 min on ice avoiding light exposure. After incubation, the 
cells were washed once with PBS (300 x g for 10 minutes at 4oC) and ressuspended in 100 µl 
of FACS buffer for immediate analysis or stored with PBS-4% paraformaldehyde solution at 
4°C under light protection for subsequent analysis. Antibodies used for FACS were labelled 
with phycoerythrin for Gr-1, CD11b (Mac-1), Sca-1, Ter119, CD4, CD19, CD23, CD24, 
CD43, sIgM, F4/80 and allophycocyanin conjugated CD11b (Mac-1), CD117 (c-kit), B220, 
and CD8. Fluorescence was detected using a FACSCalibur flow cytometer and analyzed using 
the CellQuest software. Dead cells were gated out by high propidium iodide (PI) staining and 
forward light scatter. 
4.5.20 Post mortem analysis of transgenic mice 
Transgenic and control FVB mice were anesthetized with ethyl ether and euthanized by 
cervical dislocation. The mice were wetted with 70% ethanol, put on a clean paper towel and 
fixed to a corkboard with their limbs. The dissection instruments were autoclaved and soaked 
in ethanol before use.  A vertical, ventral, midline incision was made from the neck to pubis. 
The skin was stretched laterally and pinced to the board. The peritoneum was opened and the 
diaphragm cut along the border of the ribs. The mouse was submersed in a vessel containing a 
4% paraformaldehyde solution for at least 24 hours. The post mortem and histo-pathological 
examination were performed at the Institute of Pathology, GSF, Neuherberg by Dr. 
Quintanilla-Fend. 
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5. RESULTS 
5.1. Cell Biology 
5.1.1.Sequencing of CALM/AF10  
The CALM/AF10 fusion gene used in all experiments was derived from the the U937 cell line 
(Dreyling et al., 1996) and had been cloned in Prof. Bohlander laboratory in Chicago and 
Göttingen into the pEGFP-C1 vector (Clontech). The CALM/AF10 cDNA was cloned in 
frame at the C-terminus of the EGFP coding sequence using Xho I and SacII sites at the amino 
and carboxy terminal ends, respectively. This construct was verified by sequencing before 
starting the cloning of the construct that was used in this thesis. The sequencing revealed 
almost the whole cDNA sequence of CALM (exons one to twenty, without exon 18) with the 
breakpoint at nucleotide 2091 of the CALM sequence (Dreyling et al., 1996) (gene bank 
accession number NM_001008660). The breakpoint in AF10 was located at nucleotide 424, 
corresponding to the start of exon 8. The cDNA of AF10 in this clone corresponds to the 
transcript variant 1 of AF10 (accession NT_004641) and lacks exons 18, 19 and 20. The AF10 
sequence in this insert has a different 3' end from the published AF10 reference sequence 
(Chaplin et al., 1995) (accession NT_004641). In our sequenced AF10 fragment, there are 123 
extra nucleotides between exon 28 and 29. The sequence of the complete CALM/AF10 insert 
with the restriction enzyme sites XhoI at the 5’ end and SacII at the 3’ end is shown in the 
figure 4. 
 
                       10           20           30            40           50           60 
            CT CGA GGT CGA CGG TAT CGG GGG ATC GAT CCG CAT GCG AGC TCG GTA CCC CGG CTG CTG 
       XhoI 
                       70           80            90          100          110             
            AGC GGG TGG GGT GGT GGA GGA GCT GCA GAG ATG TCC GGC CAG AGC CTG ACG GAC CGA ATC 
                                                     M   S   G   Q   S   L   T   D   R   I> 
          120          130          140           150          160          170             
            ACT GCC GCC CAG CAC AGT GTC ACC GGC TCT GCC GTA TCC AAG ACA GTA TGC AAG GCC ACG 
             T   A   A   Q   H   S   V   T   G   S   A   V   S   K   T   V   C   K   A   T> 
          180          190          200           210          220          230             
            ACC CAC GAG ATC ATG GGG CCC AAG AAA AAG CAC CTG GAC TAC TTA ATT CAG TGC ACA AAT 
             T   H   E   I   M   G   P   K   K   K   H   L   D   Y   L   I   Q   C   T   N> 
          240          250          260           270          280          290             
            GAG ATG AAT GTG AAC ATC CCA CAG TTG GCA GAC AGT TTA TTT GAA AGA ACT ACT AAT AGT 
             E   M   N   V   N   I   P   Q   L   A   D   S   L   F   E   R   T   T   N   S> 
          300          310          320           330          340          350             
            AGT TGG GTG GTG GTC TTC AAA TCT CTC ATT ACA ACT CAT CAT TTG ATG GTG TAT GGA AAT 
             S   W   V   V   V   F   K   S   L   I   T   T   H   H   L   M   V   Y   G   N> 
          360          370          380           390          400          410             
            GAG CGT TTT ATT CAG TAT TTG GCT TCA AGA AAC ACG TTG TTT AAC TTA AGC AAT TTT TTG 
             E   R   F   I   Q   Y   L   A   S   R   N   T   L   F   N   L   S   N   F   L> 
          420          430          440           450          460          470             
            GAT AAA AGT GGA TTG CAA GGA TAT GAC ATG TCT ACA TTT ATT AGG CGG TAT AGT AGA TAT 
             D   K   S   G   L   Q   G   Y   D   M   S   T   F   I   R   R   Y   S   R   Y> 
          480          490          500           510          520          530             
            TTA AAT GAG AAA GCA GTT TCA TAC AGA CAA GTT GCA TTT GAT TTC ACA AAA GTG AAG AGA 
             L   N   E   K   A   V   S   Y   R   Q   V   A   F   D   F   T   K   V   K   R> 
          540          550          560           570          580          590             
            GGG GCT GAT GGA GTT ATG AGA ACA ATG AAC ACA GAA AAA CTC CTA AAA ACT GTA CCA ATT 
             G   A   D   G   V   M   R   T   M   N   T   E   K   L   L   K   T   V   P   I> 
          600          610          620           630          640          650             
            ATT CAG AAT CAA ATG GAT GCA CTT CTT GAT TTT AAT GTT AAT AGC AAT GAA CTT ACA AAT 
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             I   Q   N   Q   M   D   A   L   L   D   F   N   V   N   S   N   E   L   T   N> 
          660          670          680           690          700          710             
            GGG GTA ATA AAT GCT GCC TTC ATG CTC CTG TTC AAA GAT GCC ATT AGA CTG TTT GCA GCA 
             G   V   I   N   A   A   F   M   L   L   F   K   D   A   I   R   L   F   A   A> 
          720          730          740           750          760          770             
            TAC AAT GAA GGA ATT ATT AAT TTG TTG GAA AAA TAT TTT GAT ATG AAA AAG AAC CAA TGC 
             Y   N   E   G   I   I   N   L   L   E   K   Y   F   D   M   K   K   N   Q   C> 
          780          790          800           810          820          830             
            AAA GAA GGT CTT GAC ATC TAT AAG AAG TTC CTA ACT AGG ATG ACA AGA ATC TCA GAG TTC 
             K   E   G   L   D   I   Y   K   K   F   L   T   R   M   T   R   I   S   E   F> 
          840          850          860           870          880          890             
            CTC AAA GTT GCA GAG CAA GTT GGA ATT GAC AGA GGT GAT ATA CCA GAC CTT TCA CAG GCC 
             L   K   V   A   E   Q   V   G   I   D   R   G   D   I   P   D   L   S   Q   A> 
          900          910          920           930          940          950             
            CCT AGC AGT CTT CTT GAT GCT TTG GAA CAA CAT TTA GCT TCC TTG GAA GGA AAG AAA ATC 
             P   S   S   L   L   D   A   L   E   Q   H   L   A   S   L   E   G   K   K   I> 
          960          970          980           990         1000         1010             
            AAA GAT TCT ACA GCT GCA AGC AGG GCA ACT ACA CTT TCC AAT GCA GTG TCT TCC CTG GCA 
             K   D   S   T   A   A   S   R   A   T   T   L   S   N   A   V   S   S   L   A> 
         1020         1030         1040          1050         1060         1070             
            AGC ACT GGT CTA TCT CTG ACC AAA GTG GAT GAA AGG GAA AAG CAG GCA GCA TTA GAG GAA 
             S   T   G   L   S   L   T   K   V   D   E   R   E   K   Q   A   A   L   E   E> 
         1080         1090         1100          1110         1120         1130             
            GAA CAG GCA CGT TTG AAA GCT TTA AAG GAA CAG CGC CTA AAA GAA CTT GCA AAG AAA CCT 
             E   Q   A   R   L   K   A   L   K   E   Q   R   L   K   E   L   A   K   K   P> 
         1140         1150         1160          1170         1180         1190             
            CAT ACC TCT TTA ACA ACT GCA GCC TCT CCT GTA TCC ACC TCA GCA GGA GGG ATA ATG ACT 
             H   T   S   L   T   T   A   A   S   P   V   S   T   S   A   G   G   I   M   T> 
         1200         1210         1220          1230         1240         1250             
            GCA CCA GCC ATT GAC ATA TTT TCT ACC CCT AGT TCT TCT AAC AGC ACA TCA AAG CTG CCC 
             A   P   A   I   D   I   F   S   T   P   S   S   S   N   S   T   S   K   L   P> 
         1260         1270         1280          1290         1300         1310             
            AAT GAT CTG CTT GAT TTG CAG CAG CCA ACT TTT CAC CCA TCT GTA CAT CCT ATG TCA ACT 
             N   D   L   L   D   L   Q   Q   P   T   F   H   P   S   V   H   P   M   S   T> 
         1320         1330         1340          1350         1360         1370             
            GCT TCT CAG GTA GCA AGT ACA TGG GGA GAT CCT TTC TCT GCT ACT GTA GAT GCT GTT GAT 
             A   S   Q   V   A   S   T   W   G   D   P   F   S   A   T   V   D   A   V   D> 
         1380         1390         1400          1410         1420         1430             
            GAT GCC ATT CCA AGC TTA AAT CCT TTC CTC ACA AAA AGT AGT GGT GAT GTT CAC CTT TCC 
             D   A   I   P   S   L   N   P   F   L   T   K   S   S   G   D   V   H   L   S> 
         1440         1450         1460          1470         1480         1490             
            ATT TCT TCA GAT GTA TCT ACT TTT ACT ACT AGG ACA CCT ACT CAT GAA ATG TTT GTT GGA 
             I   S   S   D   V   S   T   F   T   T   R   T   P   T   H   E   M   F   V   G> 
         1500         1510         1520          1530         1540         1550             
            TTC ACT CCT TCT CCA GTT GCA CAG CCA CAC CCT TCA GCT GGC CTT AAT GTT GAC TTT GAA 
             F   T   P   S   P   V   A   Q   P   H   P   S   A   G   L   N   V   D   F   E> 
         1560         1570         1580          1590         1600         1610             
            TCT GTG TTT GGA AAT AAA TCT ACA AAT GTT ATT GTA GAT TCT GGG GGC TTT GAT GAA CTA 
             S   V   F   G   N   K   S   T   N   V   I   V   D   S   G   G   F   D   E   L> 
         1620         1630         1640          1650         1660         1670             
            GGT GGA CTT CTC AAA CCA ACA GTG GCC TCT CAG AAC CAG AAC CTT CCT GTT GCC AAA CTC 
             G   G   L   L   K   P   T   V   A   S   Q   N   Q   N   L   P   V   A   K   L> 
         1680         1690         1700          1710         1720         1730             
            CCA CCT AGC AAG TTA GTA TCT GAT GAC TTG GAT TCA TCT TTA GCC AAC CTT GTG GGC AAT 
             P   P   S   K   L   V   S   D   D   L   D   S   S   L   A   N   L   V   G   N> 
         1740         1750         1760          1770         1780         1790             
            CTT GGC ATC GGA AAT GGA ACC ACT AAG AAT GAT GTA AAT TGG AGT CAA CCA GGT GAA AAG 
             L   G   I   G   N   G   T   T   K   N   D   V   N   W   S   Q   P   G   E   K> 
         1800         1810         1820          1830         1840         1850             
            AAG TTA ACT GGG GGA TCT AAC TGG CAA CCA AAG GTT GCA CCA ACA ACC GCT TGG AAT GCG 
             K   L   T   G   G   S   N   W   Q   P   K   V   A   P   T   T   A   W   N   A> 
         1860         1870         1880          1890         1900         1910             
            GCA ACA ATG GCA CCC CCT GTA ATG GCC TAT CCT GCT ACT ACA CCA ACA GGC ATG ATA GGA 
             A   T   M   A   P   P   V   M   A   Y   P   A   T   T   P   T   G   M   I   G> 
         1920         1930         1940          1950         1960         1970             
            TAT GGA ATT CCT CCA CAA ATG GGA AGT GTT CCT GTA ATG ACG CAA CCA ACC TTA ATA TAC 
             Y   G   I   P   P   Q   M   G   S   V   P   V   M   T   Q   P   T   L   I   Y> 
         1980         1990         2000          2010         2020         2030             
            AGC CAG CCT GTC ATG AGA CCT CCA AAC CCC TTT GGC CCT GTA TCA GGA GCA CAG AGA TGT 
             S   Q   P   V   M   R   P   P   N   P   F   G   P   V   S   G   A   Q   R   C> 
         2040         2050         2060          2070         2080         2090             
            GAA CTT TGT CCC CAT AAG GAT GGA GCT TTA AAA AGA ACA GAT AAT GGG GGT TGG GCC CAT 
             E   L   C   P   H   K   D   G   A   L   K   R   T   D   N   G   G   W   A   H> 
         2100         2110         2120          2130         2140         2150             
            GTG GTT TGT GCC CTG TAT ATT CCA GAG GTA CAA TTT GCC AAT GTT TCC ACA ATG GAA CCA 
             V   V   C   A   L   Y   I   P   E   V   Q   F   A   N   V   S   T   M   E   P> 
         2160         2170         2180          2190         2200         2210             
            ATT GTT TTA CAG TCT GTT CCG CAT GAT CGT TAT AAT AAG ACT TGC TAC ATT TGT GAT GAA 
             I   V   L   Q   S   V   P   H   D   R   Y   N   K   T   C   Y   I   C   D   E> 
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         2220         2230         2240          2250         2260         2270             
            CAA GGA AGA GAA AGC AAA GCA GCC ACT GGT GCT TGC ATG ACA TGT AAT AAA CAT GGA TGT 
             Q   G   R   E   S   K   A   A   T   G   A   C   M   T   C   N   K   H   G   C> 
         2280         2290         2300          2310         2320         2330             
            CGA CAG GCT TTC CAT GTA ACA TGC GCT CAG TTT GCC GGA CTG CTT TGT GAA GAA GAA GGT 
             R   Q   A   F   H   V   T   C   A   Q   F   A   G   L   L   C   E   E   E   G> 
         2340         2350         2360          2370         2380         2390             
            AAT GGT GCC GAT AAT GTC CAA TAC TGT GGC TAC TGT AAA TAC CAT TTT AGT AAG CTG AAA 
             N   G   A   D   N   V   Q   Y   C   G   Y   C   K   Y   H   F   S   K   L   K> 
         2400         2410         2420          2430         2440         2450             
            AAG AGC AAA CGG GGA TCT AAT AGG TCA TAT GAT CAA AGT TTA AGT GAT TCT TCC TCT CAC 
             K   S   K   R   G   S   N   R   S   Y   D   Q   S   L   S   D   S   S   S   H> 
         2460         2470         2480          2490         2500         2510             
            TCT CAG GAT AAA CAT CAT GAG AAA GAG AAA AAA AAA TAT AAA GAG AAG GAC AAA CAC AAA 
             S   Q   D   K   H   H   E   K   E   K   K   K   Y   K   E   K   D   K   H   K> 
         2520         2530         2540          2550         2560         2570             
            CAG AAA CAC AAG AAG CAG CCA GAA CCA TCA CCT GCA TTG GTT CCA TCC TTG ACT GTT ACT 
             Q   K   H   K   K   Q   P   E   P   S   P   A   L   V   P   S   L   T   V   T> 
         2580         2590         2600          2610         2620         2630             
            ACA GAA AAA ACT TAT ACA AGC ACT AGC AAC AAC TCT ATA TCT GGA TCA TTG AAG CGC TTG 
             T   E   K   T   Y   T   S   T   S   N   N   S   I   S   G   S   L   K   R   L> 
         2640         2650         2660          2670         2680         2690             
            GAA GAT ACT ACT GCA CGA TTT ACA AAT GCA AAT TTC CAG GAA GTC TCT GCA CAC ACC TCT 
             E   D   T   T   A   R   F   T   N   A   N   F   Q   E   V   S   A   H   T   S> 
         2700         2710         2720          2730         2740         2750             
            AGT GGA AAA GAT GTT TCA GAG ACT AGA GGG TCA GAG GGC AAA GGG AAG AAA TCT TCA GCT 
             S   G   K   D   V   S   E   T   R   G   S   E   G   K   G   K   K   S   S   A> 
         2760         2770         2780          2790         2800         2810             
            CAC AGC TCA GGT CAA AGG GGA AGA AAG CCT GGT GGT GGA AGA AAT CCA GGA ACA ACT GTG 
             H   S   S   G   Q   R   G   R   K   P   G   G   G   R   N   P   G   T   T   V> 
         2820         2830         2840          2850         2860         2870             
            TCA GCA GCT AGC CCT TTT CCT CAA GGC AGT TTT TCA GGA ACT CCA GGC AGT GTA AAG TCA 
             S   A   A   S   P   F   P   Q   G   S   F   S   G   T   P   G   S   V   K   S> 
         2880         2890         2900          2910         2920         2930             
            TCT TCT GGA AGT TCA GTG CAG TCT CCC CAG GAT TTC CTG AGC TTT ACA GAC TCA GAT CTG 
             S   S   G   S   S   V   Q   S   P   Q   D   F   L   S   F   T   D   S   D   L> 
         2940         2950         2960          2970         2980         2990             
            CGT AAT GAC AGT TAC TCT CAC TCC CAA CAG TCA TCA GCA ACC AAA GAT GTA CAT AAA GGA 
             R   N   D   S   Y   S   H   S   Q   Q   S   S   A   T   K   D   V   H   K   G> 
         3000         3010         3020          3030         3040         3050             
            GAG TCT GGA AGC CAG GAA GGG GGG GTA AAT AGT TTT AGT ACC TTA ATT GGC CTC CCT TCA 
             E   S   G   S   Q   E   G   G   V   N   S   F   S   T   L   I   G   L   P   S> 
         3060         3070         3080          3090         3100         3110             
            ACC TCA GCT GTT ACT TCA CAG CCT AAA AGC TTT GAA AAT TCA CCT GGA GAT TTG GGT AAT 
             T   S   A   V   T   S   Q   P   K   S   F   E   N   S   P   G   D   L   G   N> 
         3120         3130         3140          3150         3160         3170             
            TCC AGC CTT CCT ACA GCA GGA TAT AAG CGG GCT CAA ACT TCT GGC ATA GAA GAA GAA ACT 
             S   S   L   P   T   A   G   Y   K   R   A   Q   T   S   G   I   E   E   E   T> 
         3180         3190         3200          3210         3220         3230             
            GTA AAG GAA AAG AAA AGG AAA GGA AAT AAA CAA AGT AAG CAT GGG CCT GGC AGA CCC AAA 
             V   K   E   K   K   R   K   G   N   K   Q   S   K   H   G   P   G   R   P   K> 
         3240         3250         3260          3270         3280         3290             
            GGA AAC AAA AAT CAA GAG AAT GTT TCT CAT CTC TCA GTT TCT TCT GCT TCA CCA ACA TCA 
             G   N   K   N   Q   E   N   V   S   H   L   S   V   S   S   A   S   P   T   S> 
         3300         3310         3320          3330         3340         3350             
            TCT GTA GCA TCA GCT GCA GGA AGC ATA ACA AGC TCT AGT CTG CAG AAA TCT CCT ACA TTG 
             S   V   A   S   A   A   G   S   I   T   S   S   S   L   Q   K   S   P   T   L> 
         3360         3370         3380          3390         3400         3410             
            CTC AGG AAT GGA AGT TTA CAG AGC CTC AGT GTT GGC TCA TCT CCA GTT GGT TCA GAA ATT 
             L   R   N   G   S   L   Q   S   L   S   V   G   S   S   P   V   G   S   E   I> 
         3420         3430         3440          3450         3460         3470             
            TCC ATG CAG TAT CGG CAT GAT GGA GCT TGC CCA ACA ACT AGT ATT TAT AAC AGC AAT GAT 
             S   M   Q   Y   R   H   D   G   A   C   P   T   T   S   I   Y   N   S   N   D> 
         3480         3490         3500          3510         3520         3530             
            GTA GCA GTA TCG TTT CCA AAT GTA GTA TCT GGC TCG GGA TCT AGT ACT CCT GTC TCC AGC 
             V   A   V   S   F   P   N   V   V   S   G   S   G   S   S   T   P   V   S   S> 
         3540         3550         3560          3570         3580         3590             
            TCT CAC TTA CCT CAG CAG TCT TCT GGG CAT TTG CAA CAA GTA GGA GCG CTC TCT CCC TCA 
             S   H   L   P   Q   Q   S   S   G   H   L   Q   Q   V   G   A   L   S   P   S> 
         3600         3610         3620          3630         3640         3650             
            GCT GTG TCA TCT GCA GCC CCT GCT GTT GCT ACA ACT CAG GCA AAT ACT CTA TCT GGA TCT 
             A   V   S   S   A   A   P   A   V   A   T   T   Q   A   N   T   L   S   G   S> 
         3660         3670         3680          3690         3700         3710             
            TCT CTC AGT CAG GCA CCA TCT CAT ATG TAT GGC AAT AGA TCA AAT TCA TCA ATG GCA GCT 
             S   L   S   Q   A   P   S   H   M   Y   G   N   R   S   N   S   S   M   A   A> 
         3720         3730         3740          3750         3760         3770             
            CTT ATA GCT CAG TCT GAA AAC AAT CAA ACA GAT CAA GAT CTT GGA GAC AAT AGC CGC AAC 
             L   I   A   Q   S   E   N   N   Q   T   D   Q   D   L   G   D   N   S   R   N> 
         3780         3790         3800          3810         3820         3830             
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            CTA GTT GGC AGA GGA AGC TCA CCC CGA GGA AGT CTC TCG CCA CGA TCC CCT GTA AGC AGC 
             L   V   G   R   G   S   S   P   R   G   S   L   S   P   R   S   P   V   S   S> 
         3840         3850         3860          3870         3880         3890             
            TTA CAG ATT CGC TAT GAT CAA CCA GGC AAC AGC AGT TTG GAA AAT CTG CCT CCA GTA GCA 
             L   Q   I   R   Y   D   Q   P   G   N   S   S   L   E   N   L   P   P   V   A> 
         3900         3910         3920          3930         3940         3950             
            GCC AGC ATA GAA CAG CTT TTG GAG AGG CAG TGG AGT GAA GGA CAG CAA TTT TTA CTA GAA 
             A   S   I   E   Q   L   L   E   R   Q   W   S   E   G   Q   Q   F   L   L   E> 
         3960         3970         3980          3990         4000         4010             
            CAG GGT ACT CCT AGT GAC ATT TTA GGA ATG CTG AAG TCA TTA CAC CAA CTT CAA GTT GAA 
             Q   G   T   P   S   D   I   L   G   M   L   K   S   L   H   Q   L   Q   V   E> 
         4020         4030         4040          4050         4060         4070             
            AAC CGA AGA TTA GAG GAA CAA ATT AAA AAC TTG ACT GCC AAA AAG GAA CGG CTT CAG TTA 
             N   R   R   L   E   E   Q   I   K   N   L   T   A   K   K   E   R   L   Q   L> 
         4080         4090         4100          4110         4120         4130             
            TTG AAT GCA CAG CTT TCA GTG CCT TTT CCA ACA ATA ACA GCA AAT CCT AGT CCG TCT CAT 
             L   N   A   Q   L   S   V   P   F   P   T   I   T   A   N   P   S   P   S   H> 
         4140         4150         4160          4170         4180         4190             
            CAA ATA CAC ACA TTT TCA GCA CAG ACT GCT CCT ACT ACT GAT TCC TTG AAC AGC AGT AAG 
             Q   I   H   T   F   S   A   Q   T   A   P   T   T   D   S   L   N   S   S   K> 
         4200         4210         4220          4230         4240         4250             
            AGC CCT CAT ATA GGA AAC AGC TTT TTA CCT GAT AAT TCT CTT CCT GTA TTA AAT CAG GAC 
             S   P   H   I   G   N   S   F   L   P   D   N   S   L   P   V   L   N   Q   D> 
         4260         4270         4280          4290         4300         4310             
            TTA ACC TCC AGT GGA CAA AGT ACC AGC AGC TCA TCA GCT CTT TCT ACC CCA CCT CCT GCT 
             L   T   S   S   G   Q   S   T   S   S   S   S   A   L   S   T   P   P   P   A> 
         4320         4330         4340          4350         4360         4370             
            GGG CAG AGT CCG GCT CAA CAA GGC TCA GGA GTG AGT GGA GTT CAG CAG GTC AAT GGC GTG 
             G   Q   S   P   A   Q   Q   G   S   G   V   S   G   V   Q   Q   V   N   G   V> 
         4380         4390         4400          4410         4420         4430             
            ACA GTG GGG GCA CTA GCT AGT GGA ATG CAG CCT GTA ACT TCC ACC ATT CCT GCC GTG TCT 
             T   V   G   A   L   A   S   G   M   Q   P   V   T   S   T   I   P   A   V   S> 
         4440         4450         4460          4470         4480         4490             
            GCA GTG GGT GGA ATA ATT GGA GCT TTG CCA GGT AAC CAA CTG GCA ATT AAT GGC ATT GTA 
             A   V   G   G   I   I   G   A   L   P   G   N   Q   L   A   I   N   G   I   V> 
         4500         4510         4520          4530         4540         4550             
            GGA GCT TTA AAT GGG GTT ATG CAG ACT CCT GTC ACA ATG TCC CAG AAC CCT ACC CCT CTC 
             G   A   L   N   G   V   M   Q   T   P   V   T   M   S   Q   N   P   T   P   L> 
         4560         4570         4580          4590         4600         4610             
            ACC CAC ACA ACC GTA CCA CCT AAT GCA ACA CAT CCA ATG CCA GCT ACA CTG ACT AAC AGT 
             T   H   T   T   V   P   P   N   A   T   H   P   M   P   A   T   L   T   N   S> 
         4620         4630         4640          4650         4660         4670             
            GCC TCA GGA CTA GGA TTA CTT TCT GAC CAG CAA CGA CAA ATA CTT ATT CAT CAA CAG CAG 
             A   S   G   L   G   L   L   S   D   Q   Q   R   Q   I   L   I   H   Q   Q   Q> 
         4680         4690         4700          4710         4720         4730             
            TTT CAG CAG TTG TTA AAT TCT CAA CAG CTC ACA CCA GAA CAA CAT CAA GCC TTT TTG TAT 
             F   Q   Q   L   L   N   S   Q   Q   L   T   P   E   Q   H   Q   A   F   L   Y> 
         4740         4750         4760          4770         4780         4790             
            CAG TTA ATG CAA CAT CAC CAC CAG CAG CCG CAC CAA CCT GAA CTT CAG CAG CTG CAG ATC 
             Q   L   M   Q   H   H   H   Q   Q   P   H   Q   P   E   L   Q   Q   L   Q   I> 
         4800         4810         4820          4830         4840         4850             
            CCT GGA CCA ACA CAA ATA CCC ATA AAC AAC CTT CTT GCA GGT ACA CAG GCA CCC CCA CTT 
             P   G   P   T   Q   I   P   I   N   N   L   L   A   G   T   Q   A   P   P   L> 
         4860         4870         4880          4890         4900         4910             
            CAC ACA GCT ACC ACC AAC CCA TTT CTC ACC ATC CAT GGA GAT AAT GCA AGT CAG AAA GTA 
             H   T   A   T   T   N   P   F   L   T   I   H   G   D   N   A   S   Q   K   V> 
         4920         4930         4940          4950         4960         4970             
            GCA AGA CTT AGT GAT AAA ACT GGG CCT GTA GCT CAA GAG AAA AGT TGA CAC CTG AGA AAC 
             A   R   L   S   D   K   T   G   P   V   A   Q   E   K   S   *   H   L   R   N> 
         4980         4990         5000    
            ATC TAG AGC GGC CGC CAC CGC GG SacII 
             I   *   S   G   R   H   R   G> 
 
Figure 4: Sequence of the insert CALM/AF10 from XhoI to SacII. The restriction sites 
for these enzymes are underlined. The colored nucleotides represent the last 
nt. of CALM (red, 2091 in the genomic cDNA sequence) and the first nt. of 
AF10 (blue, 424 in the genomic cDNA sequence) close to the breakpoint.      
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5.1.2.Sub-cellular localization and co-localization of CALM/AF10, CALM and AF10 
Cloning 
In order to analyse the sub-cellular localization and co-localization of CALM/AF10, CALM 
and AF10, the corresponding open-reading frames were cloned in frame with the genes coding 
for the Enhanced yellow Protein and Enhanced Cyan Protein (Clontech expression vectors 
pEYFP and pECFP). A co-localization using CFP and YFP fluorescent vectors fused to the 
gene of interest allowed us to determine the localization of the fusion proteins in the cell. 
Before these cloning steps, we modified the 3’ region of the CALM/AF10 coding sequences in 
the pEGFP-CALM/AF10 plasmid to eliminate extra stop codons present in a region between 
two Xba1 restriction sites at the positions 6404 and 6568, figure 71 (appendix). One 
microgram of this vector was cut with Xba1, religated overnight (16°C) and transformed into 
XL1-Blue bacteria as described in the methods section.  Recombinant plasmids were 
sequenced and the modified pEGFP-CALM/AF10 vector lacking the region between 
nucleotides 6458 and 6622 in this vector was named pEGFP-CALM/AF10dXba1.  Two 
micrograms of pEGFP-CALM/AF10dXba1 was digested first with the restriction enzyme 
SacII. This first digestion was controlled on an agarose gel and the linearized DNA was cut 
with the enzymes XhoI (the enzyme chosen for the cloning in the correct reading frame of the 
pEYFP and pECFP) and Nsi1. The digestion with NsiI allowed us to cut the vector backbone 
and easily identify the CALM/AF10 insert on the agarose gel. After digestion and separation 
by eletrophoresis, the CALM/AF10 digested fragment was cut and extracted from the gel. 
Following the gel extraction, the expected size of the insert was verified on an agarose gel and 
the concentration was estimated by visually comparing the band to a known concentration of 
the DNA standard (1 Kb Ladder Invitrogen Life Technologies, Germany).  The digestion, 
separation and gel extraction procedures are shown for CALM/AF10 in figure 5 (A, B and C).  
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Figure 5: pEGFP-CALM/AF10 digested with XhoI, SacII and NsiI, separated on an 
0.8% agarose gel in TBE, stained with ethidium bromide (0.3µg/ml) and 
visualized under ultra violet light Digested product (A), CALM/AF10 
fragment cut from the gel (B), insert after gel extraction (C). 
 
To clone the CALM/AF10 insert into the vectors pEYFC-C1 and pECFP-C1, the vectors were 
digested with XhoI and SacII. Insert and vectors were ligated (overnight at 16°C) to each other 
and transformed into XL1-Blue bacteria. Recombinant plasmids were sequenced across the 5’ 
cloning site to confirm that the insert was in frame with the CFP or YFP open reading frame. 
For sequencing the 5’ pEGFP primer EGFPC 1240-1258 was used.  The CALM coding region 
clone used for the colocalization experiments had been cloned by Professor Stefan Bohlander 
into the vector pEGFP-C1 using the same enzymes as for CALM/AF10 coding region (Xho1 
and SacII). The CALM cDNA was cut out from this vector using Xho1 and SacII and cloned 
into pEYFP-C1 and pECFP-C1 using the same restriction enzyme sites. The resulting 
constructs were named: pEYFP-CALM and pECFP-CALM. In order to obtain a CFP-AF10 
(with the full length AF10 coding region) construct, we amplified the first 550 nucleotides of 
AF10 (encoding the first 80 amino acids of AF10 which are absent in the CALM/AF10 
fusion). The 5’ primer (AF10 T182) contained an XhoI site and the 3’ primer (AF10 B728) 
contained a SalI restriction site.  The 5’ AF10 fragment amplified by these two primers 
contains a Sal1 restriction enzyme site at position 668 of AF10. This 5’ AF10 fragment was 
cut with Xho1 and Sal1 and inserted into pECFP-CALM/AF10dXba1 from which the CALM 
coding region and part of AF10 had been removed using these two enzymes. The product of 
this cloning procedure was the pECFP-AF10 construct. The proteins which are encoded by 
these constructs are schematically represented in the figures 6, 7, 8 and 9. 
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Figure 6: Schematic representation of the protein encoded by the pEYFP-
CALM/AF10dXba1 construct. 
 
 
Figure 7: Schematic representation of the protein encoded by the pECFP-
CALM/AF10dXba1 construct. 
 
 
Figure 8: Schematic representation of the protein encoded by the pEYFP-CALM 
construct. 
 
 
Figure 9: Schematic representation of the protein encoded by the pECFP-AF10 
construct. 
 
Transfection and sub-cellular localization experiments 
We analysed the sub-cellular localization of fluorescent protein tagged CALM, AF10 and 
CALM/AF10 proteins by transiently expressing these proteins in the mouse fibroblast cell line 
NIH3T3. Cells were observed between 20 and 26 hours after transfection with an inverted epi-
fluorescence microscope. In these experiments, CALM and CALM/AF10 localize in the 
cytoplasm of the cells and they co-localize in co-transfected cells (Figures 11 and 12).  CFP-
AF10 localizes to the nucleus in a speckled pattern and does not obviously colocalize with 
CALM or CALM/AF10. A fraction of YFP-CALM/AF10 can also be seen in the nucleus 
(figure 10 and 14, A and C).  The nuclear fraction of YFP-CALM/AF10 seems to be enriched 
in big spots in the nucleus which might correspond to nucleoli. We cannot rule out that some 
of the nuclear YFP-CALM/AF10 co-localizes with CFP-AF10. However, most of the nuclear 
fraction of YFP-CALM/AF10 and CFP-AF10 seem to occupy distinct areas in the nucleus 
(fig. 14). Figures 10 to 14 illustrate the sub-cellular localization results 
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Figure 10: NIH3T3 cell transiently transfected with pECFP-AF10. Visualization with 
CFP filter. Scale = 10 mm 
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Figure 11: NIH3T3 cell transiently transfected with pEYFP-CALM. Visualization with
YFP filter. Scale = 10 μm
Figure 12: NIH3T3 cell transiently transfected with pECFP-CALM/AF10. Visualization
with CFP filter. Scale = 10 μm
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Figure 13: NIH3T3 cell transiently co-transfected with pECFP-AF10 and pEYFP-
CALM. Visualization under YFP filter (A), CFP filter (B) and merged image 
(C). Scale = 10 mm 
 
 
Figure 14: NIH3T3 cell transiently co-transfected with pECFP-AF10 and pEYFP-
CALM/AF10. Visualization with YFP filter (A), CFP filter (B) and merged 
image (C). Scale = 10 mm 
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Protein expression  
In order to confirm expression of the AF10, CALM and CALM/AF10 proteins in our 
fluorescent constructs, we over-expressed the proteins in the human embryonal kidney cell 
line (HEK293T) and performed Western analysis. We monitored the complete transfer of the 
proteins to the PVDF membrane by observing the transfer of the pre-stained molecular weight 
protein standard bands. The incubation time of the primary antibodies had to be optimized to 
18 hours at 4°C. We could detect the proteins YFP-CALM and CALM/AF10 and the 
endogenous CALM using a pool of the commercial anti-CALM antibodies (S-19, G-17 and C-
18) (figure 16). The YFP-CALM, GFP-CALM/AF10 and CFP-AF10 proteins were also 
detected using an anti-GFP antibody (Figures 15 to 17). 
 
 
 
Figure 15: 6%SDS PAGE, Western blot of protein extract (80µg/lane) from 293 cells 
transiently-transfected with pEYFP-CALM/AF10 (A) and non-transfected 
(B), incubated with an rabbit anti-GFP antibody (1:3000 in blotto A) for 2 
hours at RT. Secondary antibody, donkey anti-rabbit HRP-conjugated. 
Detection using ECL chemiluminescence’s kit, exposure-time of 15 sec. The 
arrow shows the band corresponding to the YFP-CALM/AF10 protein 
(expected molecular weight 207 kDa). 
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Figure 16: 6%SDS PAGE, Western blot of protein extract (80 µg/lane) from HEK293T 
cells transiently-transfected with pEYFP-CALM/AF10 (A) and non-
transfected (B). The primary antibodies used were Anti- CALM C-18, S-19 
and G-17, each diluted 1:1000 in blotto A, incubated over night at 4°C. 
Secondary antibody: donkey anti-goat HRP-conjugated. Detection using ECL 
chemiluminescence’s kit with exposure time of 30 sec. The upper arrow shows 
the band corresponding to the YFP-CALM/AF10 protein (expected molecular 
weight 207kDa). The two lower arrows indicate two bands of the endogenous 
CALM protein (expected molecular weight about 70 kDa). 
 
 
Figure 17: 10%SDS-PAGE, Western blot of protein extracts (50µg/lane) from HEK293T 
cells transiently-transfected with pECFP-AF10 (A), pEYFP-CALM (B), 
pEGFP-C1 (C) and non-transfected cells (D), incubated with rabbit anti-GPF 
antibody 1:3000. Secondary antibody: donkey anti-rabbit HRP-conjugated. 
Detection using ECL chemiluminescence’s kit, exposure time of 20 sec.The 
bands observed in the lanes A, B, and C correspond to the fusion proteins 
CFP-AF10, YFP-CALM and the GFP protein, respectively. 
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5.2. Transgenic Mice 
5.2.1. FVB mice expressing CALM/AF10 under control of a IgH enhancer/promoter 
Cloning of the transgenic construct 
In order to achieve transgenic expression of CALM/AF10 in B- cell precursors, we designed a 
construct in which the expression of CALM/AF10 was controlled by the IgH 
enhancer/promoter. To enhance post-transcriptional processing (splicing etc.) of the transgene, 
a small intron and a poly-adenylation signal (SV-40 splice/polyA fragment) were introduced 
at the 3’ end of the CALM/AF10 encoding sequences. We designed two primer pairs to 
amplify the IgH enhancer/promoter (1 kb) and the SV-40 splice/polyA fragment (1.6 kb) from 
the plasmid pPepB-Splice (table 6). The amplified products were cloned into the PCR 
fragment cloning vector pGEMT‚-easy™. The primers (IgHStartXhoI and IgHProEndSac1) 
for the IgH enhancer/promoter contained the enzymes XhoI (5’) and SacI (3’). The primers for 
the amplification of the SV-40 splice/polyA fragment (SV40splStartXba1 and 
SV40polAEndNot1) contained the restriction enzyme sites for XbaI (5’) and NotI (3’). First 
the SV-40 splice/polyA fragment was inserted 5’ of the CALM/AF10 cDNA via the Xho1 and 
Sac1 sites. This order of cloning was chosen because an Xba1 site is present in the IgH 
enhander/promoter fragment. The final construct was named pIGCASV-40 and is shown in 
figure 18.  
 
 
 
Figure 18: Schematic representation of the pIGCASV-40 construct. 
 
Generation of transgenic lines 
After cloning the construct was linearized for the microinjection into the male pronucleus of 
zygotes from FVB mice. The transgenic construct was liberated from the vector backbone by 
digesting with the restriction enzymes MluI and NsiI. The linearized construct was 
eletrophoretically separated from the vector backbone and purified by gel extraction. To 
estimate the concentration of the linearized transgenic construct, the DNA was loaded in 
different amounts on an agarose gel together with a standard concentration of the DNA ladder. 
Figure 19 illustrates the DNA concentration estimation. 
 
Results 
  
68 
 
Figure 19: Agarose gel electrophoresis (0.7%, stained with Ethidium bromide (0.3µg/ml), 
visualized under ultra-violet light) of the linearized pIGCASV-40 for 
estimation of the concentration by comparison with the DNA 1Kb Ladder. The 
1,6 kb (arrow) fragment of the ladder represents 10% of the total DNA 
contained in the ladder. 
 
The linearized construct was filter sterilized with a syringe filter (0.2  m) and the DNA 
concentration was adjusted to 2 ng/ml TE, pH 7.4, as recommended by Ms. Tamara Holy, who 
performed the microinjection and embryo-transfer procedures at the Gene Center. The mice 
generated by the microinjection and embryo transfer procedures were tested at 4 weeks of age, 
when the end of the tail (0.5cm) was taken for genomic DNA extraction and PCR testing. For 
the pIGCASV-40 transgenic construct, two lines were generated. The parameters of the 
transgenic mouse generation are summarized in the table16: 
Table 16: Parameters from the generation of transgenic mice with the pIGCASV- 40 
construct 
Number of injected embryos 673 
Viable embryos 365 
Transferred embryos 356 
Negative sections* 7 
Number of transfers** 16 
Embryonic reabssortion in uterus   14 
Mice born 22 
Number of dead new born mice 9 
Number of transgenic mice 2 
IgH transgenic lines generated 2 
 * Negative sections refers to euthanized non-pregnant receptor female  
** Number of embryo transfer procedures to receptor female mice   
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Identification of transgenic mice 
PCR 
Transgenic mice were identified by PCR using genomic DNA as template. In order to verify 
the integrity and quality of the genomic DNA extracted from the mouse tails, a control PCR 
was performed using the primer pair D10Mit105, which amplifies a sequence tagged site 
(STS) on mouse chromosome 10. The PCR product has a length range between 145 and 189 
bp depending on the mouse strain (www.informatics.jax.org/searches/probe.cgi?44349). 
Primers binding at the CALM and AF10 sequence close to the breakpoint of the fusion gene 
were used to identify CALM/AF10 transgenic mice (see figure 18 for primer location). Figure 
20 illustrates the PCR screening of pIGCASV-40 mice. 
 
Figure 20: PCR screening of pIGCASV-40 transgenic mice. Primer pair used:  NAT501 
(CALM1998-2023) and AF10949B (AF10949-929). Size of the CALM/AF10 
fragment: 593bp. PCR conditions: 35 cycles, annealing temperature 58°C.The 
positive control used was 30 pg of the transgenic construct mixed with wild 
type mouse genomic DNA. Approximately 100 ng of genomic DNA were used 
as template in each reaction. 
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Southern Blotting 
Southern blotting was used to confirm the PCR results and to determine the number of 
transgene integration sites in the mouse lines. We could observe one integration site of the 
transgenic construct in the lines 1 and 2 of the pIGCASV-40 mice (figure 21a). Figure 21b 
illustrates the pIGCASV-40 construct which was linearized with the enzymes Mlu1 and Xho1 
for the microinjection in FVB mouse zygote for the trangene mouse generation. The figure 
shows also the position of the fragment SV-40 used as radioactive probe for the Southern 
analysis and the position of the EcoR1 restriction site. The genomic DNA was digested with 
EcoR1 
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Figure 21a: Southern blot analysis of pIGCASV-40 transgenic mice. Lanes 1 and 2 
contained 20 mg of genomic DNA digested overnight with EcoR1 and 
hybridized with 30ng of P32-labelled SV-40 probe. 48 hours exposure. This 
southern was performed together with the pLCKCASV-40 mice, and the 
negative control is shown in the figure 41a. 
 
 
 
Figure 21b: Schematic representation of the pIGCASV-40 transgenic construct, with the 
restriction enzyme sites used for cloning or linearization for the transgenic 
mouse generation and the position of the sequence used as a radioactive probe 
for the Southern blot analysis. The transgenic construct was linearized with 
Xho1 and Mlu1 before microinjection.  
Analysis of transgene expression by RT-PCR 
In order to verify the expression of CALM/AF10 in different organs and cell types, we 
extracted RNA from different haematological and non haematological tissues and from sorted 
cells representing specific haematological cell lineages and performed expression analysis by 
RT-PCR. Prior to the cDNA synthesis, the RNA was treated with DNase A (Invitrogen) to 
eliminate any contaminating genomic DNA containing the CALM/AF10 transgene. This 
genomic DNA contamination would result in an amplification product of the same size as the 
product amplified from the CALM/AF10 cDNA. Before cDNA synthesis, the RNA treated 
with DNase A was used as PCR template to verify that no genomic DNA was present. The 
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pictures 22 to 27 show the results obtained from the PCR of the different organs of the 
pIGCASV-40 mice, lines 1 and 2 for Gapdh and CALM/AF10. The organs analysed were 
blood, bone marrow, spleen, thymus, lungs, skeletal muscle and brain. Figures 24 and 27 
illustrate the expression of the CALM/AF10 transgene, showing stronger expression of 
CALM/AF10 in haematological organs. In order to confirm and analyse the specific expression 
of CALM/AF10 in the different blood cell types, we FACS sorted (Fluorescent Activated Cell 
Sorting) cells from spleen and bone marrow with lineage specific cell surface antibodies. The 
cell populations were: B220 positive and negative cells from spleen (B-lymphoid cells), Gr-1+ 
Mac-1+ double positive cells (myeloid lineage), CD117 (cKit) / Sca-1 double positive cells 
(progenitor cells) and the Sca-1 positive cells from the bone marrow. The house-keeping gene 
controls and the expression results of CALM/AF10 in the sorted subpopulations are illustrated 
in the figures 28 to 31. 
CALM/AF10 was expressed differently between the transgenic lines 1 and 2: In the line 1, 
CALM/AF10 transcripts could be detected in splenocytes B220 positive and B220 negative 
cells, in the myeloid Gr-1+Mac-1+ double positive cells and CD117 (c-Kit) negative / Sca-1 
positive cells cells from the bone marrow. In the line 2, only the B220 negative cells and in a 
lower intensity, the B220 positive cells were expressed CALM/AF10.  
 
 
Figure 22: RT-PCR for cDNA quality control from different organs of pIGCASV-40 
mouse Line 1. RNA digested with DNaseI without reverse transcriptase as 
negative control for blood cDNA (blood -). Primer pair used: mouse Gapdh. 
PCR conditions: 30 cycles, annealing temperature 60°C. 
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Figure 23: PCR of DNase-diggested mouse RNA form different organs of pIGCASV-40 
mouse Line 1. Positive control: 2 ng of pIGCASV-40 plasmid. Primer pair 
used: mouse gapdh. PCR conditions: 30 cycles, annealing temperature 60°C. 
 
 
Figure 24: RT-PCR of different organs of pIGCASV-40 mouse Line 1. Primer pair used: 
CALM(1900-1920), AF10(448-424). PCR conditions: 30 cycles, annealing 
temperature 56°C. 
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Figure 25: RT-PCR for cDNA quality control from different organs of pIGCASV-40 
mouse Line 2. Primer pair used: mouse Gapdh. PCR conditions: 30 cycles, 
annealing temperature 60°C. 
 
Figure 26: PCR of DNase-diggested mouse RNA for quality control from different 
organs of pIGCASV-40 mouse Line 2. Primer pair used: mouse Gapdh. PCR 
conditions: 35 cycles, annealing temperature 60°C. 
 
 
Figure 27: RT-PCR of different organs of pIGCASV-40 mouse Line 2 showing 
expression of the CALM/AF10 transgene. Primer pair used: CALM(1900-
1920), AF10(448-424). PCR conditions: 30 cycles, annealing temperature 
56°C. 
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Figure 28:RT-PCR for cDNA quality control from sorted cells from spleen (B220 + and -
) and bone marrow (Gr-1, Mac-1, Sca-1 and cKit) of pIGCASV-40 mouse
Lines 1 and 2. Primer pair used: mouse Hprt. PCR conditions: 30 cycles,
annealing temperature 59°C.
Figure 29: PCR for RNA quality control from sorted cells from spleen (B220 + and -)
and bone marrow (Gr-1, Mac-1, Sca-1 and cKit) of pIGCASV-40 mouse Lines
1 and 2. RNA digested with DNaseI as negative control for cDNA of sorted
cells. Primer pair used: mouse Hprt. PCR conditions: 30 cycles, annealing
temperature 59°C.
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Figure 30: RT-PCR of sorted cells from spleen (B220 + and -) and bone marrow (Gr-1, 
Mac-1, Sca-1 and cKit) of pIGCASV-40 mouse Line 1 showing expression of 
the CALM/AF10 transgene. Primer pair used: CALM(1900-1920), AF10(448-
424). PCR conditions: 30 cycles, annealing temperature 56°C. 
 
 
Figure 31: RT-PCR of sorted cells from spleen (B220 + and -) and bone marrow (Gr-1, 
Mac-1, Sca-1 and cKit) of pIGCASV-40 mouse Line 2 showing expression of 
the CALM/AF10 transgene. Primer pair used: CALM(1900-1920), AF10(448-
424). PCR conditions: 30 cycles, annealing temperature 56°C. 
 
Analysis of transgene expression by Western blot 
Western blot analysis was performed with cell extracts of thymus, liver and spleen of 
pIGCASV-40 mice lines 1 and 2, and HEK293T cells transiently transfected with pEYFP-
CALM/AF10 as positive control. The technical procedures and antibodies used were the same 
as described for the transiently transfected cells on page 64. We were not able to detect 
CALM/AF10 protein in any of the lines.  
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Analysis of the phenotype of the transgenic mice 
The transgenic mice from the lines 1 and 2 were observed up to 15 months and no clinical 
alteration was observed when comparing to the wild type mice.  The body weight of 29 
transgenic was compared with 28 wild type adult mice (ages between 8 and 15 months) and 
there was no significative difference. Because the transgene was expected to be expressed 
specifically in B-cell progenitors (Eckhardt, 1992; Harris et al., 1988), we analysed the 
hematopoietic system by hemogram, serum immunoglobulin concentration, flow cytometry of 
splenocytes, bone marrow cells and blood. Histopathologic and immunohistopatological 
analysis was also carried out to assess any alteration of the hematopoietic system in the 
transgenic mice.   
Hemogram 
Hemograms of 45 adult transgenic and 21 wild type FVB mice aged between 5 months and 
one year were done to observe hematological difference between transgenic and control mice. 
The white blood cell (WBC) count and red blood cell (RBC) count and the WBC differential 
count was performed. The RBC count of the transgenic mice was 6.36 x 109 + 0.91 x 109 
cells/ml and 6.22 x 109 + 0.57 x 109 cells/ml for the control mice. The WBC count of the 
transgenic mice was 3.44 x 106 + 1.22 x 106 cells/ml and 3.59 x 106 + 1.09 x 106 cells/ml in the 
control mice. The total WBC and RBC count did not differ significantly between transgenic 
and control mice (p>0.05). On the microscopical examination, there was no morphological 
difference observed between transgenic and control mice blood cells. There was no statistical 
difference in the WBC differential between transgenic animals of pIGCASV-40 mice lines 1 
and 2 and control animals. The hematological values and the U Mann-Withney statistic test for 
non paired samples results are shown in the table 17. 
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Table 17: Median, median standard-deviation and statistic results for WBC differential 
count values for pIGCASV-40 mice lines 1 and 2 
Median ± standard deviation pIGASV-40 
mice 
WBC 
Positive* Negative** 
P value Result 
Lymph 87.00 ± 10.95 83.00 ± 4.03 0.2212 POS = NEG 
Neutr 8.00 ± 8.28 9.00 ± 3.89 0.8721 POS = NEG 
Mono 4.00 ± 4.37 6.00 ± 3.35 0.0509 POS = NEG 
Eosin 0.00 ± 1.30 1.00 ± 0.98 0.5929 POS = NEG 
L1 
Baso 0.00 ± 0.53 0.00 ± 0.37 0.9604 POS = NEG 
Lymph 78.50 ± 12.41 80.50 ± 13.27 0.6719 POS = NEG 
Neutr 15.00 ± 8.00 11.00 ± 9.60 0.8157 POS = NEG 
Mono 6.00 ± 6.06 7.00 ± 5.24 0.7504 POS = NEG 
Eos 0.00 ± 1.37 0.00 ± 0.99 0.7470 POS = NEG 
L2 
Baso 0.00 ± 0.85 0.00 ± 0.36 0.4952 POS = NEG 
*n = 27 (L1), n = 18 (L2) ** n = 10 (L1) n = 11 (L2) 
  
Analysis of the phenotype at the immunological level 
In order to detect any alterations in B-cell function in the pIGCASV-40 transgenic mice, the 
serum of five transgenic mice from the line 1, four transgenic mice from the line 2 and 11 wild 
type mice was analyzed. The samples were sent to the Institute of Pathology of the Technical 
University and the concentrations of the antibodies: IgA, IgG1, IgG2a, IgG2b, IgG3 and IgM 
were measured by ELISA. These tests were carried out by Olaf Gross at the Institute of 
Pathology of the Technical University of Munich. The values obtained for the optical density 
for the different serum antibodies were statistically analysed using the T- Students test for non 
paired samples considering the populations with similar variance and comparing the 
transgenic mice (Tg) and the wild type control mice (WT) from the two lines. The 
measurements were performed at different time points for the different lines and their 
respective controls. These results are graphically illustrated in the figure 32. 
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Figure 32: Graphic representation of serum immunoglobulin values for pIGCASV-40 
mice lines 1 and 2 and controls.  
 
Flow cytometry 
Analysis of immunophenotype of WBCs in blood, bone marrow and spleen was performed by 
flow cytometry aiming to observe any difference between transgenic and wild type mice in the 
WBC cell distribution in these organs. The cells were obtained from organs of euthanized 
mice and incubated with the antibodies as described in the methods section. The surface 
markers analyzed were: for the stem cell compartment: c-Kit and Sca-1, for the myeloid 
progenitor compartment Gr-1, Mac-1, and for the lymphoid compartment: B220, CD19, CD43 
and CD3. The distribution of the cell types was compared between transgenic and wild-type 
mice using the t-Test (p>0.05). The results are shown in the tables 22 to 25 (appendix) and 
graphically represented in the figures 33 to 35. 
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Immunophenotype of Blood Cells from pIGCASV-40 Mice
0 20 40 60 80 100
B220+CD43-
B220- CD43+
B220+CD43+
B220+CD19-
B220-CD19+
B220+CD19+
B220+CD3-
B220-CD3+
B220+CD3+
Gr-1+ Mac-1 -
Mac-1+ Gr-1 -
Gr-1+ Mac-1+
c-Kit+ Sca-1- 
Sca1+ c-Kit-
c-Kit+ Sca-1+
% positive cells
Control n = 5
Transgenic n = 7
 
Figure 33: Immunophenotype of blood cells from pIGCASV-40 mice and FVB control, 
graphic representation showing the average values of c-Kit, B220, Mac-1, Gr-
1, CD3, CD19 and CD43 positive WBCs.  
Immunophenotype of Bone Marrow Cells from pIGCASV-40 mice
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Figure 34: Immunophenotype of bone marrow cells from pIGCASV-40 mice and FVB 
control, graphic representation showing the average values of c-Kit, B220, 
Mac-1, Gr-1, CD3, CD19 and CD43 positive WBCs  
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Immunophenotype of Splenic Cells from pIGCASV-40 Mice
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Figure 35: Immunophenotype of splenic cells from pIGCASV-40 mice and FVB control, 
graphic representation showing the average values of c-Kit, B220, Mac-1, Gr-
1, CD3, CD19 and CD43 positive WBCs  
 
Analysis of the phenotype of the pIGCASV-40 mice at the pathological level 
Histopathology 
 
In order to observe any pathological alterations in the transgenic mice related to the expression 
of CALM/AF10 in transgenic lines 1 and 2, we sent four mice to Dr. Leticia Quintanilla-Fend 
at the Institute of Pathology of the GSF Research Center for Environment and Health in 
Neuherberg. At the time point of this analysis, the mice were kept in a temporary facility 
without specific pathogen free (SPF) conditions and presented positive serology for the mouse 
hepatitis virus.  The histologic examination of kidneys, liver, spleen, intestine, thymus and 
mesenteric lymph nodes from the control mouse revealed no alterations. For the mouse from 
the line 1, the same organs were analyzed as described above.  The small intestine showed 
increased number of plasma cells in the lamina propria with mild atrophy of the villi.  No 
evident Peyer´s patches could be observed.  The liver showed conspicuous regenerative 
changes with nodules of hepatocytes with large nuclei.  Another prominent feature was a 
marked hypertrophy and hyperplasia of Kupffer cells and sinusoidal lining cells, which were 
often laden with pigment.  Focally, small inflammatory infiltrates with necrosis of hepatocytes 
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were found.  The mesenterial lymph node showed germinal center hyperplasia accompanied 
by hyperplasia of the paracortical area.  The thymus and the spleen had a normal appearance. 
The mouse from the pIGCASV-40 line 2 had the same organs analyzed as described above.  
The small intestine also showed increased number of plasma cell in the lamina propia. 
However, the plasma cell infiltration was less prominent than the one observed in the animal 
from the line 1. The mesenteric lymph nodes showed paracortical hyperplasia with the 
presence of multiple histiocytes.  The kidneys showed focal infiltration with plasma cells. In 
some areas mitotic figures could be observed in the plasma cells.  The liver, thymus and 
spleen appeared normal. Figures 36a to 36c show the alterations observed in these mice. 
 
 
 
 
 
Figure 36a: Histopathology of pIGCASV-40 transgenic mice. Pictures in the line A show 
mesentheric lymph nodes exhibiting germinal center and paracortical area 
hyperplasia (ID2, Line 1 and ID3, line 2). The pictures in the line B show 
increased number of plasma cells (arrows) in the lamina propria of the small 
intestines. These alterations were not observed in the control animal. 
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Figure 36b: Histopathology of pIGCASV-40 transgenic mice from the lines 1 and 2. 
Pictures in the line A show the liver from a mouse from the pIGCASV-40, line 
2 showing regenerative changes with nodules of hepatocytes with large nuclei 
(arrows middle picture). Marked hypertrophy and hyperplasia of Kupfer cells 
and sinusoidal lining cells, often laden with pigment (arrows, last picture). The 
pictures at line B show focal plasma cell infiltrations in kidney (arrows). 
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Figure 36c: Immunohistopathology of a pIGCASV-40 transgenic mouse from the line 2. 
The pictures show immunohystochemistry for B-cells (B220) confirming the 
plasma cell infiltration previously described in the kidney.  Spleen and thymus 
showed normal distribution of T and B cells, as detected with B220 and CD3 
antibodies. CA = central arteriole.  
 
 
After this first analysis, all the transgenic mice were transferred to the SPF facilities at the 
Gene Center and, from these animals, we sent 2 clinically healthy adult mice of each line and 
2 control-littermates with ages of 15 months for pathological analysis. All transgenic mice 
analyzed showed pathological alterations in the lungs, such as papillary adenocarcionomas or 
papillary adenomas. The term adenocarcionoma is used according to the recommendations of 
the mouse models of Human Cancers Consortium for the classification of proliferative 
pulmonary lesions of the mouse (Nikitin et al., 2004). Four adult mice (3 from the line 1 and 1 
from the line 2) showing severe dyspnea and weight loss were sacrificed and sent for 
pathological analysis and the same pulmonary lesions were found. Figure 37 shows a 
euthanized mouse that was sent to pathology and figure 38 illustrates the pathological findings 
found in these mice. The control mice had normal lungs and did not show any other 
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pathological findings. There were no plasma cell abnormalities in these animals as observed in 
the previous pathological analysis. 
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Figure 37: Macroscopic view of a pIGCASV-40 transgenic mouse from the line 1. The 
arrow indicates a lung tumor diagnosed as papillary adenocarcinoma on 
histopathology 
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Figure 38: Lung tumors observed in pIGCASV-40 transgenic mice from lines 1 and 2. 
Picture 1 shows a macroscopic view of the lung of a mouse from the line 1 with 
an evident tumor. Picture 2a and 2b show the histopathology of the same 
organ with well differentiated papillary adenocarcinoma.  Pictures 3a and 3b 
show two papillary adenomas from the same mouse. Pictures 4a and 4b show 
two papillary adenomas from a mouse from the line 2. Staining: hematoxilin-
eosin. 
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5.2.2. FVB mice expressing CALM/AF10 under the control of the proximal Lck 
promoter 
Cloning of the transgenic construct 
CALM/AF10 transcripts have been detected in several patients with T-ALL (Silliman et al., 
1998; Narita et al., 1999; Bohlander et al., 2000; Asnafi et al., 2003 and Ou et al., 2004). With 
the objective of expressing CALM/AF10 in T-cell precursors, we decide to use the Lck 
proximal promoter, reported as to induce gene expression specifically into immature T-cell 
populations (Allen et al., 1992; Brenner et al., 2001).  
The proximal murine Lck promoter was amplified by PCR primers (MLCKprom64-
84topXho1 and MLCKprom702-681bottomSac1) from mouse genomic DNA (Garvin et al., 
1988). The 5’ primer contained an Xho1 restriction site and the 3’ primer a Sac1 restriction 
site. Using an XhoI and SacI digest, the IgH promoter/enhancer fragment was released from 
the pIGCASV-40 plasmid and replaced by the 630 bp proximal Lck promoter fragment. The 
resulting pLCK-CASV-40 construct was used for transgenic mouse production and is 
schematically shown in figure 39. 
 
Figure 39: Schematic representation of the pLCKCASV-40 construct. 
 
Generation of transgenic lines 
 
The transgenic construct was purified from the vector backbone and prepared for pro-nucleus 
injection as described above for the pIGCASV-40. The parameters for the generation of the 
transgene mice for this construct are summarized in the table 18. 
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Table 18: Parameters for the generation of transgenic mice with the pLCKCASV-40 
construct 
Number of injected embryos 377 
Viable embryos 259 
Transferred embryos 247 
Negative sections* 2 
Number of transfers** 11 
Embryonic re-absorption in uterus   22 
Number of mice born 21 
Number of dead new born mice 0 
Number of transgenic mice 3 
LCK transgenic lines generated 3 
* Negative sections refers to euthanized non-pregnant receptor female  
** Number of embryo transfer procedures to receptor female mice   
 
Identification of transgenic mice 
PCR 
Transgenic pLCKCASV-40 mice were identified by PCR using genomic DNA as template as 
described for the pIgCASV-40 transgenic mice. 
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Figure 40: PCR screening of pLCKCASV-40 transgenic mice. Primer pair used: 
CALM(1730-1753) and AF10(1086-1066). Expected size of PCR product in the 
transgenic animals: 1000bp. conditions: 35 cycles, annealing temperature 
58°C. cDNA from two CALM/AF10-positive patient samples were used as 
positive control. Note that the CALM/AF10 fusion transcripts in the patients 
have different breakpoints from the CALM/AF10 fusion used for the 
generation of the transgenic mice. These different fusion breakpoints result in 
smaller PCR products in the positive controls. 
 
Southern Blot Analysis 
Southern blot analysis was carried out to confirm the presence of the transgene in the founder 
mice and to determine the number of transgenic integrations in the mouse lines obtained. 
Although the mice from the line 3 tested positive by PCR for the CALM/AF10 transgene, 
using the SV-40 probe we could not identify any positive band on Southern blot analysis in 
more than 10 blots with different enzymes for the genomic DNA digestion. Figure 41a shows 
the Southern blot results for the pLCKCASV-40 mice from the lines 1, 2 and 3. The figure 
41b illustrates the pLCKCASV-40 construct linearized with the enzymes Mlu1 and Xho1 for 
the trangenic mice generation. The figure shows also the position of the SV-40 probe and the 
position of the EcoR1 enzyme used for the genomic DNA digestion. 
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Figure 41a: Southern blot analysis of pLCKCASV-40 transgenic mice. Lanes 1 to 7 
contained 20 mg of genomic DNA digested overnight with EcoR1 and 
hybridized with 30ng of P32-labelled SV-40 probe. 48 hours exposure.  
 
 
Figure 41b: Schematic representation of the pLCKCASV-40 transgenic construct, with 
the restriction enzyme sites used for cloning (Xho1 and SacII) and 
linearization (Xho1 and Mlu1) for the transgene and the position of the 
sequence used as a probe for Southern analysis.  
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Analysis of transgene expression by RT-PCR 
In order to verify the expression of CALM/AF10 in different organs and cell types from the 
pLCKCASV-40 transgenic mice, we extracted RNA from different haematological and non-
haematological tissues and from sorted cells from specific haematological cell lineages and 
performed expression analysis by RT-PCR. The organs analysed were blood, bone marrow, 
spleen, thymus, lungs, skeletal muscle and adipose tissue. Pictures 42a to 47 show the cDNA 
controls and the CALM/AF10 expression in these organs. In order to analyse the specific 
expression of CALM/AF10 in different blood cell types, we sorted B220 positive B-cells from 
the spleen. From the bone marrow, the myeloid lineage double positive Gr-1+ Mac-1+ were 
sorted and from the thymus the T-cells CD4+CD8+ double positive, the T-helper CD4+ cells, 
the cytotoxic CD8 positive cells, and CD3 positive CD4 and CD8 negative cells early T-cells. 
Prior to the cDNA synthesis, the RNA obtained was treated with DNase A (Invitrogen) aiming 
to avoid contamination with genomic DNA and the CALM/AF10 transgene. This genomic 
DNA contamination could generate an amplification product with the same size of the desired 
product amplified from CALM/AF10 cDNA. Before cDNA synthesis, the RNA treated with 
DNase A was tested by PCR to verify that no genomic DNA remained. The pictures 42a to 52 
show the expression results obtained for the mouse Gapdh and Hprt genes (house-keeping 
genes) and for CALM/AF10 in different organs and sorted cells.  
 
 
Figure 42a: RT-PCR for cDNA quality control from different organs of pLCKCASV-40 
mouse Line 1. RNA digested with DNaseI without reverse transcriptase (-) and 
with reverse transcriptase (+). Primer pair used: mouse Gapdh. PCR 
conditions: 30 cycles, annealing temperature 60°C 
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Figure 42b: RT-PCR for cDNA quality control from different organs of pLCKCASV-40 
mouse Line 1. RNA treated with DNaseI without reverse transcriptase (-) and 
with reverse transcriptase (+). Primer pair used: mouse Gapdh. PCR 
conditions: 30 cycles, annealing temperature 60°C. 
 
 
Figure 43: RT-PCR of different organs of pLCKCASV-40 mouse Line 1. Primer pair 
used: CALM(1900-1920), AF10(448-424). PCR conditions: 30 cycles, 
annealing temperature 56°C. 
 
 
Figure 44a: RT-PCR for cDNA quality control from different organs of pLCKCASV-40 
mouse Line 2. RNA treated with DNaseI without reverse transcriptase (-) and 
with reverse transcriptase (+). Primer pair used: mouse Gapdh. PCR 
conditions: 30 cycles, annealing temperature 60°C. 
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Figure 44b: RT-PCR for cDNA quality control from different organs of pLCKCASV-40 
mouse Line 2. RNA treated with DNaseI without reverse transcriptase (-) and 
with reverse transcriptase (+). Primer pair used: mouse Gapdh. PCR 
conditions: 30 cycles, annealing temperature 60°C. 
 
 
Figure 45 RT-PCR of different organs of pLCKCASV-40 mouse Line 2. Primer pair 
used: CALM(1900-1920), AF10(448-424). PCR conditions: 30 cycles, 
annealing temperature 56°C. 
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Figure 46a: RT-PCR for cDNA quality control from different organs of pLCKCASV-40 
mouse Line 3. RNA treated with DNaseI without reverse transcriptase (-) and 
with reverse transcriptase (+). Primer pair used: mouse Gapdh. PCR 
conditions: 30 cycles, annealing temperature 60°C. 
 
Figure 46b: RT-PCR for cDNA quality control from different organs of pLCKCASV-40 
mouse Line 3. RNA treated with DNaseI without reverse transcriptase (-) and 
with reverse transcriptase (+). Primer pair used: mouse Gapdh. PCR 
conditions: 30 cycles, annealing temperature 60°C. 
 
Figure 47: RT-PCR of different organs of pLCKCASV-40 mouse Line 3. Primer pair 
used: CALM(1900-1920), AF10(448-424). PCR conditions: 30 cycles, 
annealing temperature 56°C. 
 
The amount of RNA obtained from FACS-sorted cells from organs of mice from the 
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pLCKCASV-40 line 1 was sufficient to obtain amplification of the house-keeping gene Hprt 
in the following subpopulations B220+, Gr-1+Mac-1+, CD4+CD8+, CD4+CD8-. We could 
detect less amplification of Hprt in CD4-CD8+ and no amplification in CD4-CD8-CD3+ cells, 
due to the very low number of cells obtained by sorting.  
In the pLCKCASV-40 line 1, we detected the CALM/AF10 transcript in CD4+CD8+ cells and 
at lower expression levels in B220+ cells (figure 50). 
In pLCKCASV-40 line 2, the RNA amount obtained was sufficient to observe Hprt 
amplification for all cell types, although the cDNA obtained from the CD4+CD8-, CD4-CD8+ 
and CD4-CD8-CD3+ cells showed only low amplification levels of the Hprt genes with 30 
PCR cycles (figures 48 and 49). In this line, we could detect the CALM/AF10 transcript only 
in the CD4+CD8+ and in the CD4+CD8- cells (figure 51).  For the cytotoxic T cells (CD8+) 
the amount of RNA and cDNA was low for all three pLCKCASV-40 trangenic lines (figures 
48 and 49).  
Although the RT-PCR product using the Hprt primer pair was almost absent on the agarose 
gel for these cells, in the cells obtained from a mouse from pLCKCASV-40 line 3, the 
CALM/AF10 transcript could be detected only in the cytotoxic T cells (figure 52). 
 
 
Figure 48: RT-PCR for cDNA quality control from sorted cells from spleen (B220 + ), 
bone marrow (Gr1, Mac1) and thymus (CD4, CD8 and CD3) of pLCKCASV-
40 mouse Lines 1 and 2. "neg" denotes RNA without reverse transcriptase. 
Primer pair used: mouse Hprt. PCR conditions: 30 cycles, annealing 
temperature 59°C. 
 
 
Results 
  
97 
 
Figure 49: RT-PCR for cDNA quality control from sorted cells from spleen (B220 + ), 
bone marrow (Gr-1, Mac-1) and thymus (CD4, CD8 and CD3) of 
pLCKCASV-40 mouse Lines 2 and 3. "neg" denotes RNA without reverse 
transcriptase. Primer pair used: mouse Hprt. PCR conditions: 30 cycles, 
annealing temperature 59°C. 
 
Figure 50: RT-PCR of sorted cells from spleen (B220 + and -) and bone marrow (Gr-1, 
Mac-1, Sca-1 and cKit) of pLCKCASV-40 mouse Line 1 showing expression of 
the CALM/AF10 transgene. "neg" denotes RNA without reverse 
transcriptase. Primer pair used: CALM(1900-1920), AF10(448-424). PCR 
conditions: 30 cycles, annealing temperature 56°C. 
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Figure 51: RT-PCR of sorted cells from spleen (B220 + and -) and bone marrow (Gr-1, 
Mac-1, Sca-1 and cKit) of pLCKCASV-40 mouse Line 2 showing expression of 
the CALM/AF10 transgene. "neg" denotes RNA without reverse 
transcriptase. Primer pair used: CALM(1900-1920), AF10(448-424). PCR 
conditions: 30 cycles, annealing temperature 56°C. 
 
Figure 52: RT-PCR of sorted cells from spleen (B220 + and -) and bone marrow (Gr-1, 
Mac-1, Sca-1 and cKit) of pLCKCASV-40 mouse Line 3 showing expression of 
the CALM/AF10 transgene. "neg" denotes RNA without reverse transcriptase. 
Primer pair used: CALM(1900-1920), AF10(448-424). PCR conditions: 30 
cycles, annealing temperature 56°C. 
 
 
Analysis of transgene expression by Western blot 
Western blot analysis was performed with cell extracts of thymus, liver and spleen of 
pLCKCASV-40 mice lines 1, 2 and 3 as described for the pIGCASV-40 mice. We were 
unable to detect the CALM/AF10 protein in the organs from the transgenic mice in these 
experiments. 
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Analysis of the phenotype at haematological level 
Hemogram 
Hemograms of 11 adult transgenic and 5 wild type FVB mice aged between 5 months and one 
year were performed to observe differences between transgenic and control mice. The white 
blood cell (WBC) count and red blood cell (RBC) count and the WBC differential count was 
performed. The RBC count of the transgenic mice was 7.23 x 109 + 0.61 x 109 cells/ml and 
6.57 x 109 + 1.11 x 109 cells/ml for the control mice. The WBC count of the transgenic mice 
was 2.78 x 106 + 1.21 x 106 cells/ml and 3.328 x 106 + 1.25 x 106 cells/ml for the control mice. 
There was no statistically significant difference between transgenic and control mice in the 
total WBC and RBC count (p>0.05). We analyzed also the blood cell morphology and the 
relative WBC and RBC count in these animals. We did not observe any RBC or WBC 
morphological difference between transgenic and control mice blood cells. There was no 
statistical difference in the WBC differential count between transgenic animals of 
pLCKCASV-40 mice lines 1 and 2 and 3 and control animals. The hematological values 
evaluated and the U Mann-Withney statistic test for non paired samples results are shown in 
table 19. 
 
Table 19: Median, median standard-deviation and statistic results for WBC differential 
count values for pLCKCASV-40 mice 
Median ± standard deviation WBC 
Positive %* Negative %** 
P value Result 
Lymph 86.00 ± 5.79 90.00 ± 2.54 0.0571 POS = NEG 
Neutr 9,00 ± 4.71 8,00 ± 1.87 0.2202 POS = NEG 
Mono 2.5 ± 3.57 2.0 ± 3.35 0.1121 POS = NEG 
Eosin 0.00 ± 1.50 0.00 ± 0,98 0.4472 POS = NEG 
Baso 0.00 0.00 - POS = NEG 
*n = 11 , **n = 5 
 
Flow cytometry 
 
To analyze whether the pLCKCASV-40 mice showed alterations in the development and 
distribution of blood cells, we performed the analysis of different hematopoietic cell 
subpopulations: the bone marrow precursor markers CD117 (c-Kit) and Sca-1, the erythrocyte 
marker Ter119, the B-cell marker B220 and the myeloid markers Gr-1 and Mac-1 were used 
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to analyze the bone marrow samples from 3 transgenic and 3 control mice. The lymphoid 
antigens CD4, CD8 and CD3 were used to analyze the thymocytes of the same animals and 
cells from the spleen were analyzed with the surface antigens CD3 and B220. The values 
obtained were tested using the T-student test (p>0.05). Figure 53 shows the average values 
obtained for each antigen. There was no significant difference between transgenic and control 
mice. Table 26 (Appendix) shows the average, standard deviation and the t-test result for each 
surface antigen analyzed.     
 
 
Immunophenotype of pLCKCASV-40 mice 
0 10 20 30 40 50 60 70
c-Kit+ Sca-
Sca-1+ c-Kit-
c-Kit + Sca-1+
Ter 119+ B220-
B220+ Ter119-
Ter119+B220+
Gr-1+ Mac-1-
Mac-1+ Gr-1 -
Gr-1+Mac-1+
CD4+ CD8-
CD8+ CD4-
CD4+CD8+
CD3+ CD4-CD8-
B220+CD3-
B220-CD3+
% positive cells
Transgene n = 3
Control n = 3
 
Figure 53: Immunophenotyping of cell surface markers from bone marrow (cKIT, Sca-1, 
GR1, Mac1), thymus (CD4, CD8 and CD3) and spleen (CD3 and B220) from 
pLCKCASV-40 transgenic mice and control (p>0.05).   
 
Analysis of the phenotype of pLCKCASV-40 transgenic mice at the pathological level 
Histopathology 
For the hystopatological analysis we sent one mouse from each line ans two control mice. The 
main abnormal histological findings were in the liver, spleen, and thymus.  The liver showed 
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hyperplasia of the hepatocytes surrounding the central veins. The spleen showed hyperplasia 
of the white pulp (Figure 54b). The immunohistochemistry revealed an increase of B-cells 
(B220), however, the relationship between B- and T-cells remained normal (Figure 54b).  The 
thymus was normal in size and morphology. In the thymus medulla, a slight increase in B-
cells could be observed (Figure 54b). The lung showed no alterations in any of the transgenic 
animals. The control animal also showed hyperplasia of the hepatocytes surrounding the 
central vein.  In addition, in the spleen and thymus there was hyperplasia of lymphoid tissue, 
mainly from the B-cell compartment. The thymus was normal in size and morphology.  
The pathological findings in all transgenic pLCKCASV-40 and in the control mouse were 
similar. Thus these findings are unlikely to be due to the action of the transgene. Figures 54a 
and 54b illustrate these findings. 
 
 
 
 
Figure 54a: Immunohistopathology of pLCKCASV-40 transgenic and control mice. The 
pictures show haematoxylin-eosin staining and immunohystochemistry for B-
cells (B220) in the spleen. The staining shows hyperplasia of the white pulp 
(04-1947 to 1949) and an increase in B cell number (B220).   
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Figure 54b: Immunohistopathology of pLCKCASV-40 transgenic mice. The pictures 
show immunohystochemistry of thymus for B-cells (B220) and T-cells (CD3) 
demonstrating the relationship of T and B cells in this organ. The liver shows 
hyperplasia of hepatocytes around the central vein. 
 
 
 
5.3. Analysis of the CALM/AF10 fusion in patient samples 
 
In order to better understand the importance of the t(10;11)(p13;q14) in leukemogenesis, we 
analyzed patient samples with a t(10;11) diagnosed by cytogenetics and molecular 
cytogenetics (fluorescence in situ hybridization, FISH) for the presence of CALM/AF10 
transcripts by RT-PCR.  
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We obtained bone marrow cells or RNA samples from five patients, three with acute myeloid 
leukemia (AML) and two with T-cell acute lymphoid leukemia (T-ALL) from Dr. Cristina 
Mecucci, Perugia, Italy. cDNA from seven patients with AML, ALL or acute undifferentiated 
leukemia (AUL) with translocation t(10;11) were obtained from the Laboratory for Leukemia 
Diagnostics, Grosshadern. It was reported that the CALM/AF10 fusion gene is the most 
common fusion gene among patients with T-ALL with T cell receptor gd rearrangement 
(Asnafi et al., 2003). To confirm these results, we tested bone marrow cell samples from 
twenty-nine T-ALL patients with TCR-gd rearrangement kindly provided from Prof. Dr. 
Ludwig from the Immunologic Marker Laboratory, Charité University Clinic, Berlin. The 
samples from one patient were obtained from Prof. Dr. Borkhardt, Kinderklinik, LMU. A total 
of 17 CALM/AF10 positive patient samples were identified. 
5.3.1. Analysis of CALM/AF10 expression by RT-PCR and expression profiling of 
CALM/AF10 positive patients using microarray technology 
Identification of CALM/AF10 transcripts in patient samples 
The patients with a t(10;11), suggesting a CALM/AF10 rearrangement, were tested by RT-
PCR for the presence of CALM/AF10 fusion transcripts (figures 56 to 60). FISH analysis had 
excluded an involvement of the MLL gene in these patients. All the patients with t(10;11) 
tested positive for the CALM/AF10 transcript (figures 56 to 59 and tables 20a and b).  
The CALM/AF10 fusion gene was reported to be the most common fusion gene among 
patients with T-ALL with T cell receptor gd rearrangement (Asnafi et al., 2003). To confirm 
these results, we tested a series of 29 patients with T-ALL with T-cell receptor 
gd rearrangement for the presence of CALM/AF10 transcripts and four of these (4/29; 13.79%) 
were positive for a CALM/AF10 fusion transcript (figure 59; patients 10 to 13). 
In seven patients it was also possible to amplify the reciprocal AF10/CALM fusion transcript 
(cases 1, 3, 4, 8, 9, 10 and 14; figure 60). The position of the primers used for the 
CALM/AF10 transcript identification is schematically shown in figure 55. 
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Figure 55: Diagrammatic representation of the primers used for the identification of 
fusion transcripts in patient cDNA in the CALM and AF10 sequence. 
 
 
 
Figure 56: RT-PCR of patient samples. Primer pair used: CALM(1730-1753) and 
AF10(949-929). PCR conditions: 35 cycles, annealing temperature 58°C. 
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Figure 57: RT-PCR of patient sample. Primer-pair used: CALM(1998-2023) and 
AF10(1086-1066). PCR conditions: 35 cycles, annealing temperature 58°C. 
 
  
 
Figure 58: RT-PCR of patient samples. Primer pair used: CALM(1730-1753) and 
AF10(1086-1066). PCR conditions: 35 cycles, annealing temperature 58°C. 
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Figure 59: RT-PCR of patient samples. Primer pair used: CALM(1730-1753) and 
AF10(1086-1066). PCR conditions: 35 cycles, annealing temperature 58°C. 
 
 
Figure 60: RT-PCR of patient samples. Primer pair used: AF10(288-308) and 
CALM(2165-2144). PCR conditions: 35 cycles, annealing temperature 57°C. 
Sequencing of CALM/AF10 fusion transcripts in patient samples 
The RT-PCR products subcloned into the pGEMT-easy vector for sequencing. For 
sequencing, the same primers used for amplify of the CALM/AF10 transcripts were used. 
Figures 61 and 62 show eletropherograms from the breakpoint regions in patient 5.  
 
 
Results 
  
107 
 
Figure 61: Eletropherogram of the sequence of the breakpoint segment of the 
CALM/AF10 fusion transcript amplified from the cDNA of patient 5. 
Sequencing primer used: CALM(1730-1750).   
         
 
 
Figure 62: Eletropherogram from the sequence of the breakpoint of the AF10/CALM 
fusion transcript amplified from the cDNA of the patient 4. Primer used 
AF10(288-308). 
 
The sequence analysis from all CALM/AF10 positive patient samples revealed three different 
breakpoints in CALM at nucleotide 1926, 2091 and 2064. The patient with the breakpoint at 
position 2064 in CALM showed a 106 base pair insertion which had not been described as a 
CALM exon before. 
In AF10 four breakpoints were identified: at nucleotide position 424, 589, 883 and 979. There 
was one extra-exon in AF10 between exons 6 and 7, with 205 bases inserted 5’ of nucleotide 
424 of AF10. This exon contains a stop codon after 162 bases. The use of this exon would 
result in the translation of a truncated AF10 protein with 195 amino acids and a truncated 
CALM/AF10 protein with 751 amino acids. In this patient (case 16) another splice variant 
with the breakpoint 424 in AF10 was also seen. We did not observe any correlation between 
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disease phenotype and breakpoint location. Table 20a summarizes the patient data and the 
results observed. 
 
 
Table 20a: Clinical data and sequencing results from CALM/AF10 patients 
Patient 
No. 
Sex Type of 
leukemia 
Age at 
diagnosis 
Overall survival or 
longest follow-up 
(days) 
Breakpoint in CALM  
(last nt in fusion) 
Breakpoint in AF10  
(first nt in fusion) 
1 Female AML 
M2 
33 36 (dead) 1926/2091 883 
2 Male ABL 22 1067 (dead) 2091 883 
3 Male PreT-
ALL 
46 143 (dead) 1926 883 
4 Male AUL 25 886 2091/2064 +164bp 883 
5 Male PreT-
ALL 
35 650 2091 424 
6 Male ProT-
ALL 
33 641 1926 979 
7 Female ProT-
ALL 
28 275 1926 424 
8 Female AML 12 922 (at 22.06.05) 2091 424/589 
9 Male ALL 12 876 (at 22.06.05) 2091 424 
10 Male T-ALLgd 5 n.a. 1926 883 
11 Male T-ALLgd 32 n.a. 2091 883 
12 Female T-ALLgd 10 n.a. 2091 424 
13 Female T-ALLgd 5 n.a. 1926 883 
14 Female T-ALL n.a. n.a. 2091 589 
15 Female AML n.a. n.a. 1926 883 
16 Female AML n.a. n.a. 2091 205bp 
before424/424 
17 Female AML 12 n.a. 1926 883 
n.a. = non acessed 
From 9 of the patients we obtained the karyotype. Only three patients (1, 8 and 9) had the 
t(10,11)(p13;14) as the only chromosomal aberration. All the others presented additional 
karyotypic alterations and patients 2 and 4 had a complex aberrant karyotype (table 20b).         
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Table 20b: Cytogenetical data from CALM/AF10 patients 
Patient Karyotype   
1 46,XX,t(10;11)(p13;q14) [20] 
2 47,XY,dup(1)(q21q44),del(5)(q13q31),del(8)(p21),+del(8)(p21),der(10)t(10;11)(p12;q13),\nder(11)t(
10;11)(p12;p13)del(11)(q13),del(12)(p11.2p13) [12] 
46,XY [3] 
nach CGH:\n47,XY,der(1)del(1)(p36.1)ins(1;1)(q23;p31.2p36.1),del(5)(q15),del(7)(q32),del(8) 
3 47,XY,t(10;11)(p12;q21),+13 [2] 
46,XY [7] 
4 46,XY,del(5)(q13),t(10;11)(p12;q13),der(10)t(5;10)(q23;p15)ins(10;5)(q24;q?q?)  [5] 
6,XY [15] 
5 46,XY,t(10;11)(p12;q13),del(12)(p11) [4] 
46,XY [5] 
6 47,XY,t(10;11)(p13;q14),+21 [2] 
46,XY [18] 
7 46,XX,del(5)(q22q33),t(10;11)(p13;q14) [14] 
46,XX [6] 
8 46,XX,t(10;11)(p13;q14) 
9 46,XY,t(10;11)(p13;q14) 
 
The leucine zipper domain of AF10 was present in all putative CALM/AF10 fusion proteins 
found in the patients. We did not observe any correlation between breakpoint and diagnosis or 
diagnosis and the presence of the reciprocal fusion transcript AF10/CALM, which was found 
in seven patients. Figure 63 is a diagram of the fusion found in the patients and the resulting 
fusion proteins. 
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Figure 63: Putative CALM/AF10 and AF10/CALM fusion proteins derived from fusion 
mRNA in 17 CALM/AF10 patients. The numbers indicate breakpoint locations 
in nucleotides. 
 
Gene expression analysis of CALM/AF10 patients 
The gene expression profile of ten CALM/AF10 patient samples (patients 1, 2, 3, 5, 6, 7, 8, 9, 
10 and 11) was analysed using oligonucleotide microarrays representing 33,000 different 
genes (U133 set, Affymetrix). These analyses revealed high expression levels of the polycomb 
group gene BMI1, the homeobox gene MEIS1 and certain HOXA cluster genes: HOXA4, 
HOXA5, HOXA7, HOXA9 and HOXA10. This expression pattern is similar to the pattern 
observed for patients with acute leukemia with MLL rearragements. Figure 64 shows a 
hierarchical cluster analysis of 50 adult ALL and AML samples including the 10 CALM/AF10 
positive patient samples using a subset of HOX genes and the TALE homeobox gene MEIS1. 
Figure 65 shows the same results plotted in three-dimensional space using the three 
components capturing most of the variance in the data set (principal component analysis). In 
this picture, the CALM/AF10 patients cluster with patients with AML and MLL rearrangement. 
Only one of the CALM/AF10 patients analyzed showed a slighty different expression pattern 
for these genes. Although the expression pattern of this patient was more similar as far as the 
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HOXA genes were concerned to the expression pattern found in AML-M2 patients with 
t(8;21), the expression of MEIS1 was high as in the other CALM/AF10 patients. 
 
 
 
Figure 64: Hierarchical cluster analysis based on U133A microarray expression data of 
50 adult ALL and AML (with MLL rearrangement, blue dots, and with AML 
M2 and t(8;21), red dots, columns) samples including ten CALM/AF10 positive 
samples (yellow dots, columns) using a subset of genes (rows) (Meis 1, HOXA 
4, 5, 7, 9 and 10). The normalized expression value for each gene is coded by 
color with the scale shown at the lower left (standard deviation from mean) 
Red cells indicate high expression and green cells indicate low expression. 
MEIS1 (bottom) is highly expressed in all CALM/AF10-positive leukemias. 
 
 
 
Figure 65: Principal Component Analysis (PCA) of the expression data from 50 
leukemia patients including the 10 CALM/AF10 positive patients. The data of 
the samples are plotted in a three-dimensional space using the three 
components capturing most of the variance in the data set (principal 
component analysis, PCA). Each patient sample is represented by a color-
coded sphere. The PCA was calculated from the expression data of the 
following genes: MEIS1, HOXA4, HOXA5, HOXA7, HOXA9 and HOXA10.  
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A second analysis was performed to compare the gene expression of CALM/AF10 patients 
with groups patients, each of them consisting of 15 samples of patients with different leukemia 
diagnosis: T-ALL, ALL with MLL rearrangements, AML with MLL rearrangements, AML 
with inversion of the chromosome 16, AML showing normal karyotype, AML t(8;21), AML 
with acute promyelocytic leukemia, AML with complex abberant karyotype, and healthy bone 
marrow. This analysis showed that among the 100 statistically most significantly differentially 
expressed genes most genes (98 of 100) were expressed at a lower level in the CALM/AF10 
patient samples when compared to the other groups. Table 21 shows a selection of genes 
which were down-regulated in CALM/AF10 patients in comparison to the other groups. 
The only consistently upregulated genes in the CALM/AF10 patient samples were BMI1, 
DNAJC1 and COMMD3. Interestingly, all these genes lie immediately centromeric to the 
breakpoint of the t(10;11)(p21;q14) on 10p21. 
 
Table 21: Downregulated genes in CALM/AF10 patients compared to normal bone 
marrow and leukemic patients samples. 
Gene Affy id Fold expression 
change 
Map location Description 
RAB34 224710_at -146.846 17q11.1 RAB34, member RAS oncogene family 
TRIO 208178_x_at -9.6969 5p15.1-p14 Triple functional domain (PTPRF interacting) 
CEBPD 203973_s_at -12.153 8p11.2-p11.1 
CCAAT/enhancer binding protein (C/EBP), 
delta 
ST7 207871_s_at -14.214 7q31.1-q31.3 Suppression of Tumorigenicity 7 
H2AFJ 225245_x_at -5.19594 12p12 H2A histone family, member J 
JAG1 216268_s_at -23.7935 
20p12.1-
p11.23 jagged 1 (Alagille syndrome) 
HCK 208018_s_at -6.31031 20q11-q12 Hemopoietic cell kinase 
TEM7R 227276_at -4.18613 10p12.1 Tumor endothelial marker 7-related precursor 
CDH15 206327_s_at -3.01741 16q24.3 Cadherin 15, M-cadherin (myotubule) 
CTSZ 210042_s_at -6.5899 20q13 Cathepsin Z 
CTNNA1 200765_x_at -4.6203 5q31 
Catenin (cadherin-associated protein), alpha 
1, 102kDa 
TKR2 224301_x_at -6.689412 4q32 Toll-like receptor 2 
HOXB4 204924_at -9.855904 17q21-q22 Homeo box B 4 
USP3 231767_at -3.558808 15q22.3 Ubiquitin specific protease 3 
ZNF185 203585_at -3.74636 Xq28 Zink finger protein 185 (LIM domain) 
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5.4. Inducible expression of CALM/AF10 in cell lines 
In order to observe identifiy direct target genes of CALM/AF10, we conditionally expressed 
CALM/AF10 using a tetracycline-regulatable gene expression system, which allows the 
controlled expression of CALM/AF10 by adding docycycline to the cell culture medium. This 
system allows a kinetic study of the expression of CALM/AF10 and its target genes in the cell. 
The objective was also to establish an in vitro system where we could experimentally confirm 
the results obtained from the RNA expression analysis of the patients. 
Cloning 
In order to achieve inducible expression of the CALM/AF10 fusion protein, we cloned the 
CALM/AF10 coding sequence into the pRTS-1 vector designed by Bornkamm et al (2005). 
This is a doxycycline-regulatable vector with a unique combination of features. It carries all 
the elements for conditional gene expression including the gene of interest (CALM/AF10) on 
one EBV-derived episomally replicating plasmid. The vector is characterized by its low 
background activity in the absence of doxycycline, its high inducibility in the presence of 
doxycycline, and its graded response to increasing doxycycline. The chicken beta actin 
promoter and an element of the murine immunoglobulin heavy chain intron enhancer drive 
constitutive expression of a bicistronic expression cassette that encodes the optimized, highly 
doxycycline-sensitive reverse transactivator-VP16 fusion protein (rtTA2s-M2) (referred to as 
the reverse tet-transactivator) and a tetracycline repressor-KRAB fusion protein (referred ot as 
tet-silencer) placed behind an internal ribosomal entry site. CALM/AF10 is expressed from a 
bidirectional doxycycline regulatable promoter that allows simultaneous expression of a 
second gene (GFP), used as a marker for the CALM/AF10 expression. Tight regulation of the 
gene of interest is achieved by binding of the repressor to the doxycycline-regulated bi-
directional promoter in the absence of doxycycline, and combined relief of repression and 
binding of the reverse transactivator in the presence of doxycycline. To facilitate the cloning 
of the 5.2 kbp CALM/AF10 fusion cDNA into this vector, it was first inserted into a shuttle 
vector (pUC19Sfi1), a derivative of pUC19 modified by Rob Chapman (GSF). This vector has 
a multiple cloning site which is flanked by two Sfi1 sites which are compatible with the Sfi1 
sites which flank the luciferase gene in the pRTS-1vector. The CALM/AF10 coding sequence 
was inserted into this vector using the Xho1 at the 5’ and Xba1 at the 3’ side. The CALM/AF10 
coding fragment was then released by Sfi1 digestion from pUC19Sfi1 CALM/AF10 and used 
to replace the luciferase gene in pRTS-1 which had been removed by Sfi1 digestion from this 
vector. The resulting plasmid was named pRTS-1-CALM/AF10 and is schematically shown in 
figure 66. 
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Figure 66: Schematically representation of the construct pRTS-1-CALM/AF10.   
 
 
 
 
 
 
 
 
 
 
 
 
Stable transfection of 
mammalian cells 
Endo-free plasmid DNA preparations of the pRTS-1-CALM/AF10 construct and of the empty 
vector pRTS-1 were used to transfect mouse NIH3T3 fibroblast cells. For 106 cells (80% 
confluent in a 100 mm cell culture dish) 3 µg of DNA was used. A control transfection using 
the pEGFP vector was carried out and showed about 70% GFP-positive cells 22 h after 
transfection. To select for stably transfected cell, 1 µg/ml of puromycin was added to the 
medium 48 h after transfection. 24 h after the addition of puromycin about 80% of the cells 
transfected with pEGFP had detached from the plate. In the plates containing pRTS-1-
CALM/AF10-transfected cells and cells transfected with the pRTS-1, about 40% of the cells 
died. 48 h after the addition of puromycin to the medium, all pEGFP-transfected cells were 
dead. The plates containing the pRTS-1 and pRTS-1-CALM/AF10 transfected cells were 80% 
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confluent. After two weeks of puromycin selection, the expression of CALM/AF10 and GFP 
(for pRTS-1-CALM/AF10 cells) or the expression of GFP and luciferase (for pRTS-1 cells) 
was induced using 1 µg of doxycycilin/ml of DMEM.  24 h after doxycyclin induction, FACS 
analysis of the pRTS-1-CALM/AF10- transfected cells showed 27.54% GFP positive cells. 
Figure 67 illustrates the cells transfected with pRTS-1-CALM/AF10 (without and with 
doxycyclin induction after 24 h).   
 
 
 
Figure 67: Inducible expression of CALM/AF10 in NIH3T3 cells stably transfected with 
pRTS-1-CALM/AF10: A, without doxycyclin (phase contrast), B without 
doxycyclin (GFP channel); C, with doxycyclin (phase contrast) and D, with 
doxycyclin (GFP channel) after 24 hours. Scale = 50 mm 
 
 
CALM/AF10 Expression Analysis of Induced Cells 
Expression Analysis at Transcriptional Level  
The RNA of cells transfected with pRTS-1-CALM/AF10 cells was extracted and 200 ng were 
used for cDNA synthesis. The cDNA quality was assessed by RT-PRC using primers for 
mouse Gapdh. In order to exclude the possibility of genomic DNA contamination, we treated 
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the RNA preparation with desoxyribonuclease I before cDNA synthesis. Figure 68 illustrates 
the Gapdh PCR and the control for genomic DNA contamination. Figure 69 shows the 
expression of CALM/AF10 in cells stably transfected with the pRTS-1-CALM/AF10 construct 
at different time points after doxycyclin induction.  The DNase-treated RNA preparation 
without addition of reverse transcriptase was used as negative control for the RT-PCR reaction 
and is labeled “–“. The “+” symbol indicates RNA with reverse transcriptase.  
 
 
 
 
 
Figure 68: RNA quality control: RT-PCR of NIH3T3 cells stably transfected with pRTS-
1-CALM/AF10 before (0 h+) and after (6 h+, 12 h+ and 24 h+) doxycyclin 
induction. Primer pair used: mouse Gapdh. PCR conditions: 30 cycles, 
annealing temperature 60°C. “+” with reverse transcriptase, “-“ without 
reverse transcriptase. 
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Figure 69: Time course of CALM/AF10 fusion transcript induction. RT-PCR of NIH3T3 
cells stably-transfected with pRTS-1-CALM/AF10 before (0 h+) and after (6 
h+, 12 h+ and 24 h+) doxycyclin induction. Negative control: non-transfected 
NIH3T3 cells. Primer pair used: CALM(1900-1920), AF10(448-424). PCR 
conditions: 30 cycles, annealing temperature 56°C. “+” with reverse 
transcriptase, “-“ without reverse transcriptase. 
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Expression Analysis at Protein Level  
In order to verify the expression of the CALM/AF10 protein induced by addition of 
doxycyclin to the medium, we transiently transfected HEK293T cells with the pRTS-1-
CALM/AF10 plasmid and performed Western analysis with the cell extracts 48 hours after 
transfection and 24 hours after dox addition to the  cell culture medium. For that, 40mg of 
protein extracts were loaded on a 6% SDS PAGE gel and a Western analysis was performed to 
observe the presence of the CALM/AF10 protein in the induced cells. Figure 70 shows the 
presence of a low amount of CALM/AF10 only in the induced cells transiently transfected 
with pRTS-1-CALM/AF10.   
 
 
 
Figure 70: Western blot of specific CALM/AF10 protein expression 24h after addition of 
doxycyclin to the medium (arrow). 
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6. DISCUSSION 
6.1. Cell biology 
6.1.2. Sequencing of CALM/AF10 
We completely sequenced the CALM/AF10 expression cassette that was used in our 
experiments and observed that the CALM sequence was formed by exons 1 to 17 and 19 to 20, 
with an open reading frame region of 652 amino acids. This sequence and the breakpoint 
location correspond to the original sequence described for CALM in the U937 cell line 
(Dreyling et al., 1996). The breakpoint in AF10 corresponded also to the published breakpoint 
in U937 and was located at nucleotide 424. AF10 was composed of exons 8, 10 to 17 and 21 
to 30. In addition, we identified 123 extra nucleotides inserted between exons 28 and 29 of 
AF10, adding up to an open reading frame of 2932 nucleotides. These extra nucleotides were 
in frame with the AF10 open reading frame and did not contain a stop codon. As a result our 
sequenced construct has a total open reading frame of 4875 nt coding for a 1625 amino acid 
CALM/AF10 protein. With the exception of the amino terminal PHD domain of AF10 (Linder 
et al., 2000), all the important protein domains described for CALM (Bohlander, 2000; Ford et 
al., 2001; Legendre-Guillemin et al., 2004) and AF10 (Linder et al., 2000; DiMartino et al., 
2002) were present in the construc used in this project. 
6.1.2. Sub-cellular localization and co-localization of CALM/AF10, CALM and AF10 
In the sub-cellular localization experiments, we were able to observe the CALM and 
CALM/AF10 proteins tagged with fluorescent protein mostly in the cytoplasm, and AF10 was 
found in the nucleus, in a speckled pattern. Some of the CALM/AF10 protein could also be 
seen in the nucleus. This relatively small fraction of CALM/AF10 protein could potentially 
interact with the native AF10. AF10-AF10 interaction can occur through the CCR or extended 
PHD finger domain, which is present in the wild type AF10 and is also retained in the AF10 
part of the CALM/AF10 fusion. This motif, probably responsible for the oligomerization of 
AF10 (Linder et al., 2000) would allow the binding between CALM/AF10 and the wild type 
AF10 in the nucleus. Considering this nuclear interaction between CALM/AF10 and AF10, 
one could speculate that this binding could interfere in the normal function of AF10.  
Interestingly, Vecchi and colleagues (2001) showed that CALM shuttles between cytoplasm 
and nucleus. They performed a GAL4-based transactivation assay and demonstrated that 
CALM modulated transcription and hypothesised that, as endocytic proteins contain multiple 
protein-protein interaction sites, they could act structurally as scaffold for the nuclear 
localization of transcription factors. Under normal conditions, CALM is very quickly exported 
to the cytoplasm, but the nuclear localization of CALM/AF10 could also interfere in possible 
nuclear functions of CALM. 
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Expression of the CALM/AF10 protein 
Western analysis performed to detect the CALM/AF10 protein in transiently transfected 
HEK293T cells (with the constructs pEYFP-CALM/AF10, pEYFP-CALM and pECFP-AF10) 
was able to demonstrate the presence of CALM/AF10, CALM and AF10 proteins fused to the 
fluorescent proteins. pEYFP-CALM and pEYFP-CALM/AF10 were detected using anti-
CALM antibodies and anti-GFP antibodies; pECFP-AF10 was detected using anti-GFP 
antibodies. These results are important to confirm the expression of the CALM/AF10 protein 
from our construct, which was used for transgenic mice production. The bands obtained on the 
Western analysis for YFP-CALM and CFP-AF10 were of the predicted sizes of 99 kDa and 
127 kDa, respectively (Tebar et al., 1999; Chaplin et al., 1995). For YFP-CALM/AF10, the 
predicted size is about 200 kDa. The smaller size of approximately 160 kDa obtained for 
CALM/AF10 in our Western analysis (figures 15 and 16) could be due to protein degradation. 
When longer exposure times were used, we observed a smear pattern in the lane with the 
CALM/AF10 protein, probably due to degradation. Kim and Kim (2001) predicted five 
potential caspase 3 cleavage sites in CALM. This target sites for caspase 3 in CALM could 
explain the differences between predicted sizes and Western results for the CALM/AF10 
protein and could also explain the ‘smear’ pattern observed on longer exposures. 
6.2. Transgenic mice 
6.2.1. FVB mice expressing CALM/AF10 under control of a IgH enhancer/promoter 
Generation of transgenic lines  
We obtained two transgenic mouse lines which expressed CALM/AF10 under the control of 
the IgH enhancer/promoter. Considering that the off-spring of transgenic crossed with wild 
type animals were approximately 50% transgenic, it was expected that the transgene had only 
one integration site in these lines (Gannon et al., 1990). Southern analysis confirmed this 
assessment. As shown in the figure 21a we can observe two bands in line 1: one strong band 
with an approximate size of 8 kb and a second band of about 12 kb. In line 2, we can observe a 
fragment of 8 kb (as observed in line 1) and a second fragment of about 10 kb. It is very likely 
that this common 8 kb fragment is due to multiple tandem integrations of the transgene 
(transgene array) at the same genomic locus, because the 8 kb length corresponds to the length 
of the full construct. The occurrence of integration of several copies of the injected DNA, 
arrayed in a head-to-tail manner, at random sites in the mouse genome has been reported as a 
common phenomenon (Hamada e al., 1993; Schneider and Wolf, 2005). Because the 
restriction enzyme used for genomic DNA digestion in this Southern analysis (EcoR1) has 
only one recognition site in the pIGCASV-40 construct, the product of digestion of various 
copies integrated in an array gives products with the length of the transgene construct (8 kb). 
This fragment is detected as a strong band corresponding to the number of integrated copies. 
The second band corresponds to the line specific flanking fragment obtained by the digestion 
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of the construct and the adjacent Eco R1 restriction site in the chromosome. These line-
specific bands have different sizes of approximately 12 kb for the line 1 and of approximately 
10 kb for the line 2, indicating the occurrence of the integration of the transgene cassette in 
different locations of the genome.  
Analysis of transgene expression by RT-PCR 
The results obtained for the expression of CALM/AF10 in the different organs have to be 
looked critically. The presence of blood cells in non hematopoietic organs could lead to false-
positive CALM/AF10 results in organ tissue. Sorting of blood cell subpopulations allowed us 
to assess CALM/AF10 expression specifically in these cells. These results lead us to conclude 
that the expression of CALM/AF10 in both transgenic lines was specific and restricted to the 
hematopoetic lineages.  
In mice from line 1, the expression of CALM/AF10 was present in bone marrow immature c-
Kit negative /Sca-1 positive cell fraction and in Gr-1/Mac-1 double positive cells. The former 
cell population can contain immature common myeloid progenitors (CMPs) (Akashi et al., 
2000), in which lymphocyte differentiation is inhibited by the expression of Sca-1 (Bradfute et 
al., 2005). The Gr-1/Mac-1 cells are monocyte (macrophage) or granulocyte precursors, in 
which the IgH enhander is not active (Harris et al., 1988; Eckhardt, 1992). 
The CALM/AF10 transcript was not detected in the very early stem cell population c-Kit/Sca-1 
double positive cell fraction. This can be explained by the fact that the IgH enhancer/promoter 
is not active in these cells (Karasuyama et al., 1990; Tsubata et al., 1990).  
The B220+ and B220- splenocytes also expressed CALM/AF10. In the B220- fraction, 
CALM/AF10 could be present due to the very early cells, which do not present B220 in the 
cell surface or present at very low levels. These cells are the earliest lymphocyte progenitors 
(ELP) fraction in which the IgH enhancer is already active and these cells start to undergo DH-
JH rearrangements at the IgH locus (Koyama et al., 1997; Hardy et al., 2000; Busslinger, 
2004). 
In mice from line 2 CALM/AF10 expression was observed only in B220 positive and in B220 
negative splenocytes indicating a very specific expression of the CALM/AF10 transgene. This 
is in line with the expression data reported for the transgene expression under the control of 
the IgH enhancer promoter in the literature (Harris et al., 1988; Eckhardt, 1992).  
Analysis of transgene expression by Western blot 
The fact that we were unable to detect the CALM/AF10 fusion protein in the transgenic mice 
could be due to a low level of CALM/AF10 protein expression. This is in line with our 
attempts to detect the fusion protein in the U937 cell line, which has the CALM/AF10 fusion, 
and in the leukemic cell lines from CALM/AF10 transduced bone marrow cells, suggesting 
that a very low CALM/AF10 expression is sufficient to cause leukemia. 
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Another explanation for the failure to detecting the CALM/AF10 fusion protein in our model 
could be that the CALM/AF10 transcript is degraded by teh nonsense-mediated mRNA decay 
(NMD) pathway. NMD is a “quality control mechanism” which leads to the degradation of 
mRNAs that harbour premature translational stop codons. This mechanism prevents the 
synthesis of potentially harmful truncated proteins. NMD involves proteins described to bind 
to regions present in SV-40 mRNA which are part of our trangenes (Lejeune et al., 2002).  
Hemogram 
The transgenic animals were observed for a period of over 16 months without showing any 
alteration related to the hematopoietic system in comparison to the control animals. To analyse 
more closely the hematopoietic system, we performed total and relative WBC count and RBC 
count. The total WBC counts (3.44 + 1.22 x 106/ml leukocytes for transgenic animals and 3.59 
+ 1.09 x 106/ml for controls) were markedly lower than those reported for adult FV/B mice 
(5.6 + 1.37 for males and 5.73 + 0.79 for females) (www.jax.org). Since there were no 
differences between transgenic and control mice in the WBC count, we concluded that the 
differences of our values compared to the values reported in the literature are due to the 
presence of platelet aggregates observed in almost all blood slides analyzed. Jain (1993) 
mentions that the presence of blood clots are an important source for errors in the total WBC 
count. Because of these technical limitation, we also evaluated the WBC differential count. 
The values obtained did not differ significantly between transgenic and control animals and 
were similar to the values reported for the FVB/N strain (www.jax.org). The blood cell 
morphology was also assessed and no difference was observed between transgenic and control 
animals. 
Mice with N-ethyl-N-nitrosourea (ENU)-induced mutations at the Picalm locus displayed a 
severe phenotype, with a shortened life span, growth retard in utero, iron metabolism 
deficiency, severe anemia and B-cell deficiency (Potter et al., 1997; Klebig et al., 2003). None 
of our transgenic lines showed such a phenotype.   
Analysis of the phenotype at the immunological level 
Serum immunoglobulin levels in transgenic mice expressing CALM/AF10 under the control of 
the IgH enhancer/promoter were determined with the objective to assess the function of the B-
cells in these animals (Yu et al., 2004). As no difference was observed between transgenic and 
control mice in the immunoglobulin levels, we concluded that the CALM/AF10 transgene 
expression in B-cells of the transgenic mice did not impair the immunoglobulin production in 
these animals. These results are in line with the observation that the transgenic animals 
remained clinically healthy for the whole observation period of over 15 months. 
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Flow cytometry 
Flow cytometry of the WBCs from blood, bone marrow and spleen was performed to assess 
the hematopoietic development in the transgenic animals. As no significant differences were 
observed between progenitors and differentiated cells from the myeloid and lymphoid 
compartments between transgenic and wild type mice, we concluded that the expression of the 
CALM/AF10 transgene in the cells of the B-lineage was not able to induce any obvious 
pathological or functional alteration. 
Analysis of the phenotype at pathological level 
Transgenic mice which expressed CALM/AF10 under the control of the IgH 
enhancer/promoter were sent for pathological analysis at two different time points. At the time 
of the first analysis, the mice had been housed in a non-SPF animal facility and had positive 
serology for the mouse hepatitis virus. In these animals, the histopathology detected plasma 
cell infiltration in the lamina propria of the small intestines and focal infiltration of plasma 
cells in the kidney (line 2 only). The regenerative lesions seen in the liver tissue could be 
consequence of viral infection (Quintanilla-Fend, personal communication). The plasma cell 
infiltration in the intestine and the germinal center hyperplasia of mesenterial lymph node, 
accompanied by hyperplasia of the paracortical area could be also a consequence of local 
infectious processes. Curiously, both control animals did not show any related pathological 
alteration.  
The transgenic mice from these two lines were transferred to animal facilities with SPF 
conditions via embryo transfer and, after 13 months were again analysed by histopathology. In 
these animals, there was no histopathological alteration related to the finding reported in the 
first mice sent to analysis. The histopathology findings did not diferred between transgenic 
and control animals, except for the lung altherations. Two transgenic animals, which were sent 
to analysis because the presented with respiratory distress, hyperpneia and cyanosis, had lung 
tumors. However, Mahler and colleagues (1996) described a high incidence of lung tumors 
(14% of males and 26% of females) in 14 month old FVB/N mice. 24 month old FVB/N mice 
had tumor rates ranging from 55% in females to 66% in males. The authors suggested that the 
high incidence of lung tumors in FVB/N mice should be considered when analyzing the 
phenotypes of transgenic FVB/N mice.  
We tested CALM/AF10 transgene expression in lung tissue by RT-PCR. The very low 
expression of CALM/AF10 found in the mice from the pIGCASV-40 line 1 could be the result 
of the presence of blood cells in the lung. The CALM/AF10 transcript could not be detected in 
the lung tissue of pIGCASV-40 line 2. This findings support the argument that the occurrence 
of lung tumors in these mice is an event not related to the expression of the CALM/AF10 
transgene. 
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6.2.2. FVB mice expressing CALM/AF10 under control of the Lck proximal promoter 
Generation of transgenic lines  
We obtained three lines of transgenic mice expressing CALM/AF10 under the control of the 
LCK proximal promoter. The transgene transmission to the offspring was close to 50% in 
these three lines, leading us to conclude together with the results from the Southern analysis, 
that only one integration site was present in each line. The Southern analysis in LCK lines 1 
and 2 showed that there was a single integration of multiple transgene copies. The enzyme 
EcoR1 has two recognition sites in the transgene cassette, which are situated 5 prime relative 
to the hybridization probe. The product of the restriction enzyme digestion of the construct is a 
DNA fragment of 6 kb, the size of the stronger band detected on the Southern analysis. As 
discussed for the results of the pIGCASV-40 lines, the occurrence of higher molecular weight 
bands which were different between the lines (about 7 kb for line 1 and about 8 kb for line 2) 
corresponds to the line-specific bands.  Although the CALM/AF10 transgene was detected by 
PCR from the tail DNA of mice from line 3, and the transgene transcript was also detected in 
different cells, the results of the Southern blot analysis for this line were negative. The probe 
used for the Southern analysis corresponds to the SV-40 region of the transgene construct. Our 
hypothesis is that the transgene is possibly truncated in this region. 
Analysis of transgene expression by RT-PCR 
We tested different organs and cells for the expression of CALM/AF10 in the pLCKCASV-40 
mice with emphasis on the expression in T-cells. The Lck proximal promoter is reported to be 
active in very early thymocytes (Brenner et al., 2001). The expression of the Lck proximal 
promoter driven transgene was specific for hematopoietic organs. No CALM/AF10 transcript 
was detected in lung or brain from any of the three lines. The thymus was the organ which 
showed expression in all transgenic lines. In order to confirm the specificity, we tested the 
following sub-populations: from the bone marrow Gr-1+/Mac-1+ cells, from the spleen B220+ 
cells, early CD4+/CD8+ T-cell progenitors, CD4+/CD8- T-helper cells, CD4-/CD8+ cytotoxic 
T-cells and very early CD4-/CD8-/CD3+ T cell progenitors. Unfortunately, the amount of 
cells obtained for this latter sub-population was not sufficient for RT-PCR analysis. Our 
expression results, showing CALM/AF10 expression in CD4+/CD8+ double positive T cell 
progenitors confirmed the activity of the Lck proximal promoter in early T-cells. The 
expression of the transgene in B220 cells found in the line 1 agrees with results from Adler 
and colleagues (1998). The expression of CALM/AF10 found only in CD8+ cells in line 3 
shows a specific T-cell expression, however in mature cells. The Lck distal promoter is 
reported to be predominantly active in mature T-cells (Reynolds et al., 1990).  
Discussion 125 
  
Analysis of transgene expression by Western blot 
The Western blot results for the pLCKCASV-40 transgenic mouse lines were similar as for 
the pIGCASV-40 mice. The reasons attributed for the non-detection of the fusion protein 
could be the same as for the other transgenic model. 
Hemogram 
The transgenic animals from the three pLCKCASV-40 lines were observed for a period of 
over 14 months and, like the IgH transgenic lines, did not show any clinical peculiarity. We 
carried out haematological analyis as described for the pIGCASV-40 mice. The values 
obtained for RBC count and WBC total and differential count did not differ significantly 
between transgenic and control mice. Considering these results, we decided to analyze the 
hematopoietic development by flow cytometry.  
Flow cytometry 
Our results for the transgenic mice expressing CALM/AF10 under the control of the Lck 
proximal promoter were comparable to results obtained for the two pIGCASV-40 transgenic 
lines. There was no difference between transgenic animals and wild type control animals. 
Analysis of the phenotype at pathological level 
Like in the IgH-CALM/AF10 transgenic lines, there were no pathological findings. The 
apparent abnormal histological findings in the organs analysed could be related to the FV/B 
mouse strain and are probably not  specifically related to the expression of the CALM/AF10 
transgene. 
 
6.2.2. General considerations about the CALM/AF10 transgenic animals 
As reported in several experiments with transgenic mice, the expression of a transgene early in 
embryonic development can lead to embryonic dead, making it difficult to study the fuction of 
the transgene in hematopoiesis (Okuda et al., 1996; Yergeau et al., 1997; Rhoades et al., 
2000).  To avoid this problem, we decide to restrict the expression of the CALM/AF10 fusion 
gene to immature B or T cells with the objective to generate transgenic lines which develop 
leukemia. There are CALM/AF10 positive leukemias which show a more differentiated 
phenotype (Narita et al., 1999; Carlson et al., 2000; Jones et al., 2001; Nakamura et al., 2003). 
On the other hand, CALM/AF10-associated leukemias are non-lineage specific and can be 
myeloid, lymphoid or biphenotypic. This observation supports the notion that the target cell 
for the leukemic transformation of CALM/AF10 is a quite immature cell (Ralph et al., 1983; 
Kumon et al., 1999). This would explain the inability of our constructs, in which the transgene 
expression is driven by either a B-cell or T-cell specific promoter, to cause leukemia.  
Another relevant fact which could be associated with the absence of leukemia in mice 
expressing CALM/AF10 under the control of an IgH enhancer/promoter might be due to a 
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functional interaction with the Pax5 (Paired box gene 5) gene. In the leukemic blasts from a 
CALM/AF10 positive bone marrow transplant model, Pax5, also known as BSAP (B-cell-
specific activator protein), is not expressed in B220 positive cells (Deshpande, personal 
communication). The expression of this gene is important for B-cell lineage commitment 
(Busslinger, 2004). In absence of Pax5, lymphopoiesis is blocked at the early pro-B stage, at 
which the cells still retain myeloid-lymphoid developmental potential (Rolink et al., 1999). 
Interestingly, Pax5 was shown to induce locus contraction of the IgH gene (Fuxa et al., 2004). 
In the absence of Pax5, a dramatic reduction of the VH-DJH is reported. If the expression of 
CALM/AF10 causes Pax5 down-regulated, we would have a negative feed-back in our IgH-
CALM/AF10 transgenic mice: the CALM/AF10 expression is directed by the IgH 
enhancer/promoter, which in turn is dependent on the Pax5 expression. However, we do not 
know whether the CALM/AF10 fusion protein is indeed able to directly or indirectly affect 
Pax5 transcription. 
 
In a mouse bone marrow transplantation model, Deshpande et al. (2005) transformed mouse 
bone marrow progenitor with a CALM/AF10 retroviral construct and transplanted the 
transduced bone marrow cells into lethally irradiated mice. All transplanted animals (n=13) 
developed leukemia within a short period of three to four months. The leukemic cells 
identified in this model expressed myeloid and lymphoid markers, supporting the hypothesis 
of a very early target cell for the leukemic transformation by CALM/AF10. Stem cells, with 
their un-limited potential to self renew, have a much higher chance to accumulate enough 
mutations to develop leukemia (Gilliland, 2004). Curiously, some CALM/AF10 leukemia 
patients cited in the literature and described in this work show the t(10;11) translocation as the 
sole cytogenetic chromosomal abnormality (Kumon et al., 1999; Bohlander et al., 2000;  
Krause et al., 2004) which indicates that the CALM/AF10 fusion might not require many 
other cooperating genetic events to cause leukemia. Dyrnan and colleagues (2005) generated 
MLL fusions-associated tumors in mice using Cre-loxP recombination in vivo. In this system, 
they used an Lck-Cre allele to express the MLL/AF9 (reported in myeloid leukemia) and 
MLL/ENL (observed in myeloid and lymphoid leukemias) in T cells and their progenitors. 
After a period of 18 months, 90% of the Lck-Cre –MLL/ENL mice developed either myeloid 
or lymphoid tumors, whereas no MLL/AF9 mouse developed leukemia. As the cells causing 
myeloid leukemia in the Lck-Cre –MLL/ENL mice were most likely derived from early T-
cells, they assumed that the MLL/ENL gene targets the cells around the time of V-D-J 
recombinase gene expression. They confirmed this hypothesis demonstrating that the myeloid 
tumor cells showed recombinations at the T-cell receptor or the immunoglobulin H chain 
genes. They concluded that MLL/ENL is able to transform partially commited cells and drive it 
differentiation to other lineages.  
Comparing these results with the results obtained by Deshpande (2005) in the CALM/AF10 
mouse transplantation model in which the tumor cells presented myeloid and lymphoid 
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markers, we can assume that a longer period of observation of the pLCKCASV-40 mice might 
be required. However, we can not rule out that the expression of the CALM/AF10 transgene is 
not strong enough in our transgenic lines or that the expression of the transgene occurs in cells 
that are already too committed to a certain cell lineage. 
 
6.3. Analysis of CALM/AF10 expression by RT-PCR and expression profiling of 
CALM/AF10 positive patients using microarray technology 
 
We were able to analyse samples from 17 CALM/AF10–positive leukemic patients. The 
patients were children or young adults, between 5 and 46 (average = 22) years old, a similar 
age distribution was reported in other studies for CALM/AF10 patients (Narita et al., 1999; 
Salmon-Nguyen et al., 2000; Bohlander et al., 2000). All leukemias were acute leukemias, 
undifferentiated or from the lymphoid or myeloid lineage.  We did not see any obvious 
correlation between age, diagnosis and the location of the breakpoints in CALM or AF10 in 
our patients. 
Among a series of 29 patients with T-ALL with T-cell receptor gd rearrangement, four (14%) 
were found positive for CALM/AF10 transcripts, confirming a previous report of the high 
incidence of CALM/AF10 among this group of leukemias (Asnafi et al., 2003).  
The reciprocal AF10/CALM transcript was identified in 7 of the 17 patients. The observation 
that the AF10/CALM transcripts can only be found in some patients has also been reported 
previously (Bohlander et al., 2000; Carlson et al., 2000), suporting the notion that 
CALM/AF10 is the relevant fusion protein in these leukemias.  
Gene expression profiling is becoming an important tool in the analysis of leukemias 
(Andersson et al., 2005; Haferlach et al., 2005). ALL with chromosomal rearrangements 
involving the MLL gene can be distinguished from ALL without MLL involvement. Three 
cytogenetically defined subtypes of AML: t(15;17), t(8;21) and inv(16) can also be recognized 
based on the gene expression profile (Schoch et al., 2002).  
Among our 17 CALM/AF10 patients, we were able to analyze the gene expression profile for 
10 of them. Hierarchical clustering analysis was performed using in addition the gene 
expression profile of 20 AML patients with MLL rearrangements and 20 patients with t(8;21) 
positive AML. The hierarchical clustering analysis was restricted to the HOX A cluster genes 
and MEIS1. Furthermore, the gene expression profile of the CALM/AF10 positive patients 
was compared to the profile of groups of 15 patients from each of 9 other leukemia subtypes: 
T-ALL, ALL with MLL rearrangements, AML with MLL rearrangements, AML with 
inversion of the chromosome 16, AML showing normal karyotype, AML t(8;21), AML with 
acute promyelocytic leukemia, AML with complex aberrant karyotype, as well as from 15 
normal bone marrow control samples. 
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The hierarchical clustering revealed high expression levels of the homeobox gene MEIS1, and 
the HOXA cluster genes HOXA1, HOXA4, HOXA5, HOXA7, HOXA9, HOXA10.  The 
CALM/AF10 patients had a very similar expression pattern to patients with MLL 
rearrangements as far as these genes were concerned. Curiously, from the ten CALM/AF10 
patients analyzed, only two had a diagnosis of AML and one of an acute biphenotypic 
leukemia. The other seven patients had been diagnosed as ALL (1), T-ALL (2), Pro T-ALL 
(2) and Pre T-ALL (2). These results led to the conclusion of a common expression pattern 
between CALM/AF10 patients independently of the type of leukemia (lymphoid or myeloid), 
considering the expression of the above-cited genes.  
When looking for differentially expressed genes that were specific for CALM/AF10 
leukemias, only three genes (DNAJC1, COMMD3 and BMI1) were found to be consistenly 
higher expressed in CALM/AF10 patients compared to all other leukemia groups analyzed. 
Since these three genes are located downstream (centromeric) to the 10p21 breakpoint, a 
position effect caused by the juxtapposition of the strong CALM promoter or enhancer in the 
10;11 translocation can be assumed. This phenomenon has also been observed by Dik and 
colleagues, who showed overexpression of HOXA genes and BMI1 and the two other genes 
(DNAJC1 and COMMD3) which lie in the vicinity of the breakpoint on 10p12 (Dik et al., 
2005). They analyzed six CALM/AF10 T-ALL patients and compared their expression profiles 
to 17 T-ALL CALM/AF10 negative patients. However, they did not see higher expression 
levels of HOXA7.  
The involvement of HOX genes in acute leukemias has been widely reported (Blatt et al., 
1988; Kroon et al., 1998; Thorsteinsdottir et al., 2001; Ayton and Cleary, 2003; Soulier et al., 
2005). Ayton and Cleary (2003) showed the dependence of MLL fusion proteins on Hoxa9 and 
Hoxa7 to transform myeloid progenitors in a mouse transplantation model. The mechanism by 
which MLL fusion genes can induce leukemia is probably related to chromatin structure. MLL 
has intrinsic histone H3, lysine 4 methyltransferase activity encoded by its SET (Su(var)3-9, 
Enhancer-of-zeste, Thithorax) domain and in addition recruits the SWI/SNF chromatin 
remodelling complex. These domains are lost in MLL fusions so that the chromatin-associated 
functions might come from the fusion partner (Zeisig et al., 2005). Yi Zhang’s group (Okada 
et al. 2005) found an interaction between AF10 and MLL/AF10 and the human histone 
methyltransferase hDOT1L (disruptor of telomeric silencing 1). hDOT1L was shown to be 
able to transform myeloid progenitors when fused to MLL. It was also shown that the 
octapeptide-leucine zipper motif of AF10 is necessary and sufficient for the interaction with 
hDOT1L. MLL/AF10 associated myeloid transformation was accompanied by up-regulation 
of Hoxa9 and Hoxa7. In addition, AF10 also interacts with GAS41, a protein which interacts 
with the SWI/SNF complex. Soulier et al. (2005) observed upregulation of all HOXA genes in 
T-ALL patients, suggesting that HOXA up-regulation as a common feature of these leukemias. 
The TALE (three amino acid loop extension) homeobox cofactor Meis1 was shown to 
collaborate with HOXB3 in leukemogenesis and accelerate the onset of HOXA-induced 
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leukemias as well as to reduce the latency of leukemias in mice transplanted with cells 
retrovirally-expressing the fusion gene NUP98-HOXD13 (Thorsteinsdottir et al., 2001; 
Pineault et al., 2003).   
Considering the similar overexpression pattern of HOX genes observed in MLL- and in 
CALM/AF10-induced leukemias, the leukemogenic mechanisms in both entities could have a 
common pathway. 
When the gene expression profiles of the CALM/AF10 patients was compared to the 
expression profiles of other leukemia patients or normal bone marrow it became apparent that 
more than 90% of the top 100 differentially regulated genes were down-regulated in the 
CALM/AF10 patients. Some of the more interesting down-regulated genes (Table 21) are 
discussed in the following paragraphs. 
RAB34: was the gene with the strongest repression in the CALM/AF10 samples. The Rab 
family is associated with vesicle membrane compartment functions and is important in vesicle 
trafficking (Sun et al., 2003).  
TRIO (Triple fuctional domain) protein gene, which is involved in phagocytosis of apoptotic 
cells was found expressed at a high frequence in oral carcinomas (de Bakker et al., 2004; 
Baldwin et al., 2005). 
The CEBPD (CAAT/enhancer binding protein d) gene belongs to the C/EBP family of 
transcription factors and is important in proliferation, differentiation and apoptosis. CEBPD is 
a putative tumor suppressor gene whose deficiency in mouse fibroblasts cells caused impaired 
growth control and was associated with chromosomal instability (Huang et al., 2004). 
Mutations in C/EBPD gene are common in human breast cancer (Tang and DeWille, 2002). 
ST7 is a tumor suppressor gene which is downregulated by promoter methylation mediated by 
the PRMT5 (protein arginine methyltransferase), a protein associated with the human 
SWI/SNF complex (Pal et al., 2004). 
The expression of H2AFJ (histone family member J) was correlated with human melanocytic 
tumour (de Wit et al., 2005). 
JAG1 (jagged1) is a NOTCH ligand, whose expression is associated with bad prognosis in 
human breast cancer (Reedijk et al, 2005). 
HCK (hematopoietic cell kinase) is a src kinase family member, expressed in hematopoietic 
cells including myeloid cells and to a minor extent in B-cells (Quintrel et al., 1987). The 
inactivation of the HCK gene results in defects in phagocytosis in macrophages (Hauses et al., 
1998). 
TEM7R (tumor endothelial marker 7) is abundantly expressed in tumor endothelial cells 
(Nanda et al., 2004). 
CDH15 (Cadherin 15): Cadherins are a family of cell surface molecules involved in cellular 
structural and functional organization. The loss of heterozigosity of cadherin gene found in 
solid tumors makes these family of genes candidate tumor supressor genes (Kremmidiotis et 
al., 1998; Cool and Jolicoer, 1999). 
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CTSZ (Cystein Protease Cathepsin Z) is expressed in pancreatic cell lines (Mahlamäki et al., 
2002). 
CTNNA1(aE-catenin) can suppress tumor invasion in human cancer (Vermeulen et al., 1999). 
TKR2 (Human toll-like receptor 2) is a membrane receptor playing a role in innate immunity 
which activates NF-kB (Yang et al., 1999). 
HOXB4 is a member of the HOX B gene cluster. HOXB4 expression has been shown to 
increase the self-renewal of HSCs without disrupting differentiation (Abramovich et al., 
2005).  
USP3 (ubiquitin specific protease 3):  functions in deubiquitination processes (Sloper-Mould 
et al., 1999). 
ZNF185 (zink finger protein 185) was identified by expression profiling in prostate cancer. 
The methylation of the ZNF185 promoter transcriptional silencing of this gene is implicated in 
prostate tumorigenesis (Vanaja et al., 2003). 
The transcriptional repression of these genes of which several have important functions in 
membrane trafficking, cellular growth, self-renewal, differentiation, angiogenesis and tumor 
suppression, could very well contribute to the transforming and leukemogenic potential of 
CALM/AF10. However, more detailed functional studies as well as the proof that these genes 
are direct targets of CALM/AF10-mediated gene regulation (see also next paragraph) are 
required to corroborate these assumptions. 
6.3. Inducible expression of CALM/AF10 in cell lines 
Stable and transient transfection of mammalian cells 
Stable transfection of mouse fibroblast with the pRTS-CALM/AF10 plasmid using puromycin 
selection resulted in a polyclonal cell line that was still expressing CALM/AF10 at low basal 
levels. The inducibility of these cells, assessed flow cytometry of GFP-positive cells 24 h after 
induction, was about 30%. We asked for advise about the use of this system in the group 
which developed this vector (Michael Hölzer, personal communication) and received the 
suggestion to induce the cells a short period after transient transfection. It had been observed 
that the expression of the gene of interest from this vector became leaky after the cells were in 
culture for a period of longer than two months. The cells we were working with had been in 
culture for about 4 months and had been frozen and thawed.  
Nevertheless, this tet-inducible system was shown to be useful to induce the gene expression 
and we could obtain doxycycline-inducible CALM/AF10 protein expression.  
This system will be an important tool to define direct target genes of the CALM/AF10 fusion 
protein. Using this inducible system, we will also be able to answer the question of whether 
CALM/AF10 induced transcriptional activation or repression can become epigenitically fixed 
or whether the continued presence of the CALM/AF10 fusion protein is required to maintain 
the CALM/AF10 specific gene expression pattern. 
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7. SUMMARY 
 
The t(10;11)(p13;q14) is a recurring translocation resulting in the fusion of the CALM and 
AF10 genes. The leukemogenic CALM/AF10 fusion genes codes for a 1595 amino acids 
protein. This translocation was first identified in a patient with hystiocytic lymphoma and was 
subsequently found in patients with AML, T-ALL and malignant lymphoma. This 
translocation is found in younger patients and is associated with a poor prognosis. 
The CALM/AF10-associated leukemias can exhibit myeloid, lymphoid or mixed lymphoid-
meyloid features, indicating a stem cell or an early commited progenitor as the target cell of 
leukemic transformation. At the present time the target cells in CALM/AF10-associated 
leukemogenesis are unknown. It is also not known which target genes are up or downregulated 
by the presence of the CALM/AF10 fusion protein. 
To answer these questions, the following experiments were performed: 
1) Five transgenic mouse lines, two expressing CALM/AF10 under the control of the 
immunoglobulin heavy chain enhancer promoter and three under the control of the murine 
proximal Lck promoter were generated. Although the CALM/AF10 expression was 
confirmed to be present and specific to the cells targeted by the promoters used (B- and T-
cell progenitors for IgH and Lck promoters, respectively), the transgenic animals did not 
show a phenotype that could be detected after meticulous clinical, haematological, 
immunological, flow cytometrical and immunohistopatological analysis .  
2) We performed molecular characterization of several CALM/AF10 patient samples: A group 
of 13 patients with different types of leukemia: case 1 (AML M2), case 2 (Acute 
Biphetnotypic leukemia), case 3 (Pre T-ALL), case 4 (Acute Undifferentiated Leukemia), 
case 5 (PreT-ALL), cases 6 and 7 (ProT-ALL), case 8 (T-ALL), case 9 (AML), case 14 (T-
ALL), case 15, 16 and 17 (AML) with a t(10;11) translocation detected by cytogenetic 
analysis suggesting a CALM/AF10-rearrangement. The samples were analyzed for the 
presence of the CALM/AF10 and AF10/CALM fusion transcripts by RT-PCR and sequence 
analysis. All these patients were found to be positive for the CALM/AF10 fusion. In 
addition, we analyzed a series of twenty-nine patients with T-ALL with T-cell receptor gd 
rearrangement. Among these patients, four (case 10 to 13) were positive for the 
CALM/AF10 fusion transcript, indicating a high incidence of CALM/AF10 fusions in this 
group of leukemia.  
Three different breakpoints in CALM at nucleotide 1926, 2091 and a new exon, with 106 
bases inserted after nt 2064 of CALM in patient 4 were found. In AF10 four breakpoints 
were identified: at nucleotide position 424, 589, 883 and 979. In patient 16 we found an 
extra exon before nt 424 of AF10. In seven patients it was also possible to amplify the 
reciprocal AF10/CALM fusion transcript (case 1, 3, 4, 8, 9, 10 and 14). There was no 
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correlation between disease phenotype and breakpoint location. Ten CALM/AF10 positive 
patients were analyzed using oligonucleotide microarrays representing 33,000 different 
genes (U133 set, Affymetrix). Analysis of microarray gene expression signatures of these 
patients revealed high expression levels of the polycomb group gene BMI1, the homeobox 
gene MEIS1 and the HOXA cluster genes HOXA1, HOXA4, HOXA5, HOXA7, HOXA9, and 
HOXA10. The overexpression of HOX genes seen in these CALM/AF10 positive leukemias 
is reminiscent to the pattern seen in leukemias with rearrangements of the MLL gene, 
normal karyotypes and complex aberrant karyotypes suggesting a common effector 
pathway (i.e. HOX gene deregulation) for these diverse leukemias. In addition, the general 
pattern of gene expression of CALM/AF10 patients when compared to other leukemia 
subtypes and to normal bone marrow was dominated by a global downregulation of genes 
some of them with function identified as related to important molecular mechanisms, such 
as membrane trafficking, cell growth regulation, proliferation, differentiation and tumor 
suppression.  
3) We cloned CALM/AF10 fusion gene into a vector that allowed us to induce the expression 
of CALM/AF10 using doxycycline in transiently and stably-transfected NIH3T3 and 
HEK293 cells. This system will be an important tool to identify direct CALM/AF10 target 
genes and to answer the question whether continued CALM/AF10 expression is necessary 
to maintain the CALM/AF10-associated expression pattern.  
 
 
Zusammenfassung 134
  
  
8. ZUSAMMENFASSUNG 
Die t(10;11)(p13;q14) ist eine seltene aber wiederholt auftretende Translokation, die eine 
Fusion zwischen den Genen CALM and AF10 verursacht.  Das leukämogene CALM/AF10 
Fusionsgen kodiert für ein ca. 1600 Aminosäure langes Protein. Diese Translokation wurde in 
der U937 Zellinie, die von einem Patienten mit hystiozytischem Lymphom etabliert wurde, 
zuerst beschrieben und wurde in der Folge auch bei Patienten mit AML, T-ALL und 
malignem Lymphom gefunden. Diese Translokation kommt in jüngeren Patienten vor und 
geht mit einer eher schlechten Prognose einher.  
Die CALM/AF10-positiven Leukämien haben einen myeloischen, lymphatischen oder 
gemischte lymphatisch-meyloischen Phenotyp, was darauf hindeutet, dass eine 
hämatopoetische Stammzelle oder eine sehr frühe Blutvorläuferzelle die Zielzelle bei der 
CALM/AF10-bedingten Transformation ist. Diese Zielzelle ist noch unbekannt. Weiterhin ist 
nicht bekannt, was die Zielegene des CALM/AF10 Fusionsproteins sind. Um diese Fragen zu 
beantworten, wurden die folgende Experimente durchgeführt: 
1) Es wurden fünf transgenen Mauslinien, zwei die das CALM/AF10-Gen unter die 
Kontrolle des Immunoglobulin Heavy Chain Enhancer Promoters exprimieren und drei 
weitere, die das Transgen unter der Kontrolle proximalen murinen Lck Promoters 
exprimieren. Obwohl die zellspezifische Expression des Transgens auf RNA-Ebene 
nachgewiesen wurde, konnte nach sorgfältigen klinischen, hämatologischen, 
immunologischen, zytometrischen und immunohistopathologischen Untersuchungen keine 
durch das Transgen verursachte pathologische Veränderungen nachgewiesen werden. 
2) Es wurden CALM/AF10-positive Patientenproben molekular charakterisiert: Eine 
Gruppe von 13 Patienten mit verschiedenen Leukämien und zytogenetisch nachgewiesener 
t(10;11)(p12;q14): Patient 1  (AML M2), Patient 2 (Akute biphänotypische Leukämie), Patient 
3 (Pre T-ALL), Patient 4 (Akute undifferentierte Leukämia), Patient 5 (Pre T-ALL), Patienten 
6 und 7 (ProT-ALL), Patient 8 (T-ALL), Patient 9 (AML), Patient 14 (T-ALL), Patienten 15, 
16 und 17 (AML). Die Patientenproben wurden auf das Vorhandensein von CALM/AF10 und 
AF10/CALM Fusionstranskripten mittles RT-PCR untersucht. Bei allen Patienten wurden ein 
CALM/AF10 Fusionstranskript gefunden. Weiterhin wurde eine Gruppe von 29 Patienten, bei 
denen eine T-ALL mit T-cell Receptor g/d vorlag, auf das Vorhandensein des CALM/AF10 
Fusionstranskriptes getestet. Bei vier dieser Patienten konnte das CALM/AF10 Fusionsgen 
nachgewiesen werden, was eine hohe Prävalenz der CALM/AF10 Fusion bei dieser Gruppe 
von Leukämien anzeigt.  
Drei Bruchpunkte wurden in CALM gefunden: Bei Nukleotid 1926, 2091 und 2064. Bei 
Patient 4 wurde ein bisher nicht beschriebenes CALM Exon, mit 106 Basen gefunden. In 
AF10 wurden vier Bruchpunkte identifiziert: bei Nukleotid 424, 589, 883 und 979.  Bei 
Patient 16 wurde einen zusätzliches Exon vor Nt 424 von AF10 gefunden. Bei sieben 
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Patienten (Nr 1, 3, 4, 8, 9, 10 and 14) konnte auch das reziproke AF10/CALM 
Fusiontranskript mittels RT-PCR amplifiziert werden. Es wurde keine Korrelation zwischen 
der Art der Leukämie und der Lokalisation der Bruchpunkte in CALM oder AF10 festgestellt.  
Bei Leukämieproben von zehn CALM/AF10 positive Patienten wurden mittels 
Oligonukleotide Microarrays, die 33,000 verschiedenen Genen entschprachen (U133 set, 
Affymetrix) ein Expressionsprofil erstellt.  Die Analyse von Microarray Gene Expression 
Signaturen dieser Patienten zeigte hohe Expressionsraten des Polycombgruppe Gens BMI1, 
des Homeobox Gens MEIS1 und der HOXA Gen Cluster-Gene  HOXA1, HOXA4, HOXA5, 
HOXA7, HOXA9 und HOXA10. Die Überexpression von HOX Genen bei CALM/AF10 
positiven Leukämie wird in ähnlicher Weise bei Leukämien mit MLL Rearrangements und 
normalen so wie komplex aberranten Karyotypen beobachtet. Dies weist auf einen 
gemeisamen Pathway (i.e. HOX Gen-Deregulierung) bei diesen Leukämien hin. Insgesamt 
wurde bei den CALM/AF10 positiven Leukämien im Vergleich zu anderen Leukämieentitäten 
und zu normalem Knochenmark eine globale Repression der Genexpression beobachtet. 
Einige dieser signifikant reprimierten Gene sind an wichtigen zellulären Prozessen wie 
Membrantransport, Zellwachstum, Zellproliferation, Differenzierung und Tumorsupression 
beteiligt. 
3) Das CALM/AF10 Fusionsgen wurde in einen Vector kloniert, der die induzierbares 
Expression von CALM/AF10 in transient und stabil transfizierten NIH3T3 und HEK293 
ermöglicht. Mithilfe dieses Systems werden sich die unmittelbaren CALM/AF10 Zielgene 
identifizieren lassen. Weiterhin wird untersucht werden können, ob eine kontinuierliche 
Expression von CALM/AF10 notwendig ist, um das Expressionmuster der Zielgene 
aufrechtzuerhalten. 
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10. APPENDIX   
 
Table 22: Average, Standard Deviation and Statistical Analysis of Serum 
Immunoglobulins of pIGCASV-40 mice and FVB control mice.  
Average ± Standard deviation Line Immunoglobulin 
POS NEG 
P value Result 
IgA 2,342 ± 0,142 2,374 ± 0,179 0,7782 POS = NEG 
IgG1 3,276 ± 0,295 3,473 ± 0,204 0,3133 POS = NEG 
IgG2a 2,537 ± 0,516 2,255 ± 0,563 0,4649 POS = NEG 
IgG2b 3,038 ± 0,409 3,142 ± 0,475 0,7384 POS = NEG 
IgG3 3,005 ± 0,242 3,135 ± 0,068 0,2842 POS = NEG 
L1 
IgM 2,547 ± 0,254 2,620 ± 0,327 0,7284 POS = NEG 
IgA 1,433 ± 0,218 1,452 ± 0,116 0,8603 POS = NEG 
IgG1 1,964 ± 0,528 2,120 ± 0,426 0,6017 POS = NEG 
IgG2a 2,182 ± 0,583 2,743 ± 0,457 0,1063 POS = NEG 
IgG2b 2,338 ± 0,264 2,179 ± 0,135 0,2284 POS = NEG 
IgG3 2,493 ± 0,344 2,649 ± 0,326 0,4609 POS = NEG 
L2 
IgM 3,542 ± 0,185 3,539 ± 0,103 0,9785 POS = NEG 
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Table 23: Average, Standard Deviation and Statistical Analysis of Immunophenotype 
from Blood Cells of pIGCASV-40 mice and FVB control mice.  
Average ± standard deviation Antigen 
Transgenic %* Control %** 
P value Result 
c-Kit+ Sca-1+ 0.44 + 0.298 0.22 + 0.269  0.178 Transgenic = Control 
c-Kit- Sca-1+ 68.06 + 13.61 62.51 + 15.05  0.321 Transgenic = Control 
c-Kit+ Sca-1- 0.0525 + 0.098 0.236 + 0.304  0.203 Transgenic = Control 
Gr-1+ Mac-1+ 42.737 + 20.64 42.6 +  24.87 0.497 Transgenic = Control 
Gr-1- Mac-1 + 11.68 + 1.834 12.806 + 5.789 0.386 Transgenic = Control 
Gr-1+ Mac-1- 5.62 + 1.821 4.9 + 0.953  0.265 Transgenic = Control 
B220+ CD3+ 0.872 + 0.752 0.526 + 0.463  0.244 Transgenic = Control 
B220- CD3+ 60.467 + 15.87 55.56 + 21.001  0.376 Transgenic = Control 
B220+CD3- 5.345 + 4.297 8.57 + 9.954  0.320 Transgenic = Control 
B220+ CD19+ 32.43 + 24.38 36.67 + 28.108  0.422 Transgenic = Control 
B220- CD19+ 0.175 + 0.254 0.333 + 0.3401  0.269 Transgenic = Control 
B220+ CD19- 0.605 + 0.737 0.93 + 0.5678  0.269 Transgenic = Control 
B220+ CD43+ 85.225 + 8.637 85.06 + 1.82  0.486 Transgenic = Control 
B220- CD43+ 2.897 + 1.934 5.316 + 4.485  0.227 Transgenic = Control 
B220+ CD43- 0.152 + 0.199 1.1 + 1.75  0.223 Transgenic = Control 
*n = 7, **n = 5 
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Table 24: Average, Standard Deviation and Statistical Analysis of Immunophenotype 
from Bone Marrow Cells of pIGCASV-40 mice and FVB control mice. 
Average ± standard deviation Antigen 
Transgenic %* Control %** 
P value Result 
c-Kit+ Sca-1+ 0.775 + 0.143 0.9 + 0.221  0.225 Transgenic = Control 
c-Kit- Sca-1+ 8.71 + 4.465 6.193 + 1.145  0.174 Transgenic = Control 
c-Kit+ Sca-1- 1.612 + 0.294 1.676 + 0.747  0.449 Transgenic = Control 
Gr-1+ Mac-1+ 38.112 + 15.645 37.5 + 10.019 0.476 Transgenic = Control 
Gr-1- Mac-1 + 6.747 + 2.631 8.046 + 1.375 0.219 Transgenic = Control 
Gr-1+ Mac-1- 1.55 + 0.410 1.52 + 0.5  0.468 Transgenic = Control 
B220+ CD3+ 0.117 + 0.080 0.0733 + 0.0635 0.227 Transgenic = Control 
B220- CD3+ 1.635 + 0.964 1 + 0.398  0.148 Transgenic = Control 
B220+CD3- 19.757 + 3.509 19.086 + 3.245  0.402 Transgenic = Control 
B220+ CD19+ 21.84 + 11.279 14.383 + 3.738  0.143 Transgenic = Control 
B220- CD19+ 0.312 + 0.267 0.04 + 0.0346  0.068 Transgenic = Control 
B220+ CD19- 2.632 + 1.357 3.04 + 0.582  0.308 Transgenic = Control 
B220+ CD43+ 15.655 + 3.177 14.593 + 3.683 0.354 Transgenic = Control 
B220- CD43+ 61.915 + 9.250 58.646 + 16.793  0.390 Transgenic = Control 
B220+ CD43- 18.572 + 6.019 19.286 + 5.665 0.439 Transgenic = Control 
*n = 7, **n = 5 
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Table 25: Average, Standard Deviation and Statistical Analysis of Immunophenotype 
from Splenocytes of pIGCASV-40 mice and FVB control mice. 
Average ± standard deviation Antigen 
Transgenic %* Control %** 
P value Result 
c-Kit+ Sca-1+ 0.982 + 0.729 0.64 + 0.164  0.212 Transgenic = Control 
c-Kit- Sca-1+ 76.75 + 15.81 65.95 + 7.208  0.144 Transgenic = Control 
c-Kit+ Sca-1- 0.1925 + 0.095 0.236 + 0.021  0.214 Transgenic = Control 
Gr-1+ Mac-1+ 3.785 + 1.726 5.48 + 2.484 0.188 Transgenic = Control 
Gr-1- Mac-1 + 4.625 + 1.251 6.493 + 2.220 0.141 Transgenic = Control 
Gr-1+ Mac-1- 3.492 + 0.783 3.393 + 0.734  0.435 Transgenic = Control 
B220+ CD3+ 0.832 + 0.170 1.116 + 0.537  0.244 Transgenic = Control 
B220- CD3+ 37.587 + 10.408 45.686 + 3.863  0.112 Transgenic = Control 
B220+CD3- 23.41 + 11.15 20.126 + 3.487  0.305 Transgenic = Control 
B220+ CD19+ 55.512 + 16.310 44.79 + 2.549  0.141 Transgenic = Control 
B220- CD19+ 0.225 + 0.0858 0.323 + 0.182  0.228 Transgenic = Control 
B220+ CD19- 0.602 + 0.106 1.016 + 0.681  0.201 Transgenic = Control 
B220+ CD43+ 50.997 + 9.678 52.663 + 7.504  0.404 Transgenic = Control 
B220- CD43+ 8.74 + 6.302 10.746 + 8.942  0.379 Transgenic = Control 
B220+ CD43- 40.192 + 4.436 38.25 + 1.775  0.235 Transgenic = Control 
*n = 7, **n = 5 
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Table 26: Average, Standard Deviation and Statistical Analysis of Immunophenotype 
from WBCs of pLCKCASV-40 mice and FVB control mice. 
Average ± standard deviation WBC antigen 
Transgenic %* Control %** 
P value Result 
B220- CD3+ 28.703 + 5.504  31.643 + 3.668 0.484 Transgenic = Control 
B220+ CD3- 35.843 + 7.567 35.193 + 2.810 0.895 Transgenic = Control 
CD3+CD4-CD8- 11.783 + 1.486 14.94 + 0.521 0.053 Transgenic = Control 
CD4+CD8+ 40.073 + 3.297 39.18 + 4.702 0.800 Transgenic = Control 
CD4-CD8+ 0.8166 + 0.174 0.516 + 0.066 0.082 Transgenic = Control 
CD4+CD8- 56.5 + 2.748 57.96 + 4.616 0.662 Transgenic = Control 
Gr-1+ Mac-1- 30.863 + 3.882 22.516 + 1.744 0.0478 Transgenic = Control 
Gr-1- Mac-1 + 14.633 + 3.898 12.066 + 2.698 0.401 Transgenic = Control 
Gr-1+ Mac-1+ 2.423 + 0.669 1.926 + 0,525 0.369 Transgenic = Control 
Ter119+ B220+ 1.38 + 0.194 1.963 + 0.359 0.068 Transgenic = Control 
Ter119- B220+ 9.903 + 1.125 9.106 + 0.815 0.381 Transgenic = Control 
Ter119+ B220- 21.546 + 1.082 23.526 + 2.819 0.319 Transgenic = Control 
c-Kit+ Sca-1+ 0.843 + 0.527 1.17 + 0.615 0.524 Transgenic = Control 
c-Kit- Sca-1+ 10.063 + 1.673 10.786 + 1.054 0.561 Transgenic = Control 
c-Kit+ Sca-1- 4.14 + 4.028 5.74 + 3.420 0.628 Transgenic = Control 
*n = 3, **n = 3 
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1    TAG TTA TTA ATA GTA ATC AAT TAC GGG GTC ATT AGT TCA TAG CCC ATA TAT GGA GTT CCG    
61   CGT TAC ATA ACT TAC GGT AAA TGG CCC GCC TGG CTG ACC GCC CAA CGA CCC CCG CCC ATT                        
181  GAC GTC AAT AAT GAC GTA TGT TCC CAT AGT AAC GCC AAT AGG GAC TTT CCA TTG ACG TCA                         
241  ATG GGT GGA GTA TTT ACG GTA AAC TGC CCA CTT GGC AGT ACA TCA AGT GTA TCA TAT GCC                   
301  AAG TAC GCC CCC TAT TGA CGT CAA TGA CGG TAA ATG GCC CGC CTG GCA TTA TGC CCA GTA                        
361  CAT GAC CTT ATG GGA CTT TCC TAC TTG GCA GTA CAT CTA CGT ATT AGT CAT CGC TAT TAC  
421  CAT GGT GAT GCG GTT TTG GCA GTA CAT CAA TGG GCG TGG ATA GCG GTT TGA CTC ACG GGG   
481  ATT TCC AAG TCT CCA CCC CAT TGA CGT CAA TGG GAG TTT GTT TTG GCA CCA AAA TCA ACG   
541  GGA CTT TCC AAA ATG TCG TAA CAA CTC CGC CCC ATT GAC GCA AAT GGG CGG TAG GCG TGT                                                                                       
601  ACG GTG GGA GGT CTA TAT AAG CAG AGC TGG TTT AGT GAA CCG TCA GAT CCG CTA GCG CTA   
     CCG GTC GCC ACC ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG   
                      M   V   S   K   G   E   E   L   F   T   G   V   V   P   I   L> 
721  GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC GAG GGC GAG GGC   
      V   E   L   D   G   D   V   N   G   H   K   F   S   V   S   G   E   G   E   G> 
781  GAT GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG   
      D   A   T   Y   G   K   L   T   L   K   F   I   C   T   T   G   K   L   P   V> 
841  CCC TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC   
      P   W   P   T   L   V   T   T   L   T   Y   G   V   Q   C   F   S   R   Y   P> 
901  GAC CAC ATG AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG   
      D   H   M   K   Q   H   D   F   F   K   S   A   M   P   E   G   Y   V   Q   E> 
961  CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG   
      R   T   I   F   F   K   D   D   G   N   Y   K   T   R   A   E   V   K   F   E> 
1021 GGC GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC                          
      G   D   T   L   V   N   R   I   E   L   K   G   I   D   F   K   E   D   G   N> 
1081 ATC CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC   
      I   L   G   H   K   L   E   Y   N   Y   N   S   H   N   V   Y   I   M   A   D> 
1141 AAG CAG AAG AAC GGC ATC AAG GTG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC   
      K   Q   K   N   G   I   K   V   N   F   K   I   R   H   N   I   E   D   G   S> 
1201 GTG CAG CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG   
      V   Q   L   A   D   H   Y   Q   Q   N   T   P   I   G   D   G   P   V   L   L> 
1261 CCC GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC   
      P   D   N   H   Y   L   S   T   Q   S   A   L   S   K   D   P   N   E   K   R> 
1321 GAT CAC ATG GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG                          
      D   H   M   V   L   L   E   F   V   T   A   A   G   I   T   L   G   M   D   E> 
1381 CTG TAC AAG TCC GGA CTC AGA TCT CGA GGT CGA CGG TAT CGG GGG ATC GAT CCG CAT GCG   
      L   Y   K   S   G   L   R   S   R   G   R   R   Y   R   G   I   D   P   H   A> 
1441 AGC TCG GTA CCC CGG CTG CTG AGC GGG TGG GGT GGT GGA GGA GCT GCA GAG ATG TCC GGC   
      S   S   V   P   R   L   L   S   G   W   G   G   G   G   A   A   E   M   S   G> 
1501 CAG AGC CTG ACG GAC CGA ATC ACT GCC GCC CAG CAC AGT GTC ACC GGC TCT GCC GTA TCC  
      Q   S   L   T   D   R   I   T   A   A   Q   H   S   V   T   G   S   A   V   S> 
1561 AAG ACA GTA TGC AAG GCC ACG ACC CAC GAG ATC ATG GGG CCC AAG AAA AAG CAC CTG GAC   
      K   T   V   C   K   A   T   T   H   E   I   M   G   P   K   K   K   H   L   D> 
1621 TAC TTA ATT CAG TGC ACA AAT GAG ATG AAT GTG AAC ATC CCA CAG TTG GCA GAC AGT TTA   
      Y   L   I   Q   C   T   N   E   M   N   V   N   I   P   Q   L   A   D   S   L> 
1681 TTT GAA AGA ACT ACT AAT AGT AGT TGG GTG GTG GTC TTC AAA TCT CTC ATT ACA ACT CAT   
      F   E   R   T   T   N   S   S   W   V   V   V   F   K   S   L   I   T   T   H> 
1741 CAT TTG ATG GTG TAT GGA AAT GAG CGT TTT ATT CAG TAT TTG GCT TCA AGA AAC ACG TTG   
      H   L   M   V   Y   G   N   E   R   F   I   Q   Y   L   A   S   R   N   T   L> 
1801 TTT AAC TTA AGC AAT TTT TTG GAT AAA AGT GGA TTG CAA GGA TAT GAC ATG TCT ACA TTT   
      F   N   L   S   N   F   L   D   K   S   G   L   Q   G   Y   D   M   S   T   F> 
1861 ATT AGG CGG TAT AGT AGA TAT TTA AAT GAG AAA GCA GTT TCA TAC AGA CAA GTT GCA TTT   
      I   R   R   Y   S   R   Y   L   N   E   K   A   V   S   Y   R   Q   V   A   F> 
1921 GAT TTC ACA AAA GTG AAG AGA GGG GCT GAT GGA GTT ATG AGA ACA ATG AAC ACA GAA AAA  
      D   F   T   K   V   K   R   G   A   D   G   V   M   R   T   M   N   T   E   K> 
1981 CTC CTA AAA ACT GTA CCA ATT ATT CAG AAT CAA ATG GAT GCA CTT CTT GAT TTT AAT GTT   
      L   L   K   T   V   P   I   I   Q   N   Q   M   D   A   L   L   D   F   N   V> 
2041 AAT AGC AAT GAA CTT ACA AAT GGG GTA ATA AAT GCT GCC TTC ATG CTC CTG TTC AAA GAT   
      N   S   N   E   L   T   N   G   V   I   N   A   A   F   M   L   L   F   K   D> 
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2101 GCC ATT AGA CTG TTT GCA GCA TAC CAT GAA GGA ATT ATT AAT TTG TTG GAA AAA TAT TTT   
      A   I   R   L   F   A   A   Y   H   E   G   I   I   N   L   L   E   K   Y   F> 
2161 GAT ATG AAA AAG AAC CAA TGC AAA GAA GGT CTT GAC ATC TAT AAG AAG TTC CTA ACT AGG   
      D   M   K   K   N   Q   C   K   E   G   L   D   I   Y   K   K   F   L   T   R> 
2221 ATG ACA AGA ATC TCA GAG TTC CTC AAA GTT GCA GAG CAA GTT GGA ATT GAC AGA GGT GAT   
      M   T   R   I   S   E   F   L   K   V   A   E   Q   V   G   I   D   R   G   D> 
2281 ATA CCA GAC CTT TCA CAG GCC CCT AGC AGT CTT CTT GAT GCT TTG GAA CAA CAT TTA GCT   
      I   P   D   L   S   Q   A   P   S   S   L   L   D   A   L   E   Q   H   L   A> 
2341 TCC TTG GAA GGA AAG AAA ATC AAA GAT TCT ACA GCT GCA AGC AGG GCA ACT ACA CTT TCC   
      S   L   E   G   K   K   I   K   D   S   T   A   A   S   R   A   T   T   L   S> 
2401 AAT GCA GTG TCT TCC CTG GCA AGC ACT GGT CTA TCT CTG ACC AAA GTG GAT GAA AGG GAA   
      N   A   V   S   S   L   A   S   T   G   L   S   L   T   K   V   D   E   R   E> 
2461 AAG CAG GCA GCA TTA GAG GAA GAA CAG GCA CGT TTG AAA GCT TTA AAG GAA CAG CGC CTA 
      K   Q   A   A   L   E   E   E   Q   A   R   L   K   A   L   K   E   Q   R   L> 
2521 AAA GAA CTT GCA AAG AAA CCT CAT ACC TCT TTA ACA ACT GCA GCC TCT CCT GTA TCC ACC 
      K   E   L   A   K   K   P   H   T   S   L   T   T   A   A   S   P   V   S   T> 
2581 TCA GCA GGA GGG ATA ATG ACT GCA CCA GCC ATT GAC ATA TTT TCT ACC CCT AGT TCT TCT 
      S   A   G   G   I   M   T   A   P   A   I   D   I   F   S   T   P   S   S   S> 
2641 AAC AGC ACA TCA AAG CTG CCC AAT GAT CTG CTT GAT TTG CAG CAG CCA ACT TTT CAC CCA   
      N   S   T   S   K   L   P   N   D   L   L   D   L   Q   Q   P   T   F   H   P> 
2701 TCT GTA CAT CCT ATG TCA ACT GCT TCT CAG GTA GCA AGT ACA TGG GGA GAT CCT TTC TCT       
      S   V   H   P   M   S   T   A   S   Q   V   A   S   T   W   G   D   P   F   S> 
2761 GCT ACT GTA GAT GCT GTT GAT GAT GCC ATT CCA AGC TTA AAT CCT TTC CTC ACA AAA AGT   
      A   T   V   D   A   V   D   D   A   I   P   S   L   N   P   F   L   T   K   S> 
2721 AGT GGT GAT GTT CAC CTT TCC ATT TCT TCA GAT GTA TCT ACT TTT ACT ACT AGG ACA CCT 
      S   G   D   V   H   L   S   I   S   S   D   V   S   T   F   T   T   R   T   P> 
2881 ACT CAT GAA ATG TTT GTT GGA TTC ACT CCT TCT CCA GTT GCA CAG CCA CAC CCT TCA GCT 
      T   H   E   M   F   V   G   F   T   P   S   P   V   A   Q   P   H   P   S   A> 
2941 GGC CTT AAT GTT GAC TTT GAA TCT GTG TTT GGA AAT AAA TCT ACA AAT GTT ATT GTA GAT   
      G   L   N   V   D   F   E   S   V   F   G   N   K   S   T   N   V   I   V   D> 
3001 TCT GGG GGC TTT GAT GAA CTA GGT GGA CTT CTC AAA CCA ACA GTG GCC TCT CAG AAC CAG   
      S   G   G   F   D   E   L   G   G   L   L   K   P   T   V   A   S   Q   N   Q> 
3061 AAC CTT CCT GTT GCC AAA CTC CCA CCT AGC AAG TTA GTA TCT GAT GAC TTG GAT TCA TCT   
      N   L   P   V   A   K   L   P   P   S   K   L   V   S   D   D   L   D   S   S> 
3121 TTA GCC AAC CTT GTG GGC AAT CTT GGC ATC GGA AAT GGA ACC ACT AAG AAT GAT GTA AAT   
      A   N   L   V   G   N   L   G   I   G   N   G   T   T   K   N   D   V   N> 
3181 TGG AGT CAA CCA GGT GAA AAG AAG TTA ACT GGG GGA TCT AAC TGC GAA CCA AAG GTT GCA   
      W   S   Q   P   G   E   K   K   L   T   G   G   S   N   C   E   P   K   V   A> 
3241 CCA ACA ACC GCT TGG AAT GCT GCA ACA ATG GCA CCC CCT GTA ATG GCC TAT CCT GCT ACT   
      P   T   T   A   W   N   A   A   T   M   A   P   P   V   M   A   Y   P   A   T> 
3301 ACA CCA ACA GGC ATG ATA GGA TAT GGA ATT CCT CCA CAA ATG GGA AGT GTT CCT GTA ATG   
      T   P   T   G   M   I   G   Y   G   I   P   P   Q   M   G   S   V   P   V   M> 
3361 ACG CAA CCA ACC TTA ATA TAC AGC CAG CCT GTC ATG AGA CCT CCA AAC CCC TTT GGC CCT   
      T   Q   P   T   L   I   Y   S   Q   P   V   M   R   P   P   N   P   F   G   P> 
3421 GTA TCA GGA GCA CAG AGA TGT GAA CTT TGT CCC CAT AAG GAT GGA GCT TTA AAA AGA ACA 
      V   S   G   A   Q   R   C   E   L   C   P   H   K   D   G   A   L   K   R   T> 
3481 GAT AAT GGG GGT TGG GCC CAT GTG GTT TGT GCC CTG TAT ATT CCA GAG GTA CAA TTT GCC   
      D   N   G   G   W   A   H   V   V   C   A   L   Y   I   P   E   V   Q   F   A> 
3541 AAT GTT TCC ACA ATG GAA CCA ATT GTT TTA CAG TCT GTT CCG CAT GAT CGT TAT AAT AAG   
      N   V   S   T   M   E   P   I   V   L   Q   S   V   P   H   D   R   Y   N   K> 
3601 ACT TGC TAC ATT TGT GAT GAA CAA GGA AGA GAA AGC AAA GCA GCC ACT GGT GCT TGC ATG   
      T   C   Y   I   C   D   E   Q   G   R   E   S   K   A   A   T   G   A   C   M> 
3661 ACA TGT AAT AAA CAT GGA TGT CGA CAG GCT TTC CAT GTA ACA TGC GCT CAG TTT GCC GGA   
      T   C   N   K   H   G   C   R   Q   A   F   H   V   T   C   A   Q   F   A   G> 
3721 CTG CTT TGT GAA GAA GAA GGT AAT GGT GCC GAT AAT GTC CAA TAC TGT GGC TAC TGT AAA   
      L   L   C   E   E   E   G   N   G   A   D   N   V   Q   Y   C   G   Y   C   K> 
3781 TAC CAT TTT AGT AAG CTG AAA AAG AGC AAA CGG GGA TCT AAT AGG TCA TAT GAT CAA AGT   
      Y   H   F   S   K   L   K   K   S   K   R   G   S   N   R   S   Y   D   Q   S> 
3841 TTA AGT GAT TCT TCC TCT CAC TCT CAG GAT AAA CAT CAT GAG AAA GAG AAA AAA AAA TAT   
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      L   S   D   S   S   S   H   S   Q   D   K   H   H   E   K   E   K   K   K   Y> 
3901 AAA GAG AAG GAC AAA CAC AAA CAG AAA CAC AAG AAG CAG CCA GAA CCA TCA CCT GCA TTG   
      K   E   K   D   K   H   K   Q   K   H   K   K   Q   P   E   P   S   P   A   L> 
3961 GTT CCA TCC TTG ACT GTT ACT ACA GAA AAA ACT TAT ACA AGC ACT AGC AAC AAC TCT ATA   
      V   P   S   L   T   V   T   T   E   K   T   Y   T   S   T   S   N   N   S   I> 
4021 TCT GGA TCA TTG AAG CGC TTG GAA GAT ACT ACT GCA CGA TTT ACA AAT GCA AAT TTC CAG   
      S   G   S   L   K   R   L   E   D   T   T   A   R   F   T   N   A   N   F   Q> 
4081 GAA GTC TCT GCA CAC ACC TCT AGT GGA AAA GAT GTT TCA GAG ACT AGA GGG TCA GAG GGC   
      E   V   S   A   H   T   S   S   G   K   D   V   S   E   T   R   G   S   E   G> 
4141 AAA GGG AAG AAA TCT TCA GCT CAC AGC TCA GGT CAA AGG GGA AGA AAG CCT GGT GGT GGA   
      K   G   K   K   S   S   A   H   S   S   G   Q   R   G   R   K   P   G   G   G> 
4201 AGA AAT CCA GGA ACA ACT GTG TCA GCA GCT AGC CCT TTT CCT CAA GGC AGT TTT TCA GGA   
      R   N   P   G   T   T   V   S   A   A   S   P   F   P   Q   G   S   F   S   G> 
4261 ACT CCA GGC AGT GTA AAG TCA TCT TCT GGA AGT TCA GTG CAG TCT CCC CAG GAT TTC CTG   
      T   P   G   S   V   K   S   S   S   G   S   S   V   Q   S   P   Q   D   F   L> 
4321 AGC TTT ACA GAC TCA GAT CTG CGT AAT GAC AGT TAC TCT CAC TCC CAA CAG TCA TCA GCA   
      S   F   T   D   S   D   L   R   N   D   S   Y   S   H   S   Q   Q   S   S   A> 
4380 ACC AAA GAT GTA CAT AAA GGA GAG TCT GGA AGC CAG GAA GGG GGG GTA AAT AGT TTT AGT  
      T   K   D   V   H   K   G   E   S   G   S   Q   E   G   G   V   N   S   F   S> 
4441 ACC TTA ATT GGC CTC CCT TCA ACC TCA GCT GTT ACT TCA CAG CCT AAA AGC TTT GAA AAT   
      T   L   I   G   L   P   S   T   S   A   V   T   S   Q   P   K   S   F   E   N> 
4501 TCA CCT GGA GAT TTG GGT AAT TCC AGC CTT CCT ACA GCA GGA TAT AAG CGG GCT CAA ACT  
      S   P   G   D   L   G   N   S   S   L   P   T   A   G   Y   K   R   A   Q   T> 
4561 TCT GGC ATA GAA GAA GAA ACT GTA AAG GAA AAG AAA AGG AAA GGA AAT AAA CAA AGT AAG   
      S   G   I   E   E   E   T   V   K   E   K   K   R   K   G   N   K   Q   S   K> 
4621 CAT GGG CCT GGC AGA CCC AAA GGA AAC AAA AAT CAA GAG AAT GTT TCT CAT CTC TCA GTT   
      H   G   P   G   R   P   K   G   N   K   N   Q   E   N   V   S   H   L   S   V> 
4681 TCT TCT GCT TCA CCA ACA TCA TCT GTA GCA TCA GCT GCA GGA AGC ATA ACA AGC TCT AGT   
      S   S   A   S   P   T   S   S   V   A   S   A   A   G   S   I   T   S   S   S> 
4741 CTG CAG AAA TCT CCT ACA TTG CTC AGG AAT GGA AGT TTA CAG AGC CTC AGT GTT GGC TCA   
      L   Q   K   S   P   T   L   L   R   N   G   S   L   Q   S   L   S   V   G   S> 
4801 TCT CCA GTT GGT TCA GAA ATT TCC ATG CAG TAT CGG CAT GAT GGA GCT TGC CCA ACA ACT   
      S   P   V   G   S   E   I   S   M   Q   Y   R   H   D   G   A   C   P   T   T> 
4861 ACG TTC TCA GAG TTG CTG AAT GCA ATA CAC AAC GAC AGA GGT GAC AGT TCT ACA CTA ACA   
      T   F   S   E   L   L   N   A   I   H   N   D   R   G   D   S   S   T   L   T> 
4921 AAG CAA GAA CTT AAA TTC ATA GGT ATT TAT AAC AGC AAT GAT GTA GCA GTA TCG TTT CCA   
      K   Q   E   L   K   F   I   G   I   Y   N   S   N   D   V   A   V   S   F   P> 
4981 AAT GTA GTA TCT GGC TCG GGA TCT AGT ACT CCT GTC TCC AGC TCT CAC TTA CCT CAG CAG   
      N   V   V   S   G   S   G   S   S   T   P   V   S   S   S   H   L   P   Q   Q> 
5041 TCT TCT GGG CAT TTG CAA CAA GTA GGA GCG CTC TCT CCC TCA GCT GTG TCA TCT GCA GCC   
      S   S   G   H   L   Q   Q   V   G   A   L   S   P   S   A   V   S   S   A   A> 
5101 CCT GCT GTT GCT ACA ACT CAG GCA AAT ACT CTA TCT GGA TCT TCT CTC AGT CAG GCA CCA   
      P   A   V   A   T   T   Q   A   N   T   L   S   G   S   S   L   S   Q   A   P> 
5161 TCT CAT ATG TAT GGC AAT AGA TCA AAT TCA TCA ATG GCA GCT CTT ATA GCT CAG TCT GAA   
      S   H   M   Y   G   N   R   S   N   S   S   M   A   A   L   I   A   Q   S   E> 
5221 AAC AAT CAA ACA GAT CAA GAT CTT GGA GAC AAT AGC CGC AAC CTA GTT GGC AGA GGA AGC   
      N   N   Q   T   D   Q   D   L   G   D   N   S   R   N   L   V   G   R   G   S> 
5281 TCA CCC CGA GGA AGT CTC TCG CCA CGA TCC CCT GTA AGC AGC TTA CAG ATT CGC TAT GAT   
      S   P   R   G   S   L   S   P   R   S   P   V   S   S   L   Q   I   R   Y   D> 
5341 CAA CCA GGC AAC AGC AGT TTG GAA AAT CTG CCT CCA GTA GCA GCC AGC ATA GAA CAG CTT      
      Q   P   G   N   S   S   L   E   N   L   P   P   V   A   A   S   I   E   Q   L> 
5401 TTG GAG AGG CAG TGG AGT GAA GGA CAG CAA TTT TTA CTA GAA CAG GGT ACT CCT AGT GAC   
      L   E   R   Q   W   S   E   G   Q   Q   F   L   L   E   Q   G   T   P   S   D> 
5461 ATT TTA GGA ATG CTG AAG TCA TTA CAC CAA CTT CAA GTT GAA AAC CGA AGA TTA GAG GAA   
      I   L   G   M   L   K   S   L   H   Q   L   Q   V   E   N   R   R   L   E   E> 
5521 CAA ATT AAA AAC TTG ACT GCC AAA AAG GAA CGG CTT CAG TTA TTG AAT GCA CAG CTT TCA   
      Q   I   K   N   L   T   A   K   K   E   R   L   Q   L   L   N   A   Q   L   S> 
5581 GTG CCT TTT CCA ACA ATA ACA GCA AAT CCT AGT CCG TCT CAT CAA ATA CAC ACA TTT TCA   
      V   P   F   P   T   I   T   A   N   P   S   P   S   H   Q   I   H   T   F   S> 
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5640 GCA CAG ACT GCT CCT ACT ACT GAT TCC TTG AAC AGC AGT AAG AGC CCT CAT ATA GGA AAC  
      A   Q   T   A   P   T   T   D   S   L   N   S   S   K   S   P   H   I   G   N> 
5701 AGC TTT TTA CCT GAT AAT TCT CTT CCT GTA TTA AAT CAG GAC TTA ACC TCC AGT GGA CAA   
      S   F   L   P   D   N   S   L   P   V   L   N   Q   D   L   T   S   S   G   Q> 
5761 AGT ACC AGC AGC TCA TCA GCT CTT TCT ACC CCA CCT CCT GCT GGG CAG AGT CCG GCT CAA   
      S   T   S   S   S   S   A   L   S   T   P   P   P   A   G   Q   S   P   A   Q> 
5821 CAA GGC TCA GGA GTG AGT GGA GTT CAG CAG GTC AAT GGC GTG ACA GTG GGG GCA CTA GCT   
      Q   G   S   G   V   S   G   V   Q   Q   V   N   G   V   T   V   G   A   L   A> 
5881 AGT GGA ATG CAG CCT GTA ACT TCC ACC ATT CCT GCC GTG TCT GCA GTG GGT GGA ATA ATT   
      S   G   M   Q   P   V   T   S   T   I   P   A   V   S   A   V   G   G   I   I> 
5941 GGA GCT TTG CCA GGT AAC CAA CTG GCA ATT AAT GGC ATT GTA GGA GCT TTA AAT GGG GTT   
      G   A   L   P   G   N   Q   L   A   I   N   G   I   V   G   A   L   N   G   V> 
6001 ATG CAG ACT CCT GTC ACA ATG TCC CAG AAC CCT ACC CCT CTC ACC CAC ACA ACC GTA CCA   
      M   Q   T   P   V   T   M   S   Q   N   P   T   P   L   T   H   T   T   V   P> 
6061 CCT AAT GCA ACA CAT CCA ATG CCA GCT ACA CTG ACT AAC AGT GCC TCA GGA CTA GGA TTA   
      P   N   A   T   H   P   M   P   A   T   L   T   N   S   A   S   G   L   G   L> 
6121 CTT TCT GAC CAG CAA CGA CAA ATA CTT ATT CAT CAA CAG CAG TTT CAG CAG TTG TTA AAT   
      L   S   D   Q   Q   R   Q   I   L   I   H   Q   Q   Q   F   Q   Q   L   L   N> 
6181 TCT CAA CAG CTC ACA CCA GAA CAA CAT CAA GCC TTT TTG TAT CAG TTA ATG CAA CAT CAC   
      S   Q   Q   L   T   P   E   Q   H   Q   A   F   L   Y   Q   L   M   Q   H   H> 
6241 CAC CAG CAG CAG CAC CAA CCT GAA CTT CAG CAG CTG CAG ATC CCT GGA CCA ACA CAA ATA   
      H   Q   Q   Q   H   Q   P   E   L   Q   Q   L   Q   I   P   G   P   T   Q   I> 
6301 CCC ATA AAC AAC CTT CTT GCG AGG TCC ACA GCA CCC CCA CTT CAC ACA GCT ACC ACC AAC   
      P   I   N   N   L   L   A   R   S   T   A   P   P   L   H   T   A   T   T   N> 
6361 CCA TTT CTC ACC ATC CAT GGA GAT AAT GCA AGT CAG AAA GTA GCA AGA CTT AGT GAT AAA   
      P   F   L   T   I   H   G   D   N   A   S   Q   K   V   A   R   L   S   D   K> 
6421 ACT GGG CCT GTA GCT CAA GAG AAA AGT TGA CAC CTG AGA AAC ATC TAG AAA TTG CCT ATC   
      T   G   P   V   A   Q   E   K   S   *> 
6481 CTG CTG TTC TAG CAC TTC ATC TGG CTG CCT TTG CAG TCC TTT TAC TAC AGC TAT GAA GAA  
6541 ACG CAA CAA GAA ACT CAA TGC ACA ACA AAG GAT TAA TTG CTG CAA GGA CAT TCT TGT AAG   
6601 GCT TGA ATT CCC GGG GGA TCC ACT AGT TCT AGA GCG GCC GCC ACC GCG GGC CCG GGA TCC  
6661 ACC GGA TCT AGA TAA CTG ATC ATA ATC AGC CAT ACC ACA TTT GTA GAG GTT TTA CTT GCT 
6721 TTA AAA AAC CTC CCA CAC CTC CCC CTG AAC CTG AAA CAT AAA ATG AAT GCA ATT GTT GTT  
6781 GTT AAC TTG TTT ATT GCA GCT TAT AAT GGT TAC AAA TAA AGC AAT AGC ATC ACA AAT TTC  
6841 ACA AAT AAA GCA TTT TTT TCA CTG CAT TCT AGT TGT GGT TTG TCC AAA CTC ATC AAT GTA   
6961 AAT CAG CTC ATT TTT TAA CCA ATA GGC CGA AAT CGG CAA AAT CCC TTA TAA ATC AAA AGA   
7021 ATA GAC CGA GAT AGG GTT GAG TGT TGT TCC AGT TTG GAA CAA GAG TCC ACT ATT AAA GAA   
7081 CGT GGA CTC CAA CGT CAA AGG GCG AAA AAC CGT CTA TCA GGG CGA TGG CCC ACT ACG TGA   
7141 ACC ATC ACC CTA ATC AAG TTT TTT GGG GTC GAG GTG CCG TAA AGC ACT AAA TCG GAA CCC   
7201 TAA AGG GAG CCC CCG ATT TAG AGC TTG ACG GGG AAA GCC GGC GAA CGT GGC GAG AAA GGA   
7261 AGG GAA GAA AGC GAA AGG AGC GGG CGC TAG GGC GCT GGC AAG TGT AGC GGT CAC GCT GCG   
7321 CGT AAC CAC CAC ACC CGC CGC GCT TAA TGC GCC GCT ACA GGG CGC GTC AGG TGG CAC TTT   
7381 TCG GGG AAA TGT GCG CGG AAC CCC TAT TTG TTT ATT TTT CTA AAT ACA TTC AAA TAT GTA   
7441 TCC GCT CAT GAG ACA ATA ACC CTG ATA AAT GCT TCA ATA ATA TTG AAA AAG GAA GAG TCC   
7501 TGA GGC GGA AAG AAC CAG CTG TGG AAT GTG TGT CAG TTA GGG TGT GGA AAG TCC CCA GGC   
7561 TCC CCA GCA GGC AGA AGT ATG CAA AGC ATG CAT CTC AAT TAG TCA GCA ACC AGG TGT GGA   
7621 AAG TCC CCA GGC TCC CCA GCA GGC AGA AGT ATG CAA AGC ATG CAT CTC AAT TAG TCA GCA   
7681 ACC ATA GTC CCG CCC CTA ACT CCG CCC ATC CCG CCC CTA ACT CCG CCC AGT TCC GCC CAT 
7741 TCT CCG CCC CAT GGC TGA CTA ATT TTT TTT ATT TAT GCA GAG GCC GAG GCC GCC TCG GCC   
7801 TCT GAG CTA TTC CAG AAG TAG TGA GGA GGC TTT TTT GGA GGC CTA GGC TTT TGC AAA GAT   
7861 CGA TCA AGA GAC AGG ATG AGG ATC GTT TCG CAT GAT TGA ACA AGA TGG ATT GCA CGC AGG   
7921 TTC TCC GGC CGC TTG GGT GGA GAG GCT ATT CGG CTA TGA CTG GGC ACA ACA GAC AAT CGG   
7981 CTG CTC TGA TGC CGC CGT GTT CCG GCT GTC AGC GCA GGG GCG CCC GGT TCT TTT TGT CAA   
8041 GAC CGA CCT GTC CGG TGC CCT GAA TGA ACT GCA AGA CGA GGC AGC GCG GCT ATC GTG GCT   
8101 GGC CAC GAC GGG CGT TCC TTG CGC AGC TGT GCT CGA CGT TGT CAC TGA AGC GGG AAG GGA   
8161 CTG GCT GCT ATT GGG CGA AGT GCC GGG GCA GGA TCT CCT GTC ATC TCA CCT TGC TCC TGC   
8221 CGA GAA AGT ATC CAT CAT GGC TGA TGC AAT GCG GCG GCT GCA TAC GCT TGA TCC GGC TAC  
8281 CTG CCC ATT CGA CCA CCA AGC GAA ACA TCG CAT CGA GCG AGC ACG TAC TCG GAT GGA AGC   
8341 CGG TCT TGT CGA TCA GGA TGA TCT GGA CGA AGA GCA TCA GGG GCT CGC GCC AGC CGA ACT   
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8401 GTT CGC CAG GCT CAA GGC GAG CAT GCC CGA CGG CGA GGA TCT CGT CGT GAC CCA TGG CGA   
8461 TGC CTG CTT GCC GAA TAT CAT GGT GGA AAA TGG CCG CTT TTC TGG ATT CAT CGA CTG TGG   
8521 CCG GCT GGG TGT GGC GGA CCG CTA TCA GGA CAT AGC GTT GGC TAC CCG TGA TAT TGC TGA   
8581 AGA GCT TGG CGG CGA ATG GGC TGA CCG CTT CCT CGT GCT TTA CGG TAT CGC CGC TCC CGA   
8641 TTC GCA GCG CAT CGC CTT CTA TCG CCT TCT TGA CGA GTT CTT CTG AGC GGG ACT CTG GGG   
8701 TTC GAA ATG ACC GAC CAA GCG ACG CCC AAC CTG CCA TCA CGA GAT TTC GAT TCC ACC GCC   
8761 GCC TTC TAT GAA AGG TTG GGC TTC GGA ATC GTT TTC CGG GAC GCC GGC TGG ATG ATC CTC   
8821 CAG CGC GGG GAT CTC ATG CTG GAG TTC TTC GCC CAC CCT AGG GGG AGG CTA ACT GAA ACA   
8881 CGG AAG GAG ACA ATA CCG GAA GGA ACC CGC GCT ATG ACG GCA ATA AAA AGA CAG AAT AAA   
8941 ACG CAC GGT GTT GGG TCG TTT GTT CAT AAA CGC GGG GTT CGG TCC CAG GGC TGG CAC TCT   
9001 GTC GAT ACC CCA CCG AGA CCC CAT TGG GGC CAA TAC GCC CGC GTT TCT TCC TTT TCC CCA   
9061 CCC CAC CCC CCA AGT TCG GGT GAA GGC CCA GGG CTC GCA GCC AAC GTC GGG GCG GCA GGC   
9121 CCT GCC ATA GCC TCA GGT TAC TCA TAT ATA CTT TAG ATT GAT TTA AAA CTT CAT TTT TAA   
9181 TTT AAA AGG ATC TAG GTG AAG ATC CTT TTT GAT AAT CTC ATG ACC AAA ATC CCT TAA CGT   
9241 GAG TTT TCG TTC CAC TGA GCG TCA GAC CCC GTA GAA AAG ATC AAA GGA TCT TCT TGA GAT   
9301 CCT TTT TTT CTG CGC GTA ATC TGC TGC TTG CAA ACA AAA AAA CCA CCG CTA CCA GCG GTG   
9361 GTT TGT TTG CCG GAT CAA GAG CTA CCA ACT CTT TTT CCG AAG GTA ACT GGC TTC AGC AGA   
9421 GCG CAG ATA CCA AAT ACT GTC CTT CTA GTG TAG CCG TAG TTA GGC CAC CAC TTC AAG AAC   
9481 TCT GTA GCA CCG CCT ACA TAC CTC GCT CTG CTA ATC CTG TTA CCA GTG GCT GCT GCC AGT   
9541 GGC GAT AAG TCG TGT CTT ACC GGG TTG GAC TCA AGA CGA TAG TTA CCG GAT AAG GCG CAG   
9601 CGG TCG GGC TGA ACG GGG GGT TCG TGC ACA CAG CCC AGC TTG GAG CGA ACG ACC TAC ACC   
9661 GAA CTG AGA TAC CTA CAG CGT GAG CTA TGA GAA AGC GCC ACG CTT CCC GAA GGG AGA AAG   
9721 GCG GAC AGG TAT CCG GTA AGC GGC AGG GTC GGA ACA GGA GAG CGC ACG AGG GAG CTT CCA   
9781 GGG GGA AAC GCC TGG TAT CTT TAT AGT CCT GTC GGG TTT CGC CAC CTC TGA CTT GAG CGT   
9841 CGA TTT TTG TGA TGC TCG TCA GGG GGG CGG AGC CTA TGG AAA AAC GCC AGC AAC GCG GCC   
9901 TTT TTA CGG TTC CTG GCC TTT TGC TGG CCT TTT GCT CAC ATG TTC TTT CCT GCG TTA TCC   
9961 CCT GAT TCT GTG GAT AAC CGT ATT ACC GCC ATG CAT 
 
Figure 71: pEGFP-CALM/AF10 construct used for the cloning procedures. The 
nucleotides in bold format in the sequence represent the excised fragment 
which contained 4 stop codons (in blue). The Xba1 restriction sites are 
underlined. 
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